The	O	DET	O
hypotensive	B-Disease	ADJ	B
effect	O	NOUN	O
of	O	ADP	O
100	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
alpha-methyldopa	B-Chemical	NOUN	B
was	O	AUX	O
also	O	ADV	O
partially	O	ADV	O
reversed	O	VERB	O
by	O	ADP	O
naloxone	B-Chemical	NOUN	B
.	O	PUNCT	O


Naloxone	B-Chemical	NOUN	B
alone	O	ADV	O
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
either	O	CCONJ	O
blood	O	NOUN	B
pressure	O	NOUN	I
or	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


Lidocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cardiac	B-Disease	ADJ	B
asystole	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
had	O	AUX	O
no	O	DET	O
apparent	O	ADJ	O
associated	O	VERB	O
conditions	O	NOUN	O
which	O	DET	O
might	O	AUX	O
have	O	AUX	O
predisposed	O	VERB	B
him	O	PRON	O
to	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
bradyarrhythmias	B-Disease	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
,	O	PUNCT	O
thus	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
probably	O	ADV	O
represented	O	VERB	O
a	O	DET	O
true	O	ADJ	O
idiosyncrasy	O	NOUN	O
to	O	PART	O
lidocaine	B-Chemical	VERB	B


Suxamethonium	B-Chemical	NOUN	B
chloride	I-Chemical	NOUN	I
(	O	PUNCT	O
Sch	B-Chemical	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
i	O	PRON	O
.	O	PUNCT	O


The	O	DET	O
infusion	O	NOUN	B
was	O	AUX	O
discontinued	O	VERB	B
either	O	CCONJ	O
when	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
muscular	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
tetanic	B-Disease	ADJ	B
stimulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ulnar	O	ADJ	B
nerve	O	NOUN	I
or	O	CCONJ	O
when	O	SCONJ	O
Sch	B-Chemical	NOUN	B
120	O	NUM	O
mg	O	NOUN	O
was	O	AUX	O
exceeded	O	VERB	O
.	O	PUNCT	O


Fasciculations	B-Disease	NOUN	B
in	O	ADP	O
six	O	NUM	O
areas	O	NOUN	O
of	O	ADP	O
the	O	DET	O
body	O	NOUN	B
were	O	AUX	O
scored	O	VERB	B
from	O	ADP	O
0	O	NUM	O
to	O	PART	O
3	O	NUM	O
and	O	CCONJ	O
summated	O	VERB	B
as	O	ADP	O
a	O	DET	O
total	O	ADJ	O
fasciculation	B-Disease	NOUN	B
score	O	NOUN	B
.	O	PUNCT	O


Fasciculations	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
six	O	NUM	O
areas	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
total	O	ADJ	O
fasciculation	B-Disease	NOUN	B
score	O	NOUN	B
were	O	AUX	O
related	O	VERB	O
directly	O	ADV	O
to	O	ADP	O
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
infusion	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
studies	O	NOUN	B
into	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
necessary	O	ADJ	O
to	O	PART	O
combating	O	VERB	O
scopolamine	B-Chemical	NOUN	B


Effects	O	NOUN	B
of	O	ADP	I
uninephrectomy	O	NOUN	B
and	O	CCONJ	O
high	O	ADJ	O
protein	O	NOUN	B
feeding	O	NOUN	B
on	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Corresponding	O	ADJ	O
non	O	ADJ	B
-	O	PUNCT	O
lithium	B-Chemical	NOUN	B
pretreated	O	ADJ	B
groups	O	NOUN	B
were	O	AUX	O
generated	O	VERB	O
.	O	PUNCT	O


Consequently	O	ADV	O
,	O	PUNCT	O
lithium	B-Chemical	NOUN	B
pretreatment	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
fall	O	NOUN	B
in	O	ADP	O
filtration	O	NOUN	B
fraction	O	NOUN	I
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
fractional	O	ADJ	B
Li	B-Chemical	PROPN	B
excretion	O	NOUN	B
.	O	PUNCT	O


Lithium	B-Chemical	NOUN	B
also	O	ADV	O
caused	O	VERB	O
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
systolic	O	NOUN	B
hypertension	B-Disease	NOUN	I
in	O	ADP	O
absence	O	NOUN	B
of	O	ADP	O
glomerulosclerosis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
Li	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
when	O	SCONJ	O
the	O	DET	O
GFR	O	NOUN	B
is	O	AUX	O
only	O	ADV	O
modestly	O	ADV	O
reduced	O	VERB	B
,	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
proteinuria	B-Disease	NOUN	B
and	O	CCONJ	O
arterial	O	ADJ	B
systolic	O	NOUN	I
hypertension	B-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
model	O	NOUN	B
of	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I


Fusidic	O	ADJ	B
acid	O	NOUN	I
is	O	AUX	O
an	O	DET	O
antibiotic	O	NOUN	B
with	O	ADP	O
T	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
specific	O	ADJ	O
immunosuppressive	O	ADJ	B
effects	O	NOUN	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
of	O	ADP	O
cyclosporin	B-Chemical	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
new	O	ADJ	O
treatments	O	NOUN	B
for	O	ADP	O
Crohn's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
pharmacodynamics	O	NOUN	B
and	O	CCONJ	O
tolerability	O	NOUN	B
of	O	ADP	O
fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
treatment	O	NOUN	B
in	O	ADP	O
chronic	O	ADJ	B
active	O	ADJ	I
,	O	PUNCT	O
therapy	O	NOUN	B
-	O	PUNCT	O
resistant	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
of	O	ADP	O
8	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
63	O	NUM	O
%)	O	NOUN	O
improved	O	VERB	B
during	O	ADP	O
fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
treatment	O	NOUN	B
:	O	PUNCT	O
3	O	NUM	O
at	O	ADP	O
two	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
after	O	ADP	O
four	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
serious	O	ADJ	O
clinical	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
dose	O	NOUN	B
reduction	O	NOUN	B
was	O	AUX	O
required	O	VERB	O
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
nausea	B-Disease	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
there	O	PRON	O
seems	O	VERB	O
to	O	PART	O
exist	O	VERB	O
a	O	DET	O
scientific	O	ADJ	B
rationale	O	NOUN	I
for	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
at	O	ADP	O
the	O	DET	O
cytokine	O	NOUN	B
level	O	NOUN	B
in	O	ADP	O
inflammatory	B-Disease	ADJ	B
bowel	I-Disease	NOUN	I
disease	I-Disease	NOUN	I


The	O	DET	O
electrocardiograms	O	NOUN	B
(	O	PUNCT	I
ECG	O	PROPN	B
)	O	PUNCT	O
of	O	ADP	O
99	O	NUM	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
abusing	O	VERB	B
patients	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
ECGs	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
schizophrenic	B-Disease	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


Sulpiride	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tardive	B-Disease	NOUN	B
dystonia	I-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
a	O	DET	O
37	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
persistent	O	ADJ	B
segmental	O	ADJ	B
dystonia	B-Disease	NOUN	I
within	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
starting	O	VERB	O
sulpiride	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


Ocular	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
auditory	I-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
in	O	ADP	O
hemodialyzed	O	ADJ	B
patients	O	NOUN	I
receiving	O	VERB	O
desferrioxamine	B-Chemical	NOUN	B
.	O	PUNCT	O


Visual	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
was	O	AUX	O
of	O	ADP	O
retinal	O	ADJ	B
origin	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
tritan	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
dyschromatopsy	B-Disease	NOUN	B
,	O	PUNCT	O
sometimes	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
a	B-Disease	DET	O
loss	I-Disease	NOUN	B
of	I-Disease	ADP	O
visual	I-Disease	ADJ	B
acuity	I-Disease	NOUN	I
and	O	CCONJ	O
pigmentary	B-Disease	ADJ	B
retinal	I-Disease	ADJ	I
deposits	I-Disease	NOUN	I
.	O	PUNCT	O


Desferrioxamine	B-Chemical	NOUN	B
withdrawal	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
complete	O	ADJ	O
recovery	O	NOUN	B
of	O	ADP	O
visual	O	ADJ	B
function	O	NOUN	I
in	O	ADP	O
1	O	NUM	O
patient	O	NOUN	B
and	O	CCONJ	O
partial	O	ADJ	B
recovery	O	NOUN	B
in	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
complete	O	ADJ	O
reversal	O	NOUN	B
of	O	ADP	O
hearing	B-Disease	VERB	B
loss	I-Disease	NOUN	I
in	O	ADP	O
3	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
partial	O	ADJ	B
recovery	O	NOUN	B
in	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
audiovisual	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
is	O	AUX	O
not	O	PART	O
an	O	DET	O
infrequent	O	ADJ	B
complication	O	NOUN	B
in	O	ADP	O
hemodialyzed	O	ADJ	B
patients	O	NOUN	I
receiving	O	VERB	O
desferrioxamine	B-Chemical	NOUN	B


We	O	PRON	O
studied	O	VERB	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
no	O	DET	O
prior	O	ADJ	O
history	O	NOUN	B
of	O	ADP	O
neuromuscular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
who	O	PRON	O
became	O	VERB	O
virtually	O	ADV	O
quadriplegic	B-Disease	ADJ	B
after	O	ADP	O
parenteral	O	ADJ	B
magnesium	B-Chemical	NOUN	O
administration	O	NOUN	O
for	O	ADP	O
preeclampsia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
serum	O	NOUN	B
magnesium	B-Chemical	NOUN	B
concentration	O	NOUN	I
was	O	AUX	O
3	O	NUM	O
.	O	PUNCT	O


While	O	SCONJ	O
she	O	PRON	O
was	O	AUX	O
weak	O	ADJ	B
,	O	PUNCT	O
2	O	NUM	O
-	O	PUNCT	O
Hz	O	NOUN	O
repetitive	O	ADJ	B
stimulation	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
decrement	O	NOUN	B
without	O	ADP	O
significant	O	ADJ	B
facilitation	O	NOUN	B
at	O	ADP	O
rapid	O	ADJ	O
rates	O	NOUN	B
or	O	CCONJ	O
after	O	ADP	O
exercise	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
postsynaptic	B-Disease	ADJ	B
neuromuscular	I-Disease	ADJ	I
blockade	I-Disease	NOUN	I
.	O	PUNCT	O


Her	O	PRON	O
acetylcholine	B-Chemical	NOUN	B
receptor	O	NOUN	I
antibody	O	NOUN	I
level	O	NOUN	B
was	O	AUX	O
markedly	O	ADV	O
elevated	O	ADJ	B
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
unusually	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
the	O	DET	O
neuromuscular	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
magnesium	B-Chemical	NOUN	B
should	O	AUX	O
be	O	AUX	O
suspected	O	VERB	B
of	O	ADP	O
having	O	VERB	O
an	O	DET	O
underlying	O	ADJ	O
disorder	B-Disease	NOUN	B
of	I-Disease	ADP	O
neuromuscular	I-Disease	ADJ	B
transmission	I-Disease	NOUN	I


The	O	DET	O
data	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
CAA	B-Chemical	PROPN	B
after	O	ADP	O
i	O	PRON	O
.	O	PUNCT	O


Source	O	NOUN	B
of	O	ADP	I
pain	B-Disease	NOUN	I
and	O	CCONJ	O
primitive	O	ADJ	B
dysfunction	O	NOUN	I
in	O	ADP	O
migraine	B-Disease	NOUN	B
:	O	PUNCT	O
an	O	DET	O
identical	O	ADJ	B
site	O	NOUN	B
?	O	PUNCT	O
Twenty	O	NUM	O
common	O	ADJ	O
migraine	B-Disease	NOUN	B
patients	O	NOUN	B
received	O	VERB	O
a	O	DET	O
one	O	NUM	O
sided	O	ADJ	O
frontotemporal	O	ADJ	B
application	O	NOUN	O
of	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
placebo	O	NOUN	B
ointment	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
double	O	ADJ	O
blind	O	ADJ	O
study	O	NOUN	O
.	O	PUNCT	O


Subsequently	O	ADV	O
20	O	NUM	O
migraine	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
an	O	DET	O
early	O	ADJ	B
onset	O	NOUN	B
attack	O	NOUN	I
with	O	ADP	O
frontotemporal	O	ADJ	B
nitroglycerin	B-Chemical	NOUN	I
,	O	PUNCT	O
received	O	VERB	O
the	O	DET	O
drug	O	NOUN	B
in	O	ADP	O
a	O	DET	O
second	O	ADJ	O
induction	O	NOUN	B
test	O	NOUN	I
at	O	ADP	O
other	O	ADJ	O
body	O	NOUN	B
areas	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
early	O	ADJ	I
onset	O	NOUN	O
migraine	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Clotiazepam	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
.	O	PUNCT	O


Clotiazepam	B-Chemical	PROPN	B
withdrawal	O	NOUN	B
was	O	AUX	O
followed	O	VERB	O
by	O	ADP	O
prompt	O	ADJ	O
recovery	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
several	O	ADJ	O
benzodiazepines	B-Chemical	NOUN	B
,	O	PUNCT	O
chemically	O	ADV	B
related	O	ADJ	O
to	O	ADP	O
clotiazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
interfere	O	VERB	B
with	O	ADP	I
recovery	O	NOUN	B
and	O	CCONJ	O
did	O	AUX	O
not	O	PART	O
induce	O	VERB	B
any	O	DET	O
relapse	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


Arterial	O	ADJ	B
hypertension	B-Disease	NOUN	I
as	O	ADP	O
a	O	DET	O
complication	O	NOUN	B
of	O	ADP	O
prolonged	O	ADJ	B
ketoconazole	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
cases	O	NOUN	B
normal	O	ADJ	O
plasma	O	NOUN	B
and	O	CCONJ	O
urinary	O	ADJ	B
free	O	ADJ	I
cortisol	B-Chemical	NOUN	I
levels	O	NOUN	O
had	O	AUX	O
been	O	AUX	O
achieved	O	VERB	O
following	O	VERB	O
ketoconazole	B-Chemical	NOUN	B
therapy	O	NOUN	I
,	O	PUNCT	O
yet	O	CCONJ	O
continuous	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
monitoring	O	NOUN	B
demonstrated	O	VERB	O
hypertension	B-Disease	NOUN	B
31	O	NUM	O
(	O	PUNCT	O
patient	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
52	O	NUM	O
weeks	O	NOUN	B
(	O	PUNCT	O
patient	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patient	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
deoxycorticosterone	B-Chemical	NOUN	B
and	O	CCONJ	O
11-deoxycortisol	B-Chemical	NOUN	B
levels	O	NOUN	B
,	O	PUNCT	O
plasma	O	NOUN	B
aldosterone	B-Chemical	NOUN	O
values	O	NOUN	O
were	O	AUX	O
raised	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
concomitant	O	ADJ	B
suppression	O	NOUN	B
of	O	ADP	O
renin	O	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
an	O	DET	O
inhibitor	O	NOUN	B
of	O	ADP	O
angiotensin	B-Chemical	NOUN	B
converting	O	NOUN	I
enzyme	O	NOUN	I
(	O	PUNCT	O
Captopril	B-Chemical	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
pulmonary	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
renal	I-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
intravascular	B-Disease	ADJ	B
coagulation	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Injection	O	NOUN	B
of	O	ADP	O
Captopril	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
),	O	PUNCT	O
an	O	DET	O
inhibitor	O	NOUN	B
of	O	ADP	O
angiotensin	B-Chemical	NOUN	B
converting	O	NOUN	I
enzyme	O	NOUN	I
(	O	PUNCT	O
ACE	O	NOUN	B
),	O	PUNCT	O
reduced	O	VERB	B
both	O	CCONJ	O
pulmonary	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
renal	I-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
fibrin	O	NOUN	B
in	O	ADP	O
the	O	DET	O
kidneys	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
considerably	O	ADV	O
lower	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
animals	O	NOUN	B
which	O	DET	O
received	O	VERB	O
thrombin	O	NOUN	B
and	O	CCONJ	O
AMCA	B-Chemical	PROPN	B
alone	O	ADV	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
Captopril	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
lungs	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
attributable	O	ADJ	O
to	O	PART	O
a	O	DET	O
vasodilatory	O	ADJ	B
effect	O	NOUN	I
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
circulating	O	VERB	B
level	O	NOUN	B
of	O	ADP	O
Angiotension	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
and	O	CCONJ	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
prostacyclin	B-Chemical	NOUN	B
(	O	PUNCT	O
secondary	O	ADJ	B
to	O	PART	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
bradykinin	B-Chemical	NOUN	B
).	O	PUNCT	O
Captopril	B-Chemical	NOUN	B
may	O	AUX	O
,	O	PUNCT	O
by	O	ADP	O
the	O	DET	O
same	O	ADJ	O
mechanism	O	NOUN	B
,	O	PUNCT	O
reduce	O	VERB	B
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
occur	O	VERB	O
after	O	ADP	O
an	O	DET	O
injection	O	NOUN	B
of	O	ADP	O
thrombin	O	NOUN	B
,	O	PUNCT	O
thereby	O	ADV	O
diminishing	O	VERB	O
the	O	DET	O
aggregation	O	NOUN	B
of	O	ADP	O
fibrin	O	NOUN	B
monomers	O	NOUN	I
in	O	ADP	O
the	O	DET	O
glomeruli	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
result	O	NOUN	O
that	O	SCONJ	O
less	O	ADJ	O
fibrin	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
deposited	O	VERB	B
and	O	CCONJ	O
thus	O	ADV	O
less	O	ADJ	O
kidney	B-Disease	NOUN	B
damage	I-Disease	NOUN	O


In	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
labetalol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
and	O	CCONJ	O
nitroprusside	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
20	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
)	O	PUNCT	O
scheduled	O	VERB	B
for	O	ADP	O
major	O	ADJ	O
orthopedic	O	ADJ	B
procedures	O	NOUN	I
.	O	PUNCT	O


Each	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
subjected	O	VERB	O
to	O	PART	O
an	O	DET	O
identical	O	ADJ	B
anesthetic	O	ADJ	B
protocol	O	NOUN	I
and	O	CCONJ	O
similar	O	ADJ	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
reductions	B-Disease	NOUN	B
in	I-Disease	ADP	O
mean	I-Disease	ADJ	O
arterial	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
(	O	PUNCT	O
BP	O	NOUN	B
)(	O	NOUN	O
50	O	NUM	O
to	O	PART	O
55	O	NUM	O
mmHg	O	NOUN	B
).	O	PUNCT	O
Nitroprusside	O	NOUN	B
infusion	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significant	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


Arterial	O	ADJ	B
PO2	B-Chemical	NOUN	B
decreased	O	VERB	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Chronic	O	ADJ	B
carbamazepine	B-Chemical	NOUN	I
treatment	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
:	O	PUNCT	O
efficacy	O	NOUN	B
,	O	PUNCT	O
toxicity	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
effect	O	NOUN	B
on	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
tissue	O	NOUN	B
folate	B-Chemical	NOUN	B
concentrations	O	NOUN	B
.	O	PUNCT	O


Folate	B-Chemical	NOUN	B
depletion	O	NOUN	B
has	O	AUX	O
often	O	ADV	O
been	O	AUX	O
a	O	DET	O
problem	O	NOUN	B
in	O	ADP	O
chronic	O	ADJ	B
antiepileptic	O	ADJ	I
drug	O	NOUN	I
(	O	PUNCT	O
AED	O	NOUN	B
)	O	PUNCT	O
therapy	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
rat	O	NOUN	B
model	O	NOUN	B
was	O	AUX	O
developed	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
chronic	O	ADJ	B
CBZ	B-Chemical	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
folate	B-Chemical	NOUN	B
concentrations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


Seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
hexafluorodiethyl	B-Chemical	NOUN	B
ether	I-Chemical	NOUN	I
(	O	PUNCT	O
HFDE	B-Chemical	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
also	O	ADV	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
more	O	ADV	O
sensitive	O	ADJ	B
measure	O	NOUN	B
of	O	ADP	O
protection	O	NOUN	B
by	O	ADP	O
CBZ	B-Chemical	NOUN	B
than	O	ADP	O
seizures	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
maximal	O	ADJ	B
electroshock	O	NOUN	I
(	O	PUNCT	O
MES	O	PROPN	B
).	O	PUNCT	O
Oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
CBZ	B-Chemical	NOUN	B
as	O	ADP	O
an	O	DET	O
aqueous	O	ADJ	B
suspension	O	NOUN	B
every	O	DET	O
8	O	NUM	O
h	O	NOUN	O
at	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
250	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
was	O	AUX	O
continuously	O	ADV	O
protective	O	ADJ	O
against	O	ADP	O
HFDE	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
minimally	O	ADV	B
toxic	O	ADJ	I
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
weight	B-Disease	NOUN	B
gain	I-Disease	NOUN	I
over	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
treatment	O	NOUN	B
with	O	ADP	O
CBZ	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	O
apparent	O	ADJ	B
adverse	O	ADJ	B
effect	O	NOUN	I
on	O	ADP	O
folate	B-Chemical	NOUN	B
concentrations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
,	O	PUNCT	O
indeed	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
folate	B-Chemical	NOUN	B


3	O	NUM	O
microgram	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
min	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
comparable	O	ADJ	O
hypotension	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
hydralazine	B-Chemical	NOUN	B
or	O	CCONJ	O
nitroglycerin	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
release	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
epinephrine	B-Chemical	NOUN	B


Multiple	O	ADJ	B
cytotoxic	O	ADJ	B
drug	O	NOUN	B
administration	O	NOUN	I
is	O	AUX	O
the	O	DET	O
generally	O	ADV	O
accepted	O	VERB	B
treatment	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
stage	O	NOUN	I
of	O	ADP	O
choriocarcinoma	B-Disease	NOUN	B
.	O	PUNCT	O


213	O	NUM	O
,	O	PUNCT	O
Methotrexate	B-Chemical	NOUN	B
,	O	PUNCT	O
Cyclophosphamide	B-Chemical	NOUN	B
,	O	PUNCT	O
Actomycin-D	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Cisplatin	B-Chemical	PROPN	B
.	O	PUNCT	O


Formation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
plugs	O	NOUN	B
was	O	AUX	O
probably	O	ADV	O
due	O	ADJ	O
to	O	PART	O
extensive	O	ADJ	B
tumor	B-Disease	NOUN	B
necrosis	B-Disease	NOUN	I
at	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
the	O	DET	O
walls	O	NOUN	B
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
uterine	O	NOUN	B
veins	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
open	O	ADJ	O
exchange	O	NOUN	O
of	O	ADP	O
tumor	B-Disease	NOUN	B
plugs	O	NOUN	I
to	O	PART	O
the	O	DET	O
vascular	O	ADJ	B
spaces	O	NOUN	I
;	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
tumor	B-Disease	NOUN	B
tissue	O	NOUN	I
coherence	O	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
chemotherapy	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
further	O	ADV	O
contributed	O	VERB	O
to	O	PART	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
tumor	B-Disease	NOUN	B
emboli	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
large	O	ADJ	O
pelvic	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I


The	O	DET	O
relationship	O	NOUN	B
of	O	ADP	O
arthritis	B-Disease	NOUN	B
and	O	CCONJ	O
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
among	O	ADP	O
169	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
,	O	PUNCT	O
osteoarthritis	B-Disease	NOUN	B
and	O	CCONJ	O
spondyloarthropathy	B-Disease	NOUN	B
,	O	PUNCT	O
130	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
were	O	AUX	O
pair	O	NOUN	B
-	O	PUNCT	O
matched	O	VERB	B
to	O	PART	O
controls	O	NOUN	B
.	O	PUNCT	O


Depressed	B-Disease	ADJ	B
mood	I-Disease	NOUN	I
was	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
among	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
certain	O	ADJ	O
sexual	O	ADJ	B
difficulties	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
impotence	B-Disease	NOUN	B
.	O	PUNCT	O


Does	O	AUX	O
paracetamol	B-Chemical	NOUN	B
cause	O	VERB	O
urothelial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
or	O	CCONJ	O
renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
?	O	PUNCT	O
The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
or	O	CCONJ	O
cancer	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
renal	I-Disease	ADJ	B
pelvis,	I-Disease	NOUN	I
ureter	I-Disease	NOUN	I
or	I-Disease	CCONJ	O
bladder	I-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
consumption	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
phenacetin	B-Chemical	NOUN	B
or	O	CCONJ	O
paracetamol	B-Chemical	NOUN	B
was	O	AUX	O
calculated	O	VERB	O
from	O	ADP	O
data	O	NOUN	B
acquired	O	VERB	O
by	O	ADP	O
questionnaire	O	NOUN	B
from	O	ADP	O
381	O	NUM	O
cases	O	NOUN	B
and	O	CCONJ	O
808	O	NUM	O
controls	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
unable	O	ADJ	O
to	O	PART	O
substantiate	O	VERB	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
from	O	ADP	O
paracetamol	B-Chemical	NOUN	B
consumption	O	NOUN	I
for	O	ADP	O
renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
or	O	CCONJ	O
any	O	DET	O
of	O	ADP	O
these	O	DET	O
cancers	B-Disease	NOUN	B
although	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
suggestion	O	NOUN	O
of	O	ADP	O
an	O	DET	O
association	O	NOUN	B
with	O	ADP	I
cancer	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
ureter	I-Disease	NOUN	B


A	O	DET	O
Cambodian	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
hemoglobin	O	NOUN	B
E	O	NOUN	I
trait	O	NOUN	I
(	O	PUNCT	O
AE	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
leprosy	B-Disease	NOUN	B
developed	O	VERB	O
a	O	DET	O
Heinz	O	NOUN	B
body	O	NOUN	I
hemolytic	B-Disease	ADJ	I
anemia	I-Disease	NOUN	B
while	O	SCONJ	O
taking	O	VERB	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
dapsone	B-Chemical	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
)	O	PUNCT	O
not	O	PART	O
usually	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
clinical	O	ADJ	B
hemolysis	B-Disease	NOUN	I
.	O	PUNCT	O


Her	O	PRON	O
red	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
(	O	PUNCT	O
RBCs	O	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
increased	O	VERB	B
incubated	O	VERB	B
Heinz	O	NOUN	B
body	O	NOUN	I
formation	O	NOUN	I
,	O	PUNCT	O
decreased	O	VERB	B
reduced	O	VERB	O
glutathione	B-Chemical	NOUN	B
(	O	PUNCT	O
GSH	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
decreased	O	VERB	B
GSH	B-Chemical	NOUN	B
stability	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
AE	O	NOUN	B
RBCs	O	NOUN	B
from	O	ADP	O
an	O	DET	O
individual	O	NOUN	B
not	O	PART	O
taking	O	VERB	O
dapsone	B-Chemical	NOUN	B
had	O	AUX	O
increased	O	VERB	B
incubated	O	VERB	B
Heinz	O	NOUN	B
body	O	NOUN	I
formation	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
GSH	B-Chemical	NOUN	B
content	O	NOUN	B
and	O	CCONJ	O
GSH	B-Chemical	NOUN	B
stability	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	O
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
influx	O	NOUN	B
of	O	ADP	O
Southeast	O	PROPN	B
Asians	O	PROPN	B
into	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
,	O	PUNCT	O
oxidant	O	ADJ	B
medications	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
used	O	VERB	O
with	O	ADP	O
caution	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
if	O	SCONJ	O
an	O	DET	O
infection	B-Disease	NOUN	B


Severe	O	ADJ	B
complications	O	NOUN	B
of	O	ADP	O
antianginal	O	ADJ	B
drug	O	NOUN	B
therapy	O	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
identified	O	VERB	B
as	O	ADP	O
a	O	DET	O
poor	O	ADJ	O
metabolizer	O	NOUN	B
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
,	O	PUNCT	O
propafenone	B-Chemical	NOUN	B
,	O	PUNCT	O
diltiazem	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
sparteine	B-Chemical	NOUN	B
.	O	PUNCT	O


AV	B-Disease	NOUN	B
block	I-Disease	NOUN	I
,	O	PUNCT	O
severe	O	ADJ	B
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
impairment	B-Disease	NOUN	B
of	I-Disease	ADP	O
ventricular	I-Disease	ADJ	B
function	I-Disease	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
days	O	NOUN	B
before	O	ADP	O
admission	O	NOUN	B
diltiazem	B-Chemical	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
mg	O	NOUN	O
b	O	NOUN	O
.	O	PUNCT	O


Three	O	NUM	O
months	O	NOUN	B
later	O	ADV	O
the	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
exposed	O	VERB	O
to	O	PART	O
a	O	DET	O
single	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
,	O	PUNCT	O
diltiazem	B-Chemical	NOUN	B
,	O	PUNCT	O
propafenone	B-Chemical	NOUN	B
(	O	PUNCT	O
since	O	SCONJ	O
he	O	PRON	O
had	O	AUX	O
received	O	VERB	O
this	O	DET	O
drug	O	NOUN	B
in	O	ADP	O
the	O	DET	O
past	O	NOUN	O
),	O	PUNCT	O
and	O	CCONJ	O
sparteine	B-Chemical	NOUN	B
(	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
probe	O	NOUN	B
for	O	ADP	O
the	O	DET	O
debrisoquine	B-Chemical	NOUN	B
/	O	SYM	O
sparteine	B-Chemical	NOUN	B
type	O	NOUN	O
polymorphism	O	NOUN	B
of	O	ADP	O
oxidative	O	ADJ	B
drug	O	NOUN	I
metabolism	O	NOUN	I
).	O	PUNCT	O
It	O	PRON	O
was	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
he	O	PRON	O
was	O	AUX	O
a	O	DET	O
poor	O	ADJ	B
metabolizer	O	NOUN	B
of	O	ADP	O
all	O	DET	O
four	O	NUM	O
drugs	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
their	O	PRON	O
metabolism	O	NOUN	B
is	O	AUX	O
under	O	ADP	O
the	O	DET	O
same	O	ADJ	O
genetic	O	ADJ	B
control	O	NOUN	I
.	O	PUNCT	O


Triazolam	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
brief	O	ADJ	B
episodes	O	NOUN	I
of	O	ADP	O
secondary	O	ADJ	B
mania	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
depressed	B-Disease	ADJ	B
patient	O	NOUN	I
.	O	PUNCT	O


Features	O	NOUN	B
of	O	ADP	O
organic	B-Disease	ADJ	B
mental	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
delirium	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
not	O	PART	O
present	O	ADJ	O
.	O	PUNCT	O


Manic	B-Disease	ADJ	B
excitement	O	NOUN	B
was	O	AUX	O
coincident	O	ADJ	O
with	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
of	O	ADP	O
triazolam	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possible	O	ADJ	O
contribution	O	NOUN	B
of	O	ADP	O
the	O	DET	O
triazolo	B-Chemical	NOUN	B


The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
tolerance	O	NOUN	B
to	O	PART	O
the	O	DET	O
muscular	B-Disease	ADJ	B
rigidity	I-Disease	NOUN	I
produced	O	VERB	O
by	O	ADP	O
morphine	B-Chemical	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rigidity	B-Disease	NOUN	B
was	O	AUX	O
considerably	O	ADV	O
decreased	O	VERB	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
after	O	ADP	O
20	O	NUM	O
days	O	NOUN	B
'	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
further	O	ADJ	O
series	O	NOUN	O
of	O	ADP	O
experiments	O	NOUN	B
,	O	PUNCT	O
haloperidol	B-Chemical	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


Haloperidol	B-Chemical	NOUN	B
enhanced	O	VERB	B
the	O	DET	O
rigidity	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
A	O	NOUN	O
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rapid	O	ADJ	O
alternations	O	NOUN	B
of	O	ADP	O
rigidity	B-Disease	NOUN	B


Compression	B-Disease	NOUN	B
neuropathy	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
radial	I-Disease	ADJ	B
nerve	I-Disease	NOUN	I
due	O	ADP	O
to	O	PART	O
pentazocine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
fibrous	B-Disease	ADJ	B
myopathy	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
compression	B-Disease	NOUN	B
neuropathy	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
fibrotic	O	ADJ	B
muscle	O	NOUN	I
affected	O	VERB	B
by	O	ADP	O
pentazocine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
myopathy	B-Disease	NOUN	B
has	O	AUX	O
not	O	PART	O
previously	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


Recurrent	O	ADJ	B
reversible	O	ADJ	O
acute	B-Disease	ADJ	O
renal	I-Disease	ADJ	O
failure	I-Disease	NOUN	O
from	O	ADP	O
amphotericin	B-Chemical	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
propose	O	VERB	O
that	O	SCONJ	O
amphotericin	B-Chemical	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
setting	O	NOUN	O
of	O	ADP	O
reduced	O	VERB	B
effective	O	ADJ	B
arterial	O	ADJ	B
volume	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
activate	O	VERB	B
tubuloglomerular	O	NOUN	B
feedback	O	NOUN	I
,	O	PUNCT	O
thereby	O	ADV	O
contributing	O	VERB	O
to	O	PART	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I


A	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
sinuatrial	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
implanted	O	VERB	B
pacemaker	O	NOUN	I
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
amiodarone	B-Chemical	NOUN	B
(	O	PUNCT	O
maximum	O	ADJ	B
dose	O	NOUN	I
1000	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
maintenance	O	NOUN	B
dose	O	NOUN	B
800	O	NUM	O
mg	O	NOUN	O
daily	O	ADV	B
)	O	PUNCT	O
for	O	ADP	O
10	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
control	O	NOUN	B
of	O	ADP	O
supraventricular	B-Disease	ADJ	B
tachyarrhythmias	I-Disease	NOUN	I
.	O	PUNCT	O


He	O	PRON	O
developed	O	VERB	O
pneumonitis	B-Disease	NOUN	B
,	O	PUNCT	O
pleural	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
pericardial	I-Disease	ADJ	B
effusions	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
predominantly	O	ADV	O
proximal	B-Disease	ADJ	B
motor	I-Disease	NOUN	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Indomethacin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
renal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
:	O	PUNCT	O
recurrence	O	NOUN	B
on	O	ADP	O
rechallenge	O	NOUN	B
.	O	PUNCT	O


Prompt	O	ADJ	B
restoration	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
function	O	NOUN	I
followed	O	VERB	O
drug	O	NOUN	B
withdrawal	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
re	O	ADP	B
-	O	PUNCT	O
exposure	O	NOUN	B
to	O	PART	O
a	O	DET	O
single	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
indomethacin	B-Chemical	NOUN	B
caused	O	VERB	O
recurrence	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
reversible	O	ADJ	O
oliguria	B-Disease	NOUN	O
.	O	PUNCT	O


Our	O	PRON	O
case	O	NOUN	B
supports	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
endogenous	O	ADJ	B
renal	O	ADJ	B
prostaglandins	B-Chemical	NOUN	I
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
of	O	ADP	O
renal	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
when	O	SCONJ	O
circulating	O	VERB	B
plasma	O	NOUN	B
volume	O	NOUN	I
is	O	AUX	O
diminished	O	VERB	B
.	O	PUNCT	O


Flunitrazepam	B-Chemical	NOUN	B
0	O	NUM	O
.	O	PUNCT	O


Dizziness	B-Disease	NOUN	B
was	O	AUX	O
less	O	ADV	O
marked	O	ADJ	O
than	O	ADP	O
sedation	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
increased	O	VERB	B
with	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
timolol	B-Chemical	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
after	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
X	O	NOUN	B
-	O	PUNCT	O
ray	O	NOUN	B
in	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
study	O	NOUN	B
including	O	VERB	O
241	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
placebo	O	NOUN	B
126	O	NUM	O
,	O	PUNCT	O
timolol	B-Chemical	NOUN	B
115	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	ADP	O
period	O	NOUN	B
was	O	AUX	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
timolol	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
patients	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
small	O	ADJ	B
but	O	CCONJ	O
significant	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
from	O	ADP	O
baseline	O	NOUN	B
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
cardiomegaly	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
re	O	ADP	B
-	O	PUNCT	O
infarction	B-Disease	NOUN	B
,	O	PUNCT	O
heart	O	NOUN	B
size	O	NOUN	I
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	O
and	O	CCONJ	O
remained	O	VERB	O
unchanged	O	ADJ	B
in	O	ADP	O
the	O	DET	O
timolol	B-Chemical	NOUN	B


Large	O	ADJ	O
parenteral	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
(	O	PUNCT	O
15	O	NUM	O
to	O	PART	O
17	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
IU	O	NOUN	B
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
prolonged	O	ADJ	B
hypercalcemia	B-Disease	NOUN	B
,	O	PUNCT	O
hyperphosphatemia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
large	O	ADJ	O
increases	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
and	O	CCONJ	O
its	O	PRON	O
metabolites	O	NOUN	B
in	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
plasma	O	NOUN	I
of	O	ADP	O
nonlactating	O	VERB	B
nonpregnant	O	ADJ	B
and	O	CCONJ	O
pregnant	O	ADJ	B
Jersey	O	PROPN	I
cows	O	NOUN	B
.	O	PUNCT	O


Signs	O	NOUN	B
of	O	ADP	I
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
toxicity	B-Disease	NOUN	B
were	O	AUX	O
not	O	PART	O
observed	O	VERB	O
in	O	ADP	O
nonlactating	O	VERB	B
nonpregnant	O	ADJ	B
cows	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
pregnant	O	ADJ	B
cows	O	NOUN	I
commonly	O	ADV	O
developed	O	VERB	O
severe	O	ADJ	B
signs	O	NOUN	O
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
toxicity	B-Disease	NOUN	B
and	O	CCONJ	O
10	O	NUM	O
of	O	ADP	O
17	O	NUM	O
cows	O	NOUN	B
died	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
anatomical	O	ADJ	B
and	O	CCONJ	O
aetiological	O	ADJ	B
diagnoses	O	NOUN	I
of	O	ADP	O
peripheral	B-Disease	ADJ	B
nerve	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
excluding	O	VERB	O
its	O	PRON	O
primary	O	ADJ	B
benign	O	ADJ	I
and	O	CCONJ	O
malignant	O	ADJ	B
disorders	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
seen	O	VERB	O
in	O	ADP	O
358	O	NUM	O
Nigerians	O	PROPN	B
are	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


6	O	NUM	O
%),	O	ADJ	O
accounting	O	VERB	O
for	O	ADP	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
with	O	ADP	O
motor	B-Disease	NOUN	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Peripheral	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
nutritional	B-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	O	ADP	O
thiamine	B-Chemical	NOUN	B
and	O	CCONJ	O
riboflavin	B-Chemical	NOUN	B
was	O	AUX	O
common	O	ADJ	O
(	O	PUNCT	O
10	O	NUM	O
.	O	PUNCT	O


Diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
was	O	AUX	O
the	O	DET	O
major	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
the	O	DET	O
cases	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
aetiology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neuropathy	B-Disease	NOUN	B
was	O	AUX	O
undetermined	O	ADJ	O
.	O	PUNCT	O


Some	O	DET	O
of	O	ADP	O
the	O	DET	O
factors	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
clinical	O	ADJ	B
presentation	O	NOUN	I
and	O	CCONJ	O
pathogenesis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neuropathies	B-Disease	NOUN	B


A	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
study	O	NOUN	B
of	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
safety	O	NOUN	B
of	O	ADP	O
dothiepin	B-Chemical	NOUN	B
hydrochloride	I-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
major	O	ADJ	O
depressive	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
.	O	PUNCT	O


Dothiepin	B-Chemical	NOUN	B
and	O	CCONJ	O
amitriptyline	B-Chemical	NOUN	B
were	O	AUX	O
equally	O	ADV	O
effective	O	ADJ	B
in	O	ADP	O
alleviating	O	VERB	O
the	O	DET	O
symptoms	O	NOUN	B
of	O	ADP	O
depressive	B-Disease	ADJ	B
illness	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
both	O	DET	O
were	O	AUX	O
significantly	O	ADV	O
superior	O	ADJ	O
to	O	PART	O
placebo	O	NOUN	B
.	O	PUNCT	O


Dothiepin	B-Chemical	PROPN	B
also	O	ADV	O
produced	O	VERB	O
fewer	O	ADJ	O
CNS	O	NOUN	B
and	O	CCONJ	O
cardiovascular	O	ADJ	B
effects	O	NOUN	B
.	O	PUNCT	O


Dothiepin	B-Chemical	PROPN	B
thus	O	ADV	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
antidepressant	B-Chemical	ADJ	B
drug	O	NOUN	O
associated	O	VERB	B
with	O	ADP	I
fewer	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
than	O	ADP	O
amitriptyline	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
depressed	B-Disease	ADJ	B


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
oral	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
10	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
median	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
propranolol	B-Chemical	NOUN	B
(	O	PUNCT	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
80	O	NUM	O
mg	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
median	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
240	O	NUM	O
mg	O	NOUN	O
/	O	PUNCT	O
day	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
psychological	O	ADJ	B
performance	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
panic	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
and	O	CCONJ	O
agoraphobia	B-Disease	NOUN	B
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	NOUN	B
,	O	PUNCT	O
randomized	O	ADJ	B
and	O	CCONJ	O
crossover	O	NOUN	B
design	O	NOUN	I
.	O	PUNCT	O


Accumulation	O	NOUN	B
of	O	ADP	O
drugs	O	NOUN	B
was	O	AUX	O
not	O	PART	O
reflected	O	VERB	O
in	O	ADP	O
prolonged	O	ADJ	B
behavioral	B-Disease	ADJ	B
impairment	I-Disease	NOUN	O


Effect	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
on	O	ADP	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
epithelial	O	ADJ	B
proliferation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
urinary	O	ADJ	B
bladder	O	NOUN	I
and	O	CCONJ	O
forestomach	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
co	O	ADJ	B
-	O	PUNCT	O
administration	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
with	O	ADP	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	B-Chemical	NOUN	B
(	O	PUNCT	O
FANFT	B-Chemical	NOUN	B
)	O	PUNCT	O
to	O	PART	O
rats	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
a	O	DET	O
reduced	O	VERB	B
incidence	O	NOUN	B
of	O	ADP	O
FANFT	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
bladder	B-Disease	NOUN	B
carcinomas	I-Disease	NOUN	I
but	O	CCONJ	O
a	O	DET	O
concomitant	O	ADJ	B
induction	O	NOUN	B
of	O	ADP	O
forestomach	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


2	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
aspirin	B-Chemical	NOUN	B
at	O	ADP	O
a	O	DET	O
level	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


FANFT	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cell	O	NOUN	B
proliferation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
suppressed	O	VERB	B
by	O	ADP	O
aspirin	B-Chemical	NOUN	B
co	O	X	B
-	O	PUNCT	O
administration	O	NOUN	B
after	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
after	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
.	O	PUNCT	O


Also	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
adaptation	O	NOUN	B
by	O	ADP	O
the	O	DET	O
rats	O	NOUN	B
to	O	PART	O
the	O	DET	O
chronic	O	ADJ	B
ingestion	O	NOUN	I
of	O	ADP	O
aspirin	B-Chemical	NOUN	B


Provocation	O	NOUN	B
of	O	ADP	O
postural	O	ADJ	B
hypotension	B-Disease	NOUN	I
by	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
in	O	ADP	O
diabetic	B-Disease	ADJ	B
autonomic	I-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
?	O	PUNCT	O
The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
on	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
systolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
was	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
5	O	NUM	O
normal	O	ADJ	B
subjects	O	NOUN	I
,	O	PUNCT	O
12	O	NUM	O
diabetic	B-Disease	ADJ	B
subjects	O	NOUN	B
without	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
5	O	NUM	O
diabetic	B-Disease	ADJ	B
subjects	O	NOUN	B
with	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Characterization	O	NOUN	B
of	O	ADP	O
estrogen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
adenohypophyseal	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
Fischer	O	NOUN	B
344	O	NUM	O
rat	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cell	O	NOUN	B
populations	O	NOUN	I
were	O	AUX	O
examined	O	VERB	O
regarding	O	VERB	O
total	O	ADJ	B
cell	O	NOUN	I
recovery	O	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
gland	O	NOUN	B
weight	O	NOUN	I
,	O	PUNCT	O
intracellular	O	ADJ	B
prolactin	O	NOUN	O
(	O	PUNCT	O
PRL	O	NOUN	B
)	O	PUNCT	O
content	O	NOUN	B
and	O	CCONJ	O
subsequent	O	ADJ	O
release	O	NOUN	B
in	O	ADP	O
primary	O	ADJ	B
culture	O	NOUN	I
,	O	PUNCT	O
immunocytochemical	O	ADJ	B
PRL	O	NOUN	B
staining	O	NOUN	B
,	O	PUNCT	O
density	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
size	O	NOUN	B
alterations	O	NOUN	B
via	O	ADP	O
separation	O	NOUN	B
on	O	ADP	O
Ficoll	O	NOUN	B
-	O	PUNCT	O
Hypaque	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
unit	O	NOUN	O
gravity	O	NOUN	B
sedimentation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cell	O	NOUN	B
cycle	O	NOUN	I
analysis	O	NOUN	I
,	O	PUNCT	O
after	O	ADP	O
acriflavine	B-Chemical	NOUN	B
DNA	O	NOUN	B
staining	O	NOUN	I
,	O	PUNCT	O
by	O	ADP	O
laser	O	NOUN	B
flow	O	NOUN	I
cytometry	O	NOUN	I
.	O	PUNCT	O


4	O	NUM	O
times	O	NOUN	O
control	O	NOUN	O
levels	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
PRL	O	NOUN	B
release	O	NOUN	B
in	O	X	B
vitro	O	X	I
was	O	AUX	O
significantly	O	ADV	B
and	O	CCONJ	O
consistently	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
after	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
DES	B-Chemical	NOUN	B
exposure	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
these	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
DES	B-Chemical	NOUN	B
were	O	AUX	O
more	O	ADV	O
pronounced	O	ADJ	O
among	O	ADP	O
previously	O	ADV	O
ovariectomized	O	VERB	B
animals	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
data	O	NOUN	B
extend	O	VERB	O
the	O	DET	O
findings	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
investigators	O	NOUN	B
,	O	PUNCT	O
further	O	ADV	O
establishing	O	VERB	O
the	O	DET	O
DES	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
tumor	B-Disease	NOUN	B


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
triamterene	B-Chemical	NOUN	B
nephrolithiasis	B-Disease	NOUN	B
is	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
a	O	DET	O
man	O	NOUN	B
after	O	ADP	O
4	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
hydrochlorothiazide-triamterene	B-Chemical	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


Metabolic	O	ADJ	B
involvement	O	NOUN	B
in	O	ADP	O
adriamycin	B-Chemical	NOUN	B
cardiotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Adriamycin	B-Chemical	NOUN	B
inhibited	O	VERB	B
cell	O	NOUN	B
growth	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
rhythmic	O	ADJ	B
contractions	O	NOUN	B
characteristic	O	ADJ	B
of	O	ADP	O
myocardial	O	ADJ	B
cells	O	NOUN	I
in	O	ADP	O
culture	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
adenylate	O	ADJ	B
energy	O	NOUN	I
charge	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
significantly	O	ADV	O
decreased	O	VERB	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
phophorylcreatine	B-Chemical	NOUN	B
mole	O	NOUN	B
fraction	O	NOUN	O
was	O	AUX	O
unchanged	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
mM	O	NOUN	O
adenosine	B-Chemical	NOUN	B
to	O	PART	O
the	O	DET	O
myocardial	O	ADJ	B
cell	O	NOUN	I
cultures	O	NOUN	I
markedly	O	ADV	O
increases	O	VERB	B
the	O	DET	O
ATP	B-Chemical	NOUN	B
concentration	O	NOUN	B
through	O	ADP	O
a	O	DET	O
pathway	O	NOUN	B
reportedly	O	ADV	O
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
compartmentalized	O	ADJ	B
ATP	B-Chemical	NOUN	B
pool	O	NOUN	B
.	O	PUNCT	O


Age	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
sensitivity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
to	O	PART	O
neurotoxic	B-Disease	ADJ	B
effects	O	NOUN	O
of	O	ADP	O
streptomycin	B-Chemical	NOUN	B
.	O	PUNCT	O


Streptomycin	B-Chemical	NOUN	B
sulfate	O	NOUN	I
(	O	PUNCT	O
300	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
s	O	NOUN	O
.	O	PUNCT	O


Crescentic	O	ADJ	B
fibrillary	O	ADJ	I
glomerulonephritis	B-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
intermittent	O	ADJ	B
rifampin	B-Chemical	NOUN	O
therapy	O	NOUN	O
for	O	ADP	O
pulmonary	B-Disease	ADJ	B
tuberculosis	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
patient	O	NOUN	B
underwent	O	VERB	O
a	O	DET	O
10	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
regimen	O	NOUN	B
of	O	ADP	O
rifampin	B-Chemical	NOUN	B
and	O	CCONJ	O
isoniazid	B-Chemical	NOUN	B
for	O	ADP	O
pulmonary	B-Disease	ADJ	B
tuberculosis	I-Disease	NOUN	I
and	O	CCONJ	O
was	O	AUX	O
discovered	O	VERB	O
to	O	PART	O
have	O	AUX	O
developed	O	VERB	O
signs	O	NOUN	O
of	O	ADP	O
severe	O	ADJ	B
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
five	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
completion	O	NOUN	B
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


Renal	O	ADJ	B
biopsy	O	NOUN	I
revealed	O	VERB	O
severe	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	B
with	O	ADP	O
crescents	O	NOUN	B
,	O	PUNCT	O
electron	O	NOUN	B
dense	O	ADJ	I
fibrillar	O	ADJ	I
deposits	O	NOUN	I
and	O	CCONJ	O
moderate	O	ADJ	B
lymphocytic	O	ADJ	B
interstitial	O	ADJ	I
infiltrate	O	NOUN	I
.	O	PUNCT	O


Time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
in	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
temporal	O	ADJ	B
relationship	O	NOUN	B
between	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
and	O	CCONJ	O
proteinuria	B-Disease	NOUN	B
was	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Tissue	O	NOUN	B
lipid	O	NOUN	B
peroxidation	O	NOUN	I
was	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
whole	O	ADJ	O
homogenates	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
lipid	O	NOUN	B
extracts	O	NOUN	I
from	O	ADP	O
homogenates	O	NOUN	B
as	O	ADP	O
thiobarbituric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
reactive	O	ADJ	B
substances	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
supports	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
in	O	ADP	O
mediating	O	VERB	O
the	O	DET	O
proteinuric	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
PAN	B-Chemical	NOUN	B
nephropathy	B-Disease	NOUN	I


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
sleep	B-Disease	NOUN	B
disturbance	I-Disease	NOUN	I
,	O	PUNCT	O
induced	O	VERB	B
by	O	ADP	O
clomipramine	B-Chemical	NOUN	B
administration	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
secretory	O	ADJ	B
rate	O	NOUN	O
of	O	ADP	O
prolactin	O	NOUN	B
(	O	PUNCT	O
PRL	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
the	O	DET	O
direct	O	ADJ	O
drug	O	NOUN	B
effect	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
night	O	NOUN	B
clomipramine	B-Chemical	NOUN	B
ingestion	O	NOUN	B
altered	O	VERB	O
the	O	DET	O
complete	O	ADJ	B
sleep	O	NOUN	B
architecture	O	NOUN	O
in	O	ADP	O
that	O	SCONJ	O
it	O	PRON	O
suppressed	O	VERB	B
REM	O	NOUN	B
sleep	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
sleep	O	NOUN	B
cycles	O	NOUN	I
and	O	CCONJ	O
induced	O	VERB	B
increased	O	VERB	B
wakefulness	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
the	O	DET	O
relative	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
PRL	O	NOUN	B
secretion	O	NOUN	B
expressed	O	VERB	B
as	O	ADP	O
a	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mean	O	NOUN	O
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
night	O	NOUN	B
and	O	CCONJ	O
day	O	NOUN	B
time	O	NOUN	O
studies	O	NOUN	O
(	O	PUNCT	O
46	O	NUM	O
+/-	O	CCONJ	O
19	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
34	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
%),	O	ADJ	O
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
observed	O	VERB	B
sleep	B-Disease	NOUN	B
disturbance	I-Disease	NOUN	I
did	O	AUX	O
not	O	PART	O
interfere	O	VERB	B
with	O	ADP	I
the	O	DET	O
drug	O	NOUN	B
action	O	NOUN	I
per	O	X	O
se	O	X	O
.	O	PUNCT	O


Her	O	PRON	O
medical	O	ADJ	B
history	O	NOUN	I
included	O	VERB	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
with	O	ADP	O
previous	O	ADJ	O
myocardial	B-Disease	ADJ	B
infarctions	I-Disease	NOUN	I
,	O	PUNCT	O
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
history	O	NOUN	B
of	O	ADP	O
angioedema	B-Disease	NOUN	B
secondary	O	ADJ	B
to	O	PART	I
lisinopril	B-Chemical	NOUN	B
therapy	O	NOUN	I
was	O	AUX	O
elicited	O	VERB	O
.	O	PUNCT	O


Current	O	ADJ	B
medications	O	NOUN	B
did	O	AUX	O
not	O	PART	O
include	O	VERB	O
angiotensin	B-Chemical	NOUN	B
-	O	PUNCT	O
converting	O	VERB	B
enzyme	O	NOUN	B
inhibitors	O	NOUN	I
or	O	CCONJ	O
beta	O	NOUN	B
-	O	PUNCT	O
blockers	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
angioedema	B-Disease	NOUN	B
resolved	O	VERB	B
after	O	ADP	O
therapy	O	NOUN	B
with	O	ADP	O
intravenous	O	ADJ	B
steroids	B-Chemical	NOUN	I
and	O	CCONJ	O
diphenhydramine	B-Chemical	NOUN	B


Coniine	B-Chemical	PROPN	B
,	O	PUNCT	O
an	O	DET	O
alkaloid	O	NOUN	B
from	O	ADP	O
Conium	O	PROPN	B
maculatum	O	X	I
(	O	PUNCT	O
poison	O	NOUN	B
hemlock	O	NOUN	I
),	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
teratogenic	O	ADJ	B
in	O	ADP	O
livestock	O	NOUN	B
.	O	PUNCT	O


Concentrations	O	NOUN	B
of	O	ADP	O
coniine	B-Chemical	NOUN	B
and	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
were	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


Both	O	DET	O
compounds	O	NOUN	B
caused	O	VERB	O
deformations	B-Disease	NOUN	B
and	O	CCONJ	O
lethality	O	NOUN	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


75	O	NUM	O
%.	O	NOUN	O
The	O	DET	O
deformations	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
both	O	CCONJ	O
coniine	B-Chemical	NOUN	B
and	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
were	O	AUX	O
excessive	B-Disease	ADJ	B
flexion	I-Disease	NOUN	B
or	I-Disease	CCONJ	O
extension	I-Disease	NOUN	B
of	I-Disease	ADP	O
one	I-Disease	NUM	O
or	I-Disease	CCONJ	O
more	I-Disease	ADJ	O
toes	I-Disease	NOUN	B
.	O	PUNCT	O


01	O	NUM	O
)	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
movement	O	NOUN	B
in	O	ADP	O
coniine	B-Chemical	NOUN	B
and	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
treated	O	ADJ	B
chicks	O	NOUN	B
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
ultrasound	O	NOUN	B
.	O	PUNCT	O


95	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
a	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
min	O	NOUN	B
interval	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
movement	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
for	O	ADP	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
treated	O	ADJ	B
chicks	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
summary	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
chick	O	NOUN	B
embryo	O	NOUN	B
provides	O	VERB	O
a	O	DET	O
reliable	O	ADJ	B
and	O	CCONJ	O
simple	O	ADJ	O
experimental	O	ADJ	B
animal	O	NOUN	O
model	O	NOUN	O
of	O	ADP	O
coniine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arthrogryposis	B-Disease	NOUN	B


To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
E1	I-Chemical	NOUN	I
(	O	PUNCT	O
PGE1	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
trimethaphan	B-Chemical	NOUN	B
(	O	PUNCT	O
TMP	B-Chemical	NOUN	B
)	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
on	O	ADP	O
epidural	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
(	O	PUNCT	O
EBF	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
spinal	O	ADJ	B
surgery	O	NOUN	I
,	O	PUNCT	O
EBF	O	NOUN	B
was	O	AUX	O
measured	O	VERB	B
using	O	VERB	O
the	O	DET	O
heat	O	NOUN	B
clearance	O	NOUN	I
method	O	NOUN	I
in	O	ADP	O
30	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
underwent	O	VERB	O
postero	O	NOUN	B
-	O	PUNCT	O
lateral	O	ADJ	B
interbody	O	NOUN	B
fusion	O	NOUN	I
under	O	ADP	O
isoflurane	B-Chemical	NOUN	B
anaesthesia	O	NOUN	I
.	O	PUNCT	O


min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
TMP	B-Chemical	PROPN	B
(	O	PUNCT	O
15	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
intravenously	O	ADV	B
after	O	ADP	O
the	O	DET	O
dural	O	ADJ	B
opening	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
dose	O	NOUN	B
was	O	AUX	O
adjusted	O	VERB	O
to	O	PART	O
maintain	O	VERB	O
the	O	DET	O
mean	O	ADJ	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
(	O	PUNCT	O
MAP	O	NOUN	B
)	O	PUNCT	O
at	O	ADP	O
about	O	ADV	O
60	O	NUM	O
mmHg	O	NOUN	B
.	O	PUNCT	O


EBFF	O	NOUN	B
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
during	O	ADP	O
PGE1	B-Chemical	NOUN	B
infusion	O	NOUN	B
whereas	O	SCONJ	O
in	O	ADP	O
the	O	DET	O
TMP	B-Chemical	PROPN	B
group	O	NOUN	B
,	O	PUNCT	O
EBF	O	NOUN	B
decreased	O	VERB	B
significantly	O	ADV	O
at	O	ADP	O
30	O	NUM	O
and	O	CCONJ	O
60	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
TMP	B-Chemical	NOUN	B
(	O	PUNCT	O
preinfusion	O	NOUN	B
:	O	PUNCT	O
45	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)).	O	NOUN	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
PGE1	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
preferable	O	ADJ	O
to	O	PART	O
TMP	B-Chemical	PROPN	B
for	O	ADP	O
hypotensive	B-Disease	ADJ	B
anaesthesia	O	NOUN	I
in	O	ADP	O
spinal	O	ADJ	B
surgery	O	NOUN	I
because	O	SCONJ	O
TMP	B-Chemical	PROPN	B


Immunohistochemical	O	ADJ	B
studies	O	NOUN	I
with	O	ADP	O
antibodies	O	NOUN	B
to	O	PART	O
neurofilament	O	ADJ	B
proteins	O	NOUN	I
on	O	ADP	O
axonal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
in	O	ADP	O
experimental	O	ADJ	B
focal	O	ADJ	I
lesions	O	NOUN	I
in	O	ADP	O
rat	O	NOUN	B
.	O	PUNCT	O


Infarcts	B-Disease	NOUN	B
in	I-Disease	ADP	O
substantia	I-Disease	NOUN	B
nigra	I-Disease	NOUN	I
pars	I-Disease	X	I
reticulata	I-Disease	NOUN	I
were	O	AUX	O
evoked	O	VERB	O
by	O	ADP	O
prolonged	O	ADJ	B
pilocarpine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
status	B-Disease	NOUN	B
epilepticus	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
immunohistochemical	O	ADJ	B
changes	O	NOUN	B
of	O	ADP	O
NFs	O	NOUN	B
can	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
for	O	ADP	O
axonal	B-Disease	ADJ	B
damage	I-Disease	NOUN	O
in	O	ADP	O
various	O	ADJ	O
experimental	O	ADJ	B
traumatic	B-Disease	ADJ	B


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
increased	O	VERB	B
amount	O	NOUN	B
of	O	ADP	O
motor	B-Disease	NOUN	B
disability	I-Disease	NOUN	I
in	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
idiopathic	B-Disease	ADJ	B
Parkinson's	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
the	O	DET	O
antidepressant	B-Chemical	ADJ	B
fluoxetine	B-Chemical	NOUN	B
.	O	PUNCT	O


Acetaminophen	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
demonstrated	O	VERB	O
to	O	PART	O
produce	O	VERB	O
symptoms	O	NOUN	B
of	O	ADP	O
anaphylaxis	B-Disease	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
sensitive	O	ADJ	B
individuals	O	NOUN	B
.	O	PUNCT	O


Other	O	ADJ	O
symptoms	O	NOUN	B
of	O	ADP	O
allergic	B-Disease	ADJ	B
reactions	I-Disease	NOUN	I
were	O	AUX	O
not	O	PART	O
clinically	O	ADV	O
detectable	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
reports	O	NOUN	B
illustrate	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
clinicians	O	NOUN	B
to	O	PART	O
consider	O	VERB	O
acetaminophen	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hypotension	B-Disease	NOUN	B


An	O	DET	O
80	O	NUM	O
-	O	PUNCT	O
yr	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
developed	O	VERB	O
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
shortly	O	ADV	O
after	O	ADP	O
ingesting	O	VERB	B
oral	O	ADJ	B
ceftriaxone	B-Chemical	NOUN	I
.	O	PUNCT	O


These	O	DET	O
responded	O	VERB	O
to	O	PART	O
systemic	O	ADJ	B
steroids	B-Chemical	NOUN	I
and	O	CCONJ	O
immunoglobulins	O	NOUN	B
.	O	PUNCT	O


Conventional	O	ADJ	B
agents	O	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
unwanted	O	ADJ	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
effects	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
(	O	PUNCT	O
EPS	B-Disease	NOUN	B
),	O	PUNCT	O
tardive	B-Disease	NOUN	B
dyskinesia	I-Disease	NOUN	I
,	O	PUNCT	O
sedation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
possible	O	ADJ	O
impairment	O	NOUN	B
of	O	ADP	O
some	O	DET	O
cognitive	O	ADJ	B
measures	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
cardiac	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	B
,	O	PUNCT	O
hepatic	O	ADJ	B
changes	O	NOUN	I
,	O	PUNCT	O
anticholinergic	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
,	O	PUNCT	O
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
weight	B-Disease	NOUN	B
gain	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
newer	O	ADJ	O
atypical	O	ADJ	B
agents	O	NOUN	I
have	O	AUX	O
a	O	DET	O
lower	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
EPS	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
are	O	AUX	O
associated	O	VERB	O
in	O	ADP	O
varying	O	VERB	O
degrees	O	NOUN	B
with	O	ADP	O
sedation	O	NOUN	B
,	O	PUNCT	O
cardiovascular	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
anticholinergic	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
weight	B-Disease	NOUN	B
gain	I-Disease	NOUN	I
,	O	PUNCT	O
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
hepatic	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
lowered	O	VERB	B
seizure	B-Disease	ADJ	O
threshold	O	NOUN	B
(	O	PUNCT	O
primarily	O	ADV	O
clozapine	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
agranulocytosis	B-Disease	NOUN	B
(	O	PUNCT	O
clozapine	B-Chemical	NOUN	B


Tetrandrine	B-Chemical	NOUN	B
(	O	PUNCT	O
TET	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
fangchinoline	B-Chemical	NOUN	B
(	O	PUNCT	O
FAN	B-Chemical	NOUN	B
)	O	PUNCT	O
are	O	AUX	O
two	O	NUM	O
naturally	O	ADV	O
occurring	O	VERB	O
analogues	O	NOUN	B
with	O	ADP	O
a	O	DET	O
bisbenzylisoquinoline	B-Chemical	NOUN	B
structure	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
TET	B-Chemical	NOUN	B
and	O	CCONJ	O
FAN	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
thrombosis	B-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
collagen	O	NOUN	B
plus	O	CCONJ	O
epinephrine	B-Chemical	NOUN	B
(	O	PUNCT	O
EP	B-Chemical	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
mice	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
platelet	B-Disease	NOUN	B
aggregation	I-Disease	NOUN	I
and	O	CCONJ	O
blood	B-Disease	NOUN	B
coagulation	I-Disease	NOUN	I
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
vitro	O	X	O
human	O	ADJ	B
platelet	B-Disease	NOUN	B
aggregations	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
the	O	DET	O
agonists	O	NOUN	B
used	O	VERB	O
in	O	ADP	O
tests	O	NOUN	B
,	O	PUNCT	O
TET	B-Chemical	NOUN	B
and	O	CCONJ	O
FAN	B-Chemical	PROPN	B
showed	O	VERB	O
the	O	DET	O
inhibitions	O	NOUN	B
dose	O	NOUN	B
dependently	O	ADV	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
antithrombosis	O	NOUN	B
of	O	ADP	O
TET	B-Chemical	NOUN	B
and	O	CCONJ	O
FAN	B-Chemical	NOUN	B


Recent	O	ADJ	O
reports	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
single	O	ADJ	B
agent	O	NOUN	I
therapy	O	NOUN	I
with	O	ADP	O
vinorelbine	B-Chemical	NOUN	B
(	O	PUNCT	O
VNB	B-Chemical	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
gemcitabine	B-Chemical	NOUN	B
(	O	PUNCT	O
GEM	B-Chemical	NOUN	B
)	O	PUNCT	O
may	O	AUX	O
obtain	O	VERB	O
a	O	DET	O
response	O	NOUN	B
rate	O	NOUN	I
of	O	ADP	O
20	O	NUM	O
-	O	SYM	O
30	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
acceptable	O	ADJ	O
toxicity	B-Disease	NOUN	B
and	O	CCONJ	O
improvement	O	NOUN	B
in	O	ADP	O
symptoms	O	NOUN	B
and	O	CCONJ	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Forty	O	NUM	B
-	O	PUNCT	O
nine	O	NUM	B
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
NSCLC	B-Disease	NOUN	B
were	O	AUX	O
included	O	VERB	O
,	O	PUNCT	O
38	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
were	O	AUX	O
age	O	NOUN	B
>/=	O	NOUN	O
70	O	NUM	O
years	O	NOUN	B
and	O	CCONJ	O
11	O	NUM	O
were	O	AUX	O
age	O	NOUN	B
<	O	ADP	O
70	O	NUM	O
years	O	NOUN	B
but	O	CCONJ	O
who	O	PRON	O
had	O	AUX	O
some	O	DET	O
contraindication	O	NOUN	B
to	O	ADP	O
receiving	O	VERB	O
cisplatin	B-Chemical	NOUN	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
evaluable	O	ADJ	O
for	O	ADP	O
response	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
World	O	PROPN	B
Health	O	PROPN	I
Organization	O	PROPN	I
Grade	O	PROPN	I
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
neutropenia	B-Disease	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
Grade	O	PROPN	B
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
thrombocytopenia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
Grade	O	PROPN	B
3	O	NUM	I
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
median	O	ADJ	B
age	O	NOUN	B
of	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
developing	O	VERB	O
Grade	O	NOUN	B
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
neutropenia	B-Disease	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
patients	O	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
years	O	NOUN	B
vs	O	ADV	O
.	O	PUNCT	O


047	O	NUM	O
).	O	PUNCT	O
CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
GEM	B-Chemical	NOUN	B
and	O	CCONJ	O
VNB	B-Chemical	NOUN	B
is	O	AUX	O
moderately	O	ADV	O
active	O	ADJ	B
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	VERB	B
except	O	SCONJ	O
in	O	ADP	O
patients	O	NOUN	B
age	O	NOUN	B
>/=	O	NOUN	O
75	O	NUM	O
years	O	NOUN	B
.	O	PUNCT	O


New	O	ADJ	B
chemotherapy	O	NOUN	I
combinations	O	NOUN	B
with	O	ADP	O
higher	O	ADJ	O
activity	O	NOUN	B
and	O	CCONJ	O
lower	O	ADJ	B
toxicity	B-Disease	NOUN	B
are	O	AUX	O
needed	O	VERB	O
for	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
NSCLC	B-Disease	NOUN	B


The	O	DET	O
present	O	ADJ	O
studies	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
growth	O	NOUN	B
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
treatment	O	NOUN	B
enhance	O	VERB	B
the	O	DET	O
extent	O	NOUN	B
of	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
given	O	VERB	O
sufficient	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
Warfarin	B-Chemical	NOUN	B
to	O	PART	O
inhibit	O	VERB	B
gamma	O	NOUN	B
-	O	PUNCT	O
carboxylation	O	NOUN	B
of	O	ADP	O
matrix	O	NOUN	B
Gla	O	NOUN	I
protein	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
calcification	B-Disease	NOUN	B
inhibitor	O	NOUN	B
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
expressed	O	VERB	B
by	O	ADP	O
smooth	O	ADJ	B
muscle	O	NOUN	I
cells	O	NOUN	I
and	O	CCONJ	O
macrophages	O	NOUN	B
in	O	ADP	O
the	O	DET	O
artery	O	NOUN	B
wall	O	NOUN	I
.	O	PUNCT	O


Treatment	O	NOUN	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
with	O	ADP	O
Warfarin	B-Chemical	NOUN	B
caused	O	VERB	O
massive	O	ADJ	B
focal	O	ADJ	B
calcification	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
artery	I-Disease	NOUN	B
media	O	NOUN	I
in	O	ADP	O
20	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
rats	O	NOUN	B
and	O	CCONJ	O
less	O	ADV	O
extensive	O	ADJ	O
focal	O	ADJ	B
calcification	B-Disease	NOUN	I
in	O	ADP	O
42	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
directly	O	ADV	O
examine	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
growth	O	NOUN	B
to	O	ADP	O
Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
in	O	ADP	O
animals	O	NOUN	B
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
age	O	NOUN	B
,	O	PUNCT	O
20	O	NUM	O
-	O	PUNCT	O
day	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
rats	O	NOUN	B
were	O	AUX	O
fed	O	VERB	B
for	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
either	O	CCONJ	O
an	O	DET	O
ad	O	NOUN	B
libitum	O	NOUN	I
diet	O	NOUN	I
or	O	CCONJ	O
a	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
g	O	NOUN	B
/	O	SYM	O
d	O	NOUN	B
restricted	O	ADJ	B
diet	O	NOUN	B
that	O	PRON	O
maintains	O	VERB	B
weight	O	NOUN	B
but	O	CCONJ	O
prevents	O	VERB	B
growth	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
explanation	O	NOUN	B
for	O	ADP	O
the	O	DET	O
association	O	NOUN	B
between	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
and	O	CCONJ	O
growth	O	NOUN	B
status	O	NOUN	I
cannot	O	NOUN	O
be	O	AUX	O
determined	O	VERB	O
from	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
higher	O	ADJ	B
serum	O	NOUN	B
phosphate	B-Chemical	NOUN	I
and	O	CCONJ	O
susceptibility	O	NOUN	B
to	O	PART	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
30	O	NUM	O
%	O	NOUN	O
higher	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
phosphate	B-Chemical	NOUN	I
in	O	ADP	O
young	O	ADJ	B
,	O	PUNCT	O
ad	O	NOUN	B
libitum	O	NOUN	I
-	O	PUNCT	O
fed	O	VERB	B
rats	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
either	O	DET	O
of	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
that	O	PRON	O
was	O	AUX	O
resistant	O	ADJ	B
to	O	ADP	O
Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
,	O	PUNCT	O
ie	O	X	O
,	O	PUNCT	O
the	O	DET	O
10	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
rats	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
restricted	O	ADJ	B
-	O	PUNCT	O
diet	O	NOUN	B
,	O	PUNCT	O
growth	O	NOUN	B
-	O	PUNCT	O
inhibited	O	VERB	B
young	O	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
set	O	NOUN	O
of	O	ADP	O
experiments	O	NOUN	B
examined	O	VERB	B
the	O	DET	O
possible	O	ADJ	O
synergy	O	NOUN	B
between	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
and	O	CCONJ	O
Warfarin	B-Chemical	NOUN	B
in	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
.	O	PUNCT	O


High	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
the	O	DET	O
vitamin	B-Chemical	NOUN	B
K	I-Chemical	NOUN	I
antagonist	O	NOUN	I
Warfarin	B-Chemical	PROPN	B
are	O	AUX	O
also	O	ADV	O
known	O	VERB	O
to	O	PART	O
cause	O	VERB	O
calcification	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
artery	I-Disease	NOUN	B
media	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
at	O	ADP	O
treatment	O	NOUN	B
times	O	NOUN	O
of	O	ADP	O
2	O	NUM	O
weeks	O	NOUN	B
or	O	CCONJ	O
longer	O	ADV	O
yet	O	ADV	O
not	O	PART	O
at	O	ADP	O
1	O	NUM	O
week	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
close	O	ADJ	O
parallel	O	NOUN	O
between	O	ADP	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
dose	O	NOUN	B
on	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
and	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
dose	O	NOUN	B
on	O	ADP	O
the	O	DET	O
elevation	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I
,	O	PUNCT	O
which	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
may	O	AUX	O
induce	O	VERB	B
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
through	O	ADP	O
its	O	PRON	O
effect	O	NOUN	B
on	O	ADP	O
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I
.	O	PUNCT	O


High	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
matrix	O	NOUN	B
Gla	O	NOUN	I
protein	O	NOUN	I
are	O	AUX	O
found	O	VERB	O
at	O	ADP	O
sites	O	NOUN	B
of	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
plus	O	CCONJ	O
Warfarin	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
chemical	O	NOUN	B
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
protein	O	NOUN	B
that	O	PRON	O
accumulated	O	VERB	O
was	O	AUX	O
indeed	O	ADV	O
not	O	PART	O
gamma-carboxylated	B-Chemical	VERB	B
.	O	PUNCT	O


Antidepressant	B-Chemical	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
mania	B-Disease	NOUN	B
in	O	ADP	O
bipolar	B-Disease	ADJ	B
patients	O	NOUN	B
:	O	PUNCT	O
identification	O	NOUN	B
of	O	ADP	O
risk	O	NOUN	B
factors	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
a	O	DET	O
manic	B-Disease	ADJ	B
or	O	CCONJ	O
hypomanic	B-Disease	ADJ	B
switch	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
on	O	ADP	O
several	O	ADJ	O
variables	O	NOUN	B
including	O	VERB	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
diagnosis	O	NOUN	B
(	O	PUNCT	O
DSM-IV	B-Disease	NOUN	B
bipolar	I-Disease	NOUN	I
I	I-Disease	NUM	I
vs	O	ADV	O
.	O	PUNCT	O


bipolar	B-Disease	NOUN	B
II	I-Disease	NUM	I
),	O	PUNCT	O
number	O	NOUN	O
of	O	ADP	O
previous	O	ADJ	O
manic	B-Disease	ADJ	B
episodes	O	NOUN	I
,	O	PUNCT	O
type	O	NOUN	O
of	O	ADP	O
antidepressant	B-Chemical	ADJ	B
therapy	O	NOUN	I
used	O	VERB	O
(	O	PUNCT	O
electroconvulsive	O	ADJ	B
therapy	O	NOUN	I
vs	O	CCONJ	O
.	O	PUNCT	O


bipolar	B-Disease	NOUN	B
II	I-Disease	NUM	I
),	O	PUNCT	O
and	O	CCONJ	O
additional	O	ADJ	B
treatment	O	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
switching	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
mood	O	NOUN	B
switches	O	NOUN	I
were	O	AUX	O
less	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
lithium	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
%,	O	NOUN	O
4	O	NUM	O
/	O	SYM	O
26	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
patients	O	NOUN	B
not	O	PART	O
treated	O	VERB	B
with	O	ADP	I
lithium	B-Chemical	NOUN	B
(	O	PUNCT	O
44	O	NUM	O
%,	O	NOUN	O
8	O	NUM	O
/	O	SYM	O
18	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
=.	O	NOUN	O
04	O	NUM	O
).	O	PUNCT	O
The	O	DET	O
number	O	NOUN	O
of	O	ADP	O
previous	O	ADJ	O
manic	B-Disease	ADJ	B
episodes	O	NOUN	I
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
probability	O	NOUN	B
of	O	ADP	O
switching	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
a	O	DET	O
high	O	ADJ	B
score	O	NOUN	I
on	O	ADP	O
the	O	DET	O
hyperthymia	O	NOUN	B
component	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Semistructured	O	ADJ	B
Affective	O	ADJ	I
Temperament	O	PROPN	I
Interview	O	PROPN	I
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
greater	O	ADJ	O
risk	O	NOUN	B
of	O	ADP	O
switching	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=.	O	NOUN	O
008	O	NUM	O
).	O	NOUN	O
CONCLUSION	O	NOUN	O
:	O	PUNCT	O
The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
mood	O	NOUN	B
switching	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
acute	O	ADJ	B
antidepressant	B-Chemical	ADJ	I
therapy	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
lithium	B-Chemical	NOUN	B


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
25	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
pre	O	NOUN	B
-	O	PUNCT	O
existing	O	VERB	B
mitral	B-Disease	ADJ	B
valve	I-Disease	NOUN	I
prolapse	I-Disease	NOUN	I
who	O	PRON	O
developed	O	VERB	O
intractable	O	ADJ	B
ventricular	B-Disease	ADJ	B
fibrillation	I-Disease	NOUN	I
after	O	ADP	O
consuming	O	VERB	O
a	O	DET	O
"	O	PUNCT	O
natural	O	ADJ	B
energy	O	NOUN	I
"	O	PUNCT	O
guarana	O	NOUN	B
health	O	NOUN	B
drink	O	NOUN	I
containing	O	VERB	O
a	O	DET	O
high	O	ADJ	O
concentration	O	NOUN	B
of	O	ADP	O
caffeine	B-Chemical	NOUN	B


Fentanyl	B-Chemical	NOUN	B
,	O	PUNCT	O
an	O	DET	O
opioid	O	NOUN	B
analgesic	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
frequently	O	ADV	O
used	O	VERB	O
in	O	ADP	O
the	O	DET	O
neonatal	O	ADJ	B
intensive	O	ADJ	B
care	O	NOUN	I
unit	O	NOUN	I
setting	O	VERB	O
for	O	ADP	O
these	O	DET	O
very	O	ADJ	O
purposes	O	NOUN	O
.	O	PUNCT	O


Various	O	ADJ	O
reported	O	ADJ	O
side	O	NOUN	B
effects	O	NOUN	I
of	O	ADP	O
fentanyl	B-Chemical	NOUN	B
administration	O	NOUN	I
include	O	VERB	O
chest	B-Disease	ADJ	B
wall	I-Disease	NOUN	I
rigidity	I-Disease	NOUN	B
,	O	PUNCT	O
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
respiratory	B-Disease	ADJ	B
depression	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
.	O	PUNCT	O


Combined	O	ADJ	B
antiretroviral	O	ADJ	B
therapy	O	NOUN	I
causes	O	VERB	O
cardiomyopathy	B-Disease	NOUN	B
and	O	CCONJ	O
elevates	O	VERB	B
plasma	O	NOUN	B
lactate	B-Chemical	NOUN	I
in	O	ADP	O
transgenic	O	ADJ	B
AIDS	B-Disease	NOUN	I
mice	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
mitochondrial	O	ADJ	B
events	O	NOUN	I
from	O	ADP	O
HAART	O	NOUN	B
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
8	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
hemizygous	O	ADJ	B
transgenic	O	ADJ	I
AIDS	B-Disease	NOUN	I
mice	O	NOUN	I
(	O	PUNCT	O
NL4	O	NOUN	B
-	O	PUNCT	O
3Delta	O	NOUN	O
gag	O	NOUN	B
/	O	SYM	O
pol	O	NOUN	B
;	O	PUNCT	O
TG	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
FVB	O	PROPN	B
/	O	PUNCT	O
n	O	NOUN	B
littermates	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
the	O	DET	O
HAART	O	NOUN	B
combination	O	NOUN	B
of	O	ADP	O
zidovudine	B-Chemical	NOUN	B
,	O	PUNCT	O
lamivudine	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
indinavir	B-Chemical	NOUN	B
or	O	CCONJ	O
vehicle	O	NOUN	B
control	O	NOUN	I
for	O	ADP	O
10	O	NUM	O
days	O	NOUN	B
or	O	CCONJ	O
35	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
cumulative	O	ADJ	B
HAART	O	NOUN	B
caused	O	VERB	O
mitochondrial	O	ADJ	B
CM	B-Disease	NOUN	B
with	O	ADP	O
elevated	O	ADJ	B
LA	B-Chemical	NOUN	B
in	O	ADP	O
AIDS	B-Disease	NOUN	B


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
An	O	DET	O
association	O	NOUN	B
between	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
and	O	CCONJ	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
some	O	DET	O
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
all	O	DET	O
,	O	PUNCT	O
studies	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
this	O	DET	O
association	O	NOUN	B
,	O	PUNCT	O
according	O	VERB	O
to	O	PART	O
the	O	DET	O
type	O	NOUN	O
of	O	ADP	O
progestagen	B-Chemical	NOUN	B
included	O	VERB	O
in	O	ADP	O
third	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


Subjects	O	NOUN	B
supplied	O	VERB	O
information	O	NOUN	B
on	O	ADP	O
oral-contraceptive	B-Chemical	ADJ	B
use	O	NOUN	I
and	O	CCONJ	O
major	O	ADJ	O
cardiovascular	O	ADJ	B
risk	O	NOUN	I
factors	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
analysis	O	NOUN	B
for	O	ADP	O
factor	O	NOUN	B
V	O	PROPN	I
Leiden	O	PROPN	I
and	O	CCONJ	O
the	O	DET	O
G20210A	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
prothrombin	O	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
in	O	ADP	O
217	O	NUM	O
patients	O	NOUN	B
and	O	CCONJ	O
763	O	NUM	O
controls	O	NOUN	B
RESULTS	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
odds	O	NOUN	B
ratio	O	NOUN	I
for	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
among	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
any	O	DET	O
type	O	NOUN	O
of	O	ADP	O
combined	O	ADJ	O
oral	B-Chemical	ADJ	O
contraceptive	I-Chemical	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
nonusers	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
)	O	PUNCT	O
among	O	ADP	O
those	O	DET	O
who	O	PRON	O
used	O	VERB	O
third	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
third	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
were	O	AUX	O
inconclusive	O	ADJ	B
but	O	CCONJ	O
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
risk	O	NOUN	B
was	O	AUX	O
lower	O	ADJ	O
than	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
second	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
among	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	B


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptor	O	NOUN	I
ligands	O	NOUN	B
microinjected	O	VERB	B
into	O	ADP	O
the	O	DET	O
subregions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nucleus	O	NOUN	B
accumbens	O	NOUN	I
(	O	PUNCT	O
the	O	DET	O
shell	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
core	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
locomotor	B-Disease	NOUN	B
hyperactivity	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
cocaine	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
10	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
CP	B-Chemical	NOUN	B
93129	I-Chemical	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


When	O	SCONJ	O
injected	O	VERB	B
into	O	ADP	O
the	O	DET	O
accumbens	O	NOUN	B
shell	O	NOUN	B
(	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
the	O	DET	O
core	O	NOUN	B
)	O	PUNCT	O
before	O	ADP	O
cocaine	B-Chemical	NOUN	B
,	O	PUNCT	O
CP	B-Chemical	NOUN	B
93129	I-Chemical	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
later	O	ADJ	O
enhancement	O	NOUN	B
was	O	AUX	O
attenuated	O	VERB	B
after	O	ADP	O
intra	O	ADJ	B
-	O	PUNCT	O
accumbens	O	NOUN	B
shell	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
(	O	PUNCT	O
1	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
).	O	PUNCT	O
Our	O	PRON	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
cocaine	B-Chemical	NOUN	B
induced	O	VERB	B
hyperlocomotion	B-Disease	NOUN	B
is	O	AUX	O
modified	O	VERB	B
by	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptor	O	NOUN	I
ligands	O	NOUN	B
microinjected	O	VERB	B
into	O	ADP	O
the	O	DET	O
accumbens	O	NOUN	B
shell	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
core	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
modification	O	NOUN	B
consisting	O	VERB	O
in	O	ADP	O
inhibitory	O	ADJ	B
and	O	CCONJ	O
facilitatory	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptor	O	NOUN	I
antagonist	O	NOUN	I
(	O	PUNCT	O
GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
agonist	O	NOUN	B
(	O	PUNCT	O
CP	B-Chemical	NOUN	B
93129	I-Chemical	NUM	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
2	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
,	O	PUNCT	O
investigate	O	VERB	B
its	O	PRON	O
mechanism	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
compare	O	VERB	B
the	O	DET	O
observed	O	VERB	O
main	O	ADJ	O
characteristics	O	NOUN	B
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
published	O	VERB	B
cases	O	NOUN	I
.	O	PUNCT	O


T	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
stimulation	O	NOUN	B
by	O	ADP	O
therapeutic	O	ADJ	B
concentration	O	NOUN	B
of	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
was	O	AUX	O
demonstrated	O	VERB	O
in	O	X	B
vitro	O	X	I
in	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
healthy	O	ADJ	B
controls	O	NOUN	I
.	O	PUNCT	O


DISCUSSION	O	NOUN	O
:	O	PUNCT	O
Cholestatic	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	O
complication	O	NOUN	B
of	O	ADP	O
the	O	DET	O
antiplatelet	O	NOUN	B
agent	O	NOUN	I
ticlopidine	B-Chemical	NOUN	B
;	O	PUNCT	O
several	O	ADJ	O
cases	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
but	O	CCONJ	O
few	O	ADJ	O
in	O	ADP	O
the	O	DET	O
English	O	ADJ	B
literature	O	NOUN	I
.	O	PUNCT	O


Hepatitis	B-Disease	NOUN	B
may	O	AUX	O
develop	O	VERB	O
weeks	O	NOUN	B
after	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
run	O	VERB	O
a	O	DET	O
prolonged	O	ADJ	B
course	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
complete	O	ADJ	O
remission	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
all	O	DET	O
reported	O	VERB	O
cases	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mechanisms	O	NOUN	B
of	O	ADP	O
this	O	DET	O
ticlopidine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cholestasis	B-Disease	NOUN	B
are	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


This	O	DET	O
complication	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
observed	O	VERB	B
even	O	ADV	O
less	O	ADV	O
often	O	ADV	O
in	O	ADP	O
the	O	DET	O
future	O	NOUN	O
as	O	ADP	O
ticlopidine	B-Chemical	NOUN	B
is	O	AUX	O
being	O	AUX	O
replaced	O	VERB	O
by	O	ADP	O
the	O	DET	O
newer	O	ADJ	O
antiplatelet	O	NOUN	B
agent	O	NOUN	I
clopidogrel	B-Chemical	NOUN	B


Epithelial	O	ADJ	B
sodium	B-Chemical	NOUN	I
channel	O	NOUN	I
(	O	PUNCT	O
ENaC	O	NOUN	O
)	O	PUNCT	O
subunit	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
rate	O	NOUN	B
-	O	PUNCT	O
limiting	O	VERB	B
constituent	O	NOUN	B
of	O	ADP	O
collecting	O	VERB	O
duct	O	NOUN	B
sodium	B-Chemical	NOUN	I
transport	O	NOUN	I
is	O	AUX	O
the	O	DET	O
epithelial	O	ADJ	B
sodium	B-Chemical	NOUN	I
channel	O	NOUN	I
(	O	PUNCT	O
ENaC	O	NOUN	B
).	O	PUNCT	O
We	O	PRON	O
examined	O	VERB	O
the	O	DET	O
abundance	O	NOUN	B
of	O	ADP	O
ENaC	O	NOUN	B
subunit	O	NOUN	I
mRNAs	O	NOUN	B
and	O	CCONJ	O
proteins	O	NOUN	B
in	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
nephrotic	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
kinetics	O	NOUN	B
of	O	ADP	O
urinary	O	ADJ	B
sodium	B-Chemical	NOUN	I
excretion	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
appearance	O	NOUN	B
of	O	ADP	O
proteinuria	B-Disease	NOUN	B
were	O	AUX	O
comparable	O	ADJ	O
with	O	ADP	O
those	O	DET	O
reported	O	VERB	O
previously	O	ADV	O
.	O	PUNCT	O


A	O	DET	O
significant	O	ADJ	O
up	O	ADV	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
alphaENaC	O	NOUN	B
and	O	CCONJ	O
betaENaC	O	NOUN	B
mRNA	O	NOUN	B
abundance	O	NOUN	B
on	O	ADP	O
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
preceded	O	VERB	O
sodium	B-Chemical	NOUN	B
retention	O	NOUN	I
on	O	ADP	O
days	O	NOUN	B
2	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
amounts	O	NOUN	O
of	O	ADP	O
alphaENaC	O	NOUN	B
,	O	PUNCT	O
betaENaC	O	NOUN	B
and	O	CCONJ	O
gammaENaC	O	NOUN	B
proteins	O	NOUN	I
were	O	AUX	O
not	O	PART	O
increased	O	VERB	B
during	O	ADP	O
PAN	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
sodium	B-Chemical	NOUN	B
retention	O	NOUN	I
.	O	PUNCT	O


NO	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
:	O	PUNCT	O
strong	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
calcitonin	B-Chemical	NOUN	O
gene-related	I-Chemical	ADJ	O
peptide	I-Chemical	NOUN	O
(	O	PUNCT	O
CGRP	B-Chemical	NOUN	B
)	O	PUNCT	O
concentration	O	NOUN	B
and	O	CCONJ	O
negative	O	ADJ	B
correlation	O	NOUN	B
with	O	ADP	O
platelet	O	NOUN	B
serotonin	B-Chemical	NOUN	I
release	O	NOUN	B
.	O	PUNCT	O


Fifteen	O	NUM	O
female	O	ADJ	B
migraineurs	B-Disease	NOUN	I
(without	I-Disease	ADP	O
aura)	I-Disease	ADJ	B
and	O	CCONJ	O
eight	O	NUM	O
controls	O	NOUN	B
participated	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Blood	O	NOUN	B
was	O	AUX	O
collected	O	VERB	O
from	O	ADP	O
the	O	DET	O
antecubital	O	ADJ	B
vein	O	NOUN	I
four	O	NUM	O
times	O	NOUN	O
:	O	PUNCT	O
60	O	NUM	O
min	O	NOUN	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
the	O	DET	O
nitroglycerin	B-Chemical	NOUN	B
application	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
60	O	NUM	O
and	O	CCONJ	O
120	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
the	O	DET	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
344	O	NUM	O
and	O	CCONJ	O
404	O	NUM	O
min	O	NOUN	O
;	O	PUNCT	O
12	O	NUM	O
subjects	O	NOUN	B
).	O	PUNCT	B
In	O	ADP	O
those	O	DET	O
subjects	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
no	O	DET	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
subjects	O	NOUN	B
)	O	PUNCT	O
a	O	DET	O
similar	O	ADJ	O
time	O	NOUN	B
schedule	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
.	O	PUNCT	O


Plasma	O	NOUN	B
CGRP	B-Chemical	NOUN	B
concentration	O	NOUN	B
increased	O	VERB	B
significantly	O	ADV	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
both	O	DET	O
change	O	NOUN	B
and	O	CCONJ	O
peak	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
significant	O	ADJ	O
positive	O	ADJ	B
correlations	O	NOUN	B
with	O	ADP	O
migraine	B-Disease	NOUN	B
headache	B-Disease	NOUN	I
intensity	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


Basal	O	ADJ	B
CGRP	B-Chemical	NOUN	B
concentration	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
and	O	CCONJ	O
platelet	O	NOUN	B
5-HT	B-Chemical	NOUN	I
content	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
lower	O	ADJ	O
in	O	ADP	O
subjects	O	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
a	O	DET	O
migraine	B-Disease	NOUN	B
attack	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
plasma	O	NOUN	B
CGRP	B-Chemical	NOUN	B
concentration	O	NOUN	B
correlates	O	VERB	B
with	O	ADP	O
the	O	DET	O
timing	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
a	O	DET	O
migraine	B-Disease	NOUN	B
headache	B-Disease	NOUN	I
suggests	O	VERB	O
a	O	DET	O
direct	O	ADJ	O
relationship	O	NOUN	B
between	O	ADP	O
CGRP	B-Chemical	NOUN	B
and	O	CCONJ	O
migraine	B-Disease	NOUN	B
.	O	PUNCT	O


Coronary	B-Disease	ADJ	B
aneurysm	I-Disease	NOUN	I
after	O	ADP	O
implantation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
paclitaxel	B-Chemical	NOUN	B
-	O	PUNCT	O
eluting	O	VERB	B
stent	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
asymptomatic	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
aneurysm	B-Disease	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
a	O	DET	O
routine	O	ADJ	O
control	O	NOUN	B
.	O	PUNCT	O


Behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
urotensin-II	B-Chemical	NOUN	B
centrally	O	ADV	O
administered	O	VERB	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


v	O	DET	O
.)	O	ADJ	O
injection	O	NOUN	B
of	O	ADP	O
U-II	B-Chemical	NOUN	B
causes	O	VERB	O
hypertension	B-Disease	NOUN	B
and	O	CCONJ	O
bradycardia	B-Disease	NOUN	B
and	O	CCONJ	O
stimulates	O	VERB	B
prolactin	O	NOUN	B
and	O	CCONJ	O
thyrotropin	O	NOUN	B
secretion	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
centrally	O	ADV	B
administered	O	VERB	I
U-II	B-Chemical	NOUN	B
have	O	AUX	O
received	O	VERB	O
little	O	ADJ	O
attention	O	NOUN	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
graded	O	VERB	B
doses	O	NOUN	I
of	O	ADP	O
U-II	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
-	O	SYM	O
10	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mouse	O	NOUN	B
)	O	PUNCT	O
provoked	O	VERB	O
:(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
head	O	NOUN	B
dips	O	NOUN	I
in	O	ADP	O
the	O	DET	O
hole	O	NOUN	B
-	O	PUNCT	O
board	O	NOUN	B
test	O	NOUN	I
;(	O	ADV	O
2	O	X	O
)	O	PUNCT	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
reduction	O	NOUN	B
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
entries	O	NOUN	B
in	O	ADP	O
the	O	DET	O
white	O	ADJ	B
chamber	O	NOUN	I
in	O	ADP	O
the	O	DET	O
black	O	ADJ	B
-	O	PUNCT	O
and	O	CCONJ	O
-	O	PUNCT	O
white	O	ADJ	B
compartment	O	NOUN	O
test	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
entries	O	NOUN	B
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
platform	O	NOUN	I
and	O	CCONJ	O
open	O	ADJ	O
arms	O	NOUN	O
in	O	ADP	O
the	O	DET	O
plus	O	CCONJ	B
-	O	PUNCT	O
maze	O	NOUN	B
test	O	NOUN	O
;	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
duration	O	NOUN	B
of	O	ADP	O
immobility	O	NOUN	B
in	O	ADP	O
the	O	DET	O
forced	O	VERB	B
-	O	PUNCT	O
swimming	O	NOUN	B
test	O	NOUN	B
and	O	CCONJ	O
tail	O	NOUN	B
suspension	O	NOUN	I
test	O	NOUN	I
.	O	PUNCT	O


Taken	O	VERB	O
together	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
demonstrates	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
central	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
U-II	B-Chemical	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
-	O	SYM	O
10	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
ng	O	NOUN	O
/	O	SYM	O
mouse	O	NOUN	B
induces	O	VERB	O
anxiogenic	O	ADJ	B
-	O	PUNCT	O
and	O	CCONJ	O
depressant	O	ADJ	B
-	O	PUNCT	O
like	O	ADJ	B
effects	O	NOUN	B
in	O	ADP	O
mouse	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
U-II	B-Chemical	NOUN	B
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
some	O	DET	O
aspects	O	NOUN	O
of	O	ADP	O
psychiatric	B-Disease	ADJ	B
disorders	I-Disease	NOUN	I


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
woman	O	NOUN	B
complaining	O	NOUN	O
of	O	ADP	O
dysphonia	B-Disease	NOUN	B
while	O	SCONJ	O
she	O	PRON	O
was	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
acitretin	B-Chemical	NOUN	B
.	O	PUNCT	O


Pharmacological	O	ADJ	B
modulation	O	NOUN	O
of	O	ADP	O
pain	B-Disease	NOUN	B
-	O	PUNCT	O
related	O	ADJ	B
brain	O	NOUN	B
activity	O	NOUN	I
during	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
central	O	ADJ	B
sensitization	O	NOUN	I
states	O	NOUN	I
in	O	ADP	O
humans	O	NOUN	B
.	O	PUNCT	O


Abnormal	O	ADJ	B
brain	O	NOUN	B
responses	O	NOUN	I
to	O	PART	O
somatosensory	O	ADJ	B
stimuli	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hyperalgesia	B-Disease	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
normal	O	ADJ	B
subjects	O	NOUN	I
during	O	ADP	O
experimental	O	ADJ	B
central	O	ADJ	I
sensitization	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
gabapentin	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
drug	O	NOUN	B
effective	O	ADJ	B
in	O	ADP	O
neuropathic	B-Disease	ADJ	B
pain	I-Disease	NOUN	I
patients	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
brain	O	NOUN	B
processing	O	NOUN	I
of	O	ADP	O
nociceptive	O	ADJ	B
information	O	NOUN	B
in	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
central	O	ADJ	B
sensitization	O	NOUN	I
states	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
gabapentin	B-Chemical	NOUN	B
was	O	AUX	O
1	O	NUM	O
,	O	PUNCT	O
800	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
os	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
administration	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
gabapentin	B-Chemical	NOUN	B
has	O	AUX	O
a	O	DET	O
measurable	O	ADJ	O
antinociceptive	O	ADJ	B
effect	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
stronger	O	ADJ	O
antihyperalgesic	O	ADJ	B
effect	O	NOUN	I
most	O	ADV	O
evident	O	ADJ	O
in	O	ADP	O
the	O	DET	O
brain	O	NOUN	B
areas	O	NOUN	I
undergoing	O	VERB	O
deactivation	O	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
supporting	O	VERB	O
the	O	DET	O
concept	O	NOUN	B
that	O	SCONJ	O
gabapentin	B-Chemical	NOUN	B


MDMA	B-Chemical	NOUN	B
polydrug	O	NOUN	O
users	O	NOUN	O
show	O	VERB	O
process	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
central	O	ADJ	B
executive	O	ADJ	I
impairments	O	NOUN	I
coupled	O	VERB	O
with	O	ADP	O
impaired	B-Disease	ADJ	B
social	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
emotional	I-Disease	ADJ	B
judgement	I-Disease	NOUN	B
processes	I-Disease	NOUN	O
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
lend	O	VERB	O
further	O	ADJ	O
support	O	NOUN	O
to	O	ADP	O
the	O	DET	O
proposal	O	NOUN	B
that	O	SCONJ	O
cognitive	O	ADJ	B
processes	O	NOUN	I
mediated	O	VERB	O
by	O	ADP	O
the	O	DET	O
prefrontal	O	ADJ	B
cortex	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
impaired	O	VERB	B
by	O	ADP	O
recreational	O	ADJ	B
ecstasy	B-Chemical	NOUN	B


Severe	O	ADJ	B
citrate	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
complicating	O	VERB	O
volunteer	O	NOUN	B
apheresis	O	NOUN	B
platelet	O	NOUN	B
donation	O	NOUN	I
.	O	PUNCT	O


She	O	PRON	O
then	O	ADV	O
very	O	ADV	O
rapidly	O	ADV	O
developed	O	VERB	O
acute	O	ADJ	B
onset	O	NOUN	O
of	O	ADP	O
severe	O	ADJ	B
facial	O	ADJ	B
and	O	CCONJ	O
extremity	O	NOUN	B
tetany	B-Disease	NOUN	I
.	O	PUNCT	O


Empirical	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
intravenous	O	ADJ	B
calcium	B-Chemical	NOUN	O
gluconate	I-Chemical	NOUN	O
was	O	AUX	O
initiated	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
muscle	B-Disease	NOUN	B
contractions	I-Disease	NOUN	I
slowly	O	ADV	O
subsided	O	VERB	O
over	O	ADP	O
approximately	O	ADV	O
10	O	NUM	O
to	O	PART	O
15	O	NUM	O
minutes	O	NOUN	B
.	O	PUNCT	O


Upon	O	SCONJ	O
additional	O	ADJ	O
retrospective	O	ADJ	B
analysis	O	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
noted	O	VERB	O
that	O	SCONJ	O
bumetanide	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
loop	B-Chemical	NOUN	B
diuretic	I-Chemical	ADJ	B
that	O	PRON	O
may	O	AUX	O
cause	O	VERB	O
significant	O	ADJ	O
hypocalcemia	B-Disease	NOUN	B
.	O	PUNCT	O


Laboratory	O	ADJ	B
measurement	O	NOUN	I
of	O	ADP	O
pre	O	ADJ	B
-	O	PUNCT	O
procedure	O	NOUN	B
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I


Proteinuria	B-Disease	NOUN	B
after	O	ADP	O
conversion	O	NOUN	B
to	O	PART	O
sirolimus	B-Chemical	NOUN	B
in	O	ADP	O
renal	O	ADJ	B
transplant	O	NOUN	I
recipients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
retrospectively	O	ADV	B
examined	O	VERB	O
the	O	DET	O
records	O	NOUN	B
of	O	ADP	O
25	O	NUM	O
renal	O	ADJ	B
transplant	O	NOUN	I
patients	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
developed	O	VERB	O
or	O	CCONJ	O
displayed	O	VERB	O
increased	O	VERB	B
proteinuria	B-Disease	NOUN	B
after	O	ADP	O
SRL	B-Chemical	NOUN	B
conversion	O	NOUN	B
.	O	PUNCT	O


Mean	O	VERB	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
on	O	ADP	O
SRL	B-Chemical	NOUN	B
therapy	O	NOUN	B
was	O	AUX	O
20	O	NUM	O
+/-	O	CCONJ	O
12	O	NUM	O
(	O	PUNCT	O
6	O	NUM	O
to	O	PART	O
43	O	NUM	O
)	O	PUNCT	O
months	O	NOUN	B
.	O	PUNCT	O


001	O	NUM	O
).	O	PUNCT	O
Before	O	ADP	O
conversion	O	NOUN	B
8	O	NUM	O
(	O	PUNCT	O
32	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
had	O	AUX	O
no	O	DET	O
proteinuria	B-Disease	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
afterwards	O	ADV	O
all	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
proteinuria	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
it	O	PRON	O
increased	O	VERB	B
by	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
100	O	NUM	O
%.	O	NOUN	O
Twenty	O	NUM	B
-	O	PUNCT	O
eight	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
showed	O	VERB	O
increased	O	VERB	B
proteinuria	B-Disease	NOUN	B
to	O	PART	O
the	O	DET	O
nephrotic	B-Disease	ADJ	B
range	O	NOUN	O
.	O	PUNCT	O


8	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
before	O	ADP	O
SRL	B-Chemical	NOUN	B
therapy	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


Five	O	NUM	O
patients	O	NOUN	B
displayed	O	VERB	O
CAN	B-Disease	NOUN	B
and	O	CCONJ	O
Kaposi's	B-Disease	NOUN	B
sarcoma	I-Disease	NOUN	I
.	O	PUNCT	O


93	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dL	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=.	O	NOUN	O
02	O	NUM	O
).	O	PUNCT	O
Heavy	O	ADJ	B
proteinuria	B-Disease	NOUN	I
was	O	AUX	O
common	O	ADJ	O
after	O	ADP	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
SRL	B-Chemical	PROPN	B
as	O	ADP	O
rescue	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
renal	O	ADJ	B
transplantation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
de	O	X	O
novo	O	X	O
glomerular	O	ADJ	B
pathology	O	NOUN	B
under	O	ADP	O
SRL	B-Chemical	PROPN	B


In	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cystitis	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
,	O	PUNCT	O
detrusor	O	NOUN	B
function	O	NOUN	I
is	O	AUX	O
impaired	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
expression	O	NOUN	B
and	O	CCONJ	O
effects	O	NOUN	B
of	O	ADP	O
muscarinic	O	ADJ	B
receptors	O	NOUN	I
altered	O	VERB	O
.	O	PUNCT	O


Whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
the	O	DET	O
neuronal	O	ADJ	B
transmission	O	NOUN	O
may	O	AUX	O
be	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
cystitis	B-Disease	NOUN	B
was	O	AUX	O
presently	O	ADV	O
investigated	O	VERB	B
.	O	PUNCT	O


Generally	O	ADV	O
,	O	PUNCT	O
atropine	B-Chemical	NOUN	B
reduced	O	VERB	B
contractions	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
controls	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
also	O	ADV	O
reduced	O	VERB	B
responses	O	NOUN	B
to	O	PART	O
low	O	ADJ	B
electrical	O	ADJ	B
field	O	NOUN	I
stimulation	O	NOUN	I
intensity	O	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
-	O	PUNCT	O
5	O	NUM	O
Hz	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
inflamed	O	ADJ	B
preparations	O	NOUN	B
.	O	PUNCT	O


4-DAMP	B-Chemical	NOUN	B
inhibited	O	VERB	B
the	O	DET	O
tonic	O	ADJ	B
contractions	O	NOUN	B
in	O	ADP	O
controls	O	NOUN	B
more	O	ADV	O
potently	O	ADV	O
than	O	ADP	O
methoctramine	B-Chemical	NOUN	B
and	O	CCONJ	O
pirenzepine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
controls	O	NOUN	B
,	O	PUNCT	O
methoctramine	B-Chemical	NOUN	B
increased	O	VERB	B
--	O	PUNCT	O
instead	O	ADV	O
of	O	ADP	O
decreased	O	VERB	B
--	O	PUNCT	O
the	O	DET	O
tonic	O	ADJ	B
responses	O	NOUN	I
at	O	ADP	O
high	O	ADJ	O
frequencies	O	NOUN	B
.	O	PUNCT	O


Associations	O	NOUN	B
between	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
benzodiazepines	B-Chemical	NOUN	B
or	O	CCONJ	O
related	O	ADJ	O
drugs	O	NOUN	B
and	O	CCONJ	O
health	O	NOUN	B
,	O	PUNCT	O
physical	O	ADJ	B
abilities	O	NOUN	I
and	O	CCONJ	O
cognitive	O	ADJ	B
function	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
non	O	ADV	B
-	O	PUNCT	O
randomised	O	VERB	B
clinical	O	ADJ	B
study	O	NOUN	I
in	O	ADP	O
the	O	DET	O
elderly	O	ADJ	B
.	O	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
nearly	O	ADV	O
half	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
78	O	NUM	O
)	O	PUNCT	O
had	O	AUX	O
used	O	VERB	O
BZDs	B-Chemical	PROPN	B
/	O	SYM	O
RDs	O	NOUN	B
before	O	ADP	O
admission	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
remainder	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
86	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
non	O	ADJ	B
-	O	PUNCT	O
users	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
residual	O	ADJ	B
serum	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
oxazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
temazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
zopiclone	B-Chemical	NOUN	B
were	O	AUX	O
analysed	O	VERB	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
use	O	NOUN	O
of	O	ADP	O
BZDs	B-Chemical	NOUN	B
/	O	SYM	O
RDs	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
dizziness	B-Disease	NOUN	B
,	O	PUNCT	O
inability	B-Disease	NOUN	O
to	I-Disease	PART	O
sleep	I-Disease	VERB	B
after	O	ADP	O
awaking	O	VERB	B
at	O	ADP	O
night	O	NOUN	B
and	O	CCONJ	O
tiredness	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
mornings	O	NOUN	B
during	O	ADP	O
the	O	DET	O
week	O	NOUN	B
prior	O	ADV	O
to	O	ADP	O
admission	O	NOUN	B
and	O	CCONJ	O
with	O	ADP	O
stronger	O	ADJ	B
depressive	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
measured	O	VERB	B
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
the	O	DET	O
hospital	O	NOUN	B
stay	O	NOUN	I
.	O	PUNCT	O


Use	O	PROPN	O
of	O	ADP	O
BZDs	B-Chemical	PROPN	B
/	O	PUNCT	O
RDs	O	NOUN	B
tended	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
reduced	O	VERB	B
ability	O	NOUN	O
to	O	PART	O
walk	O	VERB	B
and	O	CCONJ	O
shorter	O	ADJ	B
night	O	NOUN	B
-	O	PUNCT	O
time	O	NOUN	B
sleep	O	NOUN	O
during	O	ADP	O
the	O	DET	O
week	O	NOUN	B
prior	O	ADV	O
to	O	ADP	O
admission	O	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
peripheral	B-Disease	ADJ	I
neuropathy	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
disulfiram	B-Chemical	NOUN	B
overdose	B-Disease	NOUN	B
is	O	AUX	O
very	O	ADV	O
rare	O	ADJ	B
and	O	CCONJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
report	O	NOUN	O
of	O	ADP	O
it	O	PRON	O
leading	O	VERB	O
to	O	PART	O
vocal	B-Disease	ADJ	B
fold	I-Disease	ADJ	I
palsy	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
49	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
was	O	AUX	O
transferred	O	VERB	B
to	O	ADP	O
our	O	PRON	O
department	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
quadriparesis	B-Disease	NOUN	B
,	O	PUNCT	O
lancinating	O	VERB	B
pain	B-Disease	NOUN	I
,	O	PUNCT	O
sensory	B-Disease	ADJ	B
loss	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
paresthesia	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
distal	O	ADJ	B
limbs	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
month	O	NOUN	B
previously	O	ADV	O
,	O	PUNCT	O
she	O	PRON	O
had	O	AUX	O
taken	O	VERB	O
a	O	DET	O
single	O	ADJ	O
high	O	ADJ	O
dose	O	NOUN	B
of	O	ADP	O
disulfiram	B-Chemical	NOUN	B
(	O	PUNCT	O
130	O	NUM	O
tablets	O	NOUN	B
of	O	ADP	O
ALCOHOL	B-Chemical	NOUN	B
STOP	O	NOUN	I
TAB	O	NOUN	I
,	O	PUNCT	O
Shin	O	PROPN	B
-	O	PUNCT	O
Poong	O	PROPN	B
Pharm	O	PROPN	I
.	O	PUNCT	O


She	O	PRON	O
noticed	O	VERB	O
hoarseness	B-Disease	ADJ	B
and	O	CCONJ	O
distally	O	ADV	B
accentuated	O	ADJ	I
motor	O	NOUN	B
and	O	CCONJ	O
sensory	O	ADJ	B
dysfunction	O	NOUN	I
after	O	ADP	O
she	O	PRON	O
had	O	AUX	O
recovered	O	VERB	O
from	O	ADP	O
this	O	DET	O
state	O	NOUN	B
.	O	PUNCT	O


Higher	O	ADJ	B
optical	O	ADJ	B
density	O	NOUN	I
of	O	ADP	O
an	O	DET	O
antigen	O	NOUN	B
assay	O	NOUN	I
predicts	O	VERB	O
thrombosis	B-Disease	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
.	O	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Patients	O	NOUN	B
with	O	ADP	O
more	O	ADJ	O
than	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
decrease	O	NOUN	B
in	O	ADP	O
platelet	O	NOUN	B
count	O	NOUN	I
or	O	CCONJ	O
thrombocytopenia	B-Disease	NOUN	B
(<	O	NOUN	O
150	O	NUM	O
x	O	CCONJ	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)/	O	PROPN	B
L	O	NOUN	I
)	O	PUNCT	O
after	O	ADP	O
exposure	O	NOUN	B
to	O	PART	I
heparin	B-Chemical	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
had	O	AUX	O
a	O	DET	O
positive	O	ADJ	B
two	O	NUM	O
-	O	PUNCT	O
step	O	NOUN	B
antigen	O	NOUN	O
assay	O	NOUN	O
[	O	PUNCT	O
optical	O	ADJ	B
density	O	NOUN	I
(	O	PUNCT	O
OD	O	NOUN	B
)>	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Forty	O	NUM	O
of	O	ADP	O
94	O	NUM	O
HIT	B-Disease	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
thrombosis	B-Disease	NOUN	B
at	O	ADP	O
diagnosis	O	NOUN	B
;	O	PUNCT	O
54	O	NUM	O
/	O	SYM	O
94	O	NUM	O
had	O	AUX	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B
without	O	ADP	O
thrombosis	B-Disease	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
diagnosis	O	NOUN	B
there	O	PRON	O
was	O	AUX	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
in	O	ADP	O
OD	O	NOUN	B
between	O	ADP	O
HIT	B-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
thrombosis	B-Disease	NOUN	B
and	O	CCONJ	O
those	O	DET	O
with	O	ADP	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B
.	O	PUNCT	O


89	O	NUM	O
),	O	PUNCT	O
including	O	VERB	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B
patients	O	NOUN	B
who	O	PRON	O
later	O	ADV	O
developed	O	VERB	O
thrombosis	B-Disease	NOUN	B
within	O	ADP	O
30	O	NUM	O
d	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
8	O	NUM	O
,	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


27	O	NUM	O
in	O	ADP	O
the	O	DET	O
isolated	O	VERB	B
-	O	PUNCT	O
HIT	B-Disease	NOUN	B
group	O	NOUN	B
had	O	AUX	O
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
chance	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
thrombosis	B-Disease	NOUN	B
by	O	ADP	O
day	O	NOUN	B
30	O	NUM	O
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
thrombotic	B-Disease	ADJ	B
risk	O	NOUN	I
increased	O	VERB	B
with	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
OD	O	NOUN	B
values	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
central	O	ADJ	B
retinal	B-Disease	ADJ	I
vein	I-Disease	NOUN	I
occlusion	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
clomiphene	B-Chemical	NOUN	B
citrate	I-Chemical	NOUN	I
(	O	PUNCT	O
CC	B-Chemical	NOUN	B
).	O	PUNCT	O
DESIGN	O	NOUN	O
:	O	PUNCT	O
Case	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


PATIENT	O	NOUN	B
(	O	PUNCT	O
S	O	PROPN	B
):	O	PUNCT	O
A	O	PROPN	O
36	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
referred	O	VERB	O
from	O	ADP	O
the	O	DET	O
infertility	B-Disease	NOUN	B
clinic	O	NOUN	B
for	O	ADP	O
blurred	B-Disease	ADJ	B
vision	I-Disease	NOUN	I
.	O	PUNCT	O


INTERVENTION	O	NOUN	B
(	O	PUNCT	O
S	O	PROPN	B
):	O	PUNCT	O
Ophthalmic	O	ADJ	B
examination	O	NOUN	I
after	O	ADP	O
CC	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


RESULT	O	NOUN	B
(	O	PUNCT	O
S	O	NOUN	B
):	O	PUNCT	O
A	O	PROPN	O
36	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
Chinese	O	ADJ	B
woman	O	NOUN	B
developed	O	VERB	O
central	O	ADJ	B
retinal	B-Disease	ADJ	I
vein	I-Disease	NOUN	I
occlusion	I-Disease	NOUN	I
after	O	ADP	O
eight	O	NUM	O
courses	O	NOUN	B
of	O	ADP	O
CC	B-Chemical	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
(	O	PUNCT	O
S	O	NOUN	B
):	O	PUNCT	O
This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
reported	O	VERB	O
case	O	NOUN	B
of	O	ADP	O
central	O	ADJ	B
retinal	B-Disease	ADJ	I
vein	I-Disease	NOUN	I
occlusion	I-Disease	NOUN	I
after	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
CC	B-Chemical	NOUN	B
.	O	PUNCT	O


Nicotine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nystagmus	B-Disease	NOUN	B
correlates	O	VERB	O
with	O	ADP	O
midpontine	O	ADJ	B
activation	O	NOUN	B
.	O	PUNCT	O


NIN	B-Disease	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
blood	O	NOUN	B
oxygen	B-Chemical	NOUN	I
level	O	NOUN	I
-	O	PUNCT	O
dependent	O	ADJ	B
(	O	PUNCT	O
BOLD	O	NOUN	B
)	O	PUNCT	O
activity	O	NOUN	B
levels	O	NOUN	O
in	O	ADP	O
a	O	DET	O
midpontine	O	ADJ	B
site	O	NOUN	B
in	O	ADP	O
the	O	DET	O
posterior	O	ADJ	B
basis	O	NOUN	O
pontis	O	NOUN	B
.	O	PUNCT	O


NIN	B-Disease	NOUN	B


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
gastric	O	ADJ	B
acid	O	NOUN	I
back	O	NOUN	I
-	O	PUNCT	O
diffusion	O	NOUN	B
,	O	PUNCT	O
mast	O	NOUN	B
cell	O	NOUN	I
histamine	B-Chemical	NOUN	B
release	O	NOUN	B
,	O	PUNCT	O
lipid	O	NOUN	B
peroxide	O	NOUN	I
(	O	PUNCT	O
LPO	O	NOUN	B
)	O	PUNCT	O
generation	O	NOUN	B
and	O	CCONJ	O
mucosal	O	ADJ	B
microvascular	O	ADJ	O
permeability	O	NOUN	O
in	O	ADP	O
modulating	O	VERB	B
gastric	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
and	O	CCONJ	O
ulcer	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
atherosclerosis	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
coadministration	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D2	I-Chemical	NOUN	I
and	O	CCONJ	O
cholesterol	B-Chemical	NOUN	B
.	O	PUNCT	O


0	O	NUM	O
ml	O	NOUN	O
/	O	PUNCT	O
kg	O	NOUN	B
of	O	ADP	O
corn	O	NOUN	B
oil	O	NOUN	I
containing	O	VERB	O
vitamin	B-Chemical	NOUN	B
D2	I-Chemical	NOUN	I
and	O	CCONJ	O
cholesterol	B-Chemical	NOUN	B
to	O	PART	O
induce	O	VERB	B
atherosclerosis	B-Disease	NOUN	B
.	O	PUNCT	O


Elevated	O	ADJ	B
atherosclerotic	B-Disease	ADJ	B
parameters	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I
,	O	PUNCT	O
total	O	ADJ	B
cholesterol	B-Chemical	NOUN	I
and	O	CCONJ	O
low	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
lipoprotein	O	NOUN	O
concentration	O	NOUN	O
were	O	AUX	O
obtained	O	VERB	O
in	O	ADP	O
atherosclerotic	B-Disease	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
positive	O	ADJ	B
correlation	O	NOUN	B
of	O	ADP	O
histamine	B-Chemical	NOUN	B
to	O	PART	O
gastric	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
and	O	CCONJ	O
to	O	PART	O
ulcer	B-Disease	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
those	O	DET	O
atherosclerotic	B-Disease	ADJ	B
rats	O	NOUN	B
.	O	PUNCT	O


Atherosclerosis	B-Disease	NOUN	B
could	O	AUX	O
produce	O	VERB	O
gastric	B-Disease	ADJ	B
hemorrhagic	I-Disease	ADJ	I
ulcer	B-Disease	NOUN	I
via	O	ADP	O
aggravation	O	NOUN	B
of	O	ADP	O
gastric	O	ADJ	B
acid	O	NOUN	I
back	O	NOUN	I
-	O	PUNCT	O
diffusion	O	NOUN	B
,	O	PUNCT	O
LPO	O	NOUN	B
generation	O	NOUN	B
,	O	PUNCT	O
histamine	B-Chemical	NOUN	B
release	O	NOUN	B
and	O	CCONJ	O
microvascular	O	ADJ	B
permeability	O	NOUN	I
that	O	PRON	O
could	O	AUX	O
be	O	AUX	O
ameliorated	O	VERB	B
by	O	ADP	O
verapamil	B-Chemical	NOUN	B


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
The	O	DET	O
mechanisms	O	NOUN	B
underlying	O	VERB	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
adriamycin	B-Chemical	NOUN	B
are	O	AUX	O
very	O	ADV	O
complicated	O	ADJ	B
and	O	CCONJ	O
still	O	ADV	O
unclear	O	ADJ	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
3-methyladenine	B-Chemical	NOUN	B
(	O	PUNCT	O
3MA	B-Chemical	NOUN	B
),	O	PUNCT	O
a	O	DET	O
specific	O	ADJ	O
inhibitor	O	NOUN	B
on	O	ADP	O
autophagy	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
a	O	DET	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
model	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
adriamycin	B-Chemical	NOUN	B
.	O	PUNCT	O


Neonatal	O	ADJ	B
cardiomyocytes	O	NOUN	B
were	O	AUX	O
isolated	O	VERB	B
from	O	ADP	O
Sprague	O	PROPN	B
-	O	PUNCT	O
Dawley	O	PROPN	B
rat	O	NOUN	B
hearts	O	NOUN	B
and	O	CCONJ	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
controls	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
3MA	B-Chemical	NOUN	B
plus	O	CCONJ	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
group	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
3MA	B-Chemical	NOUN	B
significantly	O	ADV	O
improved	O	VERB	O
cardiac	O	ADJ	B
function	O	NOUN	I
and	O	CCONJ	O
reduced	O	VERB	B
mitochondrial	O	ADJ	B
injury	O	NOUN	I
.	O	PUNCT	O


Mitochondrial	O	ADJ	B
injury	O	NOUN	I
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
progression	O	NOUN	B
of	O	ADP	O
heart	B-Disease	NOUN	B
failure	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
adriamycin	B-Chemical	NOUN	B


INTRODUCTION	O	NOUN	O
:	O	PUNCT	O
Confusion	B-Disease	NOUN	B
is	O	AUX	O
an	O	DET	O
adverse	O	ADJ	B
drug	O	NOUN	I
reaction	O	NOUN	I
frequently	O	ADV	O
observed	O	VERB	O
with	O	ADP	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
272	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
confusion	B-Disease	NOUN	B
were	O	AUX	O
reported	O	VERB	O
with	O	ADP	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
:	O	PUNCT	O
153	O	NUM	O
women	O	NOUN	B
and	O	CCONJ	O
119	O	NUM	O
men	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
work	O	NOUN	O
shows	O	VERB	O
that	O	SCONJ	O
confusion	B-Disease	NOUN	B
with	O	ADP	O
valproic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I


It	O	PRON	O
has	O	AUX	O
been	O	AUX	O
consistently	O	ADV	O
shown	O	VERB	O
that	O	SCONJ	O
ecstasy	B-Chemical	NOUN	B
users	O	NOUN	B
display	O	VERB	O
impairments	B-Disease	NOUN	B
in	I-Disease	ADP	O
learning	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
memory	I-Disease	NOUN	B
performance	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
working	O	VERB	B
memory	O	NOUN	I
processing	O	NOUN	O
in	O	ADP	O
ecstasy	B-Chemical	NOUN	B
users	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
neural	O	ADJ	B
alterations	O	NOUN	B
in	O	ADP	O
hippocampal	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
cortical	O	ADJ	B
regions	O	NOUN	I
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
functional	O	ADJ	B
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
(	O	PUNCT	O
fMRI	O	NOUN	B
).	O	ADJ	O
Using	O	VERB	O
functional	O	ADJ	B
imaging	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
face	O	NOUN	B
-	O	PUNCT	O
learning	O	NOUN	B
task	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
neural	O	ADJ	B
correlates	O	NOUN	B
of	O	ADP	O
encoding	O	VERB	B
and	O	CCONJ	O
recalling	O	VERB	B
face	O	NOUN	B
-	O	PUNCT	O
name	O	NOUN	B
associations	O	NOUN	B
in	O	ADP	O
20	O	NUM	O
recreational	O	ADJ	B
drug	O	NOUN	O
users	O	NOUN	O
whose	O	DET	O
predominant	O	ADJ	B
drug	O	NOUN	B
use	O	NOUN	I
was	O	AUX	O
ecstasy	B-Chemical	ADJ	B
and	O	CCONJ	O
20	O	NUM	O
controls	O	NOUN	B
.	O	PUNCT	O


Neuroimage	O	NOUN	B
40	O	NUM	O
,	O	PUNCT	O
1328	O	NUM	O
-	O	SYM	O
1339	O	NUM	O
).	O	PROPN	O
Ecstasy	B-Chemical	PROPN	B
users	O	NOUN	I
performed	O	VERB	O
significantly	O	ADV	O
worse	O	ADJ	O
in	O	ADP	O
learning	O	NOUN	B
and	O	CCONJ	O
memory	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
controls	O	NOUN	B
and	O	CCONJ	O
cannabis	B-Chemical	NOUN	B
users	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
conjunction	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
encode	O	NOUN	B
and	O	CCONJ	O
recall	O	VERB	B
phases	O	NOUN	B
of	O	ADP	O
the	O	DET	O
task	O	NOUN	B
revealed	O	VERB	O
ecstasy	B-Chemical	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
hyperactivity	B-Disease	NOUN	B
in	O	ADP	O
bilateral	O	ADJ	B
frontal	O	ADJ	O
regions	O	NOUN	O
,	O	PUNCT	O
left	O	VERB	B
temporal	O	ADJ	I
,	O	PUNCT	O
right	O	ADV	B
parietal	O	ADJ	I
,	O	PUNCT	O
bilateral	O	ADJ	B
temporal	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
bilateral	O	ADJ	B
occipital	O	ADJ	B
brain	O	NOUN	I
regions	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
both	O	DET	O
ecstasy	B-Chemical	NOUN	B
and	O	CCONJ	O
cannabis	B-Chemical	NOUN	B
groups	O	NOUN	I
brain	O	NOUN	B
activation	O	NOUN	I
was	O	AUX	O
decreased	O	VERB	B
in	O	ADP	O
the	O	DET	O
right	O	ADJ	B
medial	O	ADJ	I
frontal	O	ADJ	I
gyrus	O	NOUN	I
,	O	PUNCT	O
left	O	VERB	B
parahippocampal	O	ADJ	I
gyrus	O	NOUN	I
,	O	PUNCT	O
left	O	VERB	B
dorsal	O	ADJ	I
cingulate	O	NOUN	I
gyrus	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
left	O	VERB	B
caudate	O	NOUN	I
.	O	PUNCT	O


Prolonged	O	ADJ	B
elevation	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
argatroban	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
cardiac	O	ADJ	B
transplant	O	NOUN	I
patient	O	NOUN	B
with	O	ADP	O
a	O	DET	O
suspected	O	VERB	B
history	O	NOUN	B
of	O	ADP	O
heparin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
thrombocytopenia	B-Disease	NOUN	B
with	O	ADP	O
thrombosis	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
required	O	VERB	O
massive	O	ADJ	B
transfusion	O	NOUN	B
support	O	NOUN	O
(	O	PUNCT	O
55	O	NUM	O
units	O	NOUN	O
of	O	ADP	O
red	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
42	O	NUM	O
units	O	NOUN	B
of	O	ADP	O
fresh	O	ADJ	B
-	O	PUNCT	O
frozen	O	VERB	B
plasma	O	NOUN	B
,	O	PUNCT	O
40	O	NUM	O
units	O	NOUN	O
of	O	ADP	O
cryoprecipitate	O	NOUN	B
,	O	PUNCT	O
40	O	NUM	O
units	O	NOUN	O
of	O	ADP	O
platelets	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
three	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
recombinant	O	ADJ	B
Factor	O	NOUN	I
VIIa	O	NOUN	I
)	O	PUNCT	O
for	O	ADP	O
severe	O	ADJ	B
intraoperative	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
postoperative	I-Disease	ADJ	B
bleeding	I-Disease	NOUN	I
.	O	PUNCT	O


STUDY	O	NOUN	O
DESIGN	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
:	O	PUNCT	O
Plasma	O	NOUN	B
samples	O	NOUN	B
from	O	ADP	O
before	O	ADP	O
and	O	CCONJ	O
after	O	ADP	O
CPB	O	NOUN	B
were	O	AUX	O
analyzed	O	VERB	B
postoperatively	O	ADV	B
for	O	ADP	O
argatroban	B-Chemical	ADJ	B
concentration	O	NOUN	B
using	O	VERB	O
a	O	DET	O
modified	O	VERB	B
ecarin	O	NOUN	O
clotting	O	NOUN	O
time	O	NOUN	O
(	O	PUNCT	O
ECT	O	NOUN	B
)	O	PUNCT	O
assay	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Unexpectedly	O	ADV	O
high	O	ADJ	O
concentrations	O	NOUN	B
of	O	ADP	O
argatroban	B-Chemical	NOUN	B
were	O	AUX	O
measured	O	VERB	B
in	O	ADP	O
these	O	DET	O
samples	O	NOUN	B
(	O	PUNCT	O
range	O	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
-	O	SYM	O
32	O	NUM	O
microg	O	NOUN	B
/	O	PUNCT	O
mL	O	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
prolonged	O	ADJ	B
plasma	O	NOUN	B
argatroban	B-Chemical	NOUN	B
half	O	NOUN	O
life	O	NOUN	O
(	O	PUNCT	O
t	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	O
))	O	PUNCT	O
of	O	ADP	O
514	O	NUM	O
minutes	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
(	O	PUNCT	O
published	O	VERB	B
elimination	O	NOUN	I
t	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
/	O	SYM	O
2	O	NUM	B
)	O	PUNCT	O
is	O	AUX	O
39	O	NUM	O
-	O	SYM	O
51	O	NUM	O
minutes	O	NOUN	B
[<	O	X	B
or	O	CCONJ	O
=	O	ADJ	O
181	O	NUM	O
minutes	O	NOUN	O
with	O	ADP	O
hepatic	B-Disease	ADJ	B
impairment	I-Disease	NOUN	I
]).	O	PUNCT	O
CONCLUSIONS	O	NOUN	B
:	O	PUNCT	O
Correlation	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
argatroban	B-Chemical	ADJ	B
concentration	O	NOUN	B
versus	O	CCONJ	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
coagulation	O	NOUN	B
variables	O	NOUN	B
and	O	CCONJ	O
clinical	O	ADJ	B
course	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
prolonged	O	ADJ	B
elevated	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
argatroban	B-Chemical	NOUN	B
may	O	AUX	O
have	O	AUX	O
contributed	O	VERB	O
to	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
extended	O	VERB	O
coagulopathy	B-Disease	NOUN	B
.	O	PUNCT	O


Antituberculosis	B-Chemical	NOUN	B
therapy	O	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
acute	B-Disease	ADJ	B
liver	I-Disease	NOUN	O
failure	I-Disease	NOUN	O
:	O	PUNCT	O
magnitude	O	NOUN	B
,	O	PUNCT	O
profile	O	NOUN	B
,	O	PUNCT	O
prognosis	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
predictors	O	NOUN	B
of	O	ADP	O
outcome	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
prospectively	O	ADV	O
evaluated	O	VERB	B
the	O	DET	O
magnitude	O	NOUN	B
,	O	PUNCT	O
clinical	O	ADJ	B
course	O	NOUN	I
,	O	PUNCT	O
outcome	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
prognostic	O	ADJ	B
factors	O	NOUN	I
in	O	ADP	O
ATT	O	NOUN	B
-	O	PUNCT	O
ALF	B-Disease	PROPN	B
.	O	PUNCT	O


2	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
ATT	O	PROPN	B
and	O	CCONJ	O
simultaneous	O	ADJ	B
hepatitis	B-Disease	NOUN	B
virus	I-Disease	NOUN	I
infection	I-Disease	NOUN	O
.	O	PUNCT	O


ATT	O	PROPN	B
-	O	PUNCT	O
ALF	B-Disease	NOUN	B
patients	O	NOUN	B
were	O	AUX	O
younger	O	ADJ	B
(	O	PUNCT	O
32	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
median	O	ADJ	B
duration	O	NOUN	B
of	O	ADP	O
ATT	O	NOUN	B
before	O	ADP	O
ALF	B-Disease	NOUN	B
was	O	AUX	O
30	O	NUM	O
(	O	PUNCT	O
7	O	NUM	O
-	O	PUNCT	O
350	O	NUM	O
)	O	PUNCT	O
days	O	NOUN	B
.	O	PUNCT	O


Gastrointestinal	B-Disease	ADJ	B
bleed	I-Disease	NOUN	I
,	O	PUNCT	O
seizures	B-Disease	NOUN	B
,	O	PUNCT	O
infection	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
were	O	AUX	O
documented	O	VERB	B
in	O	ADP	O
seven	O	NUM	O
(	O	PUNCT	O
10	O	NUM	O
%),	O	ADJ	O
five	O	NUM	O
(	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
mortality	O	NOUN	B
rate	O	NOUN	I
among	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
ATT	O	NOUN	B
-	O	PUNCT	O
ALF	B-Disease	PROPN	B
was	O	AUX	O
high	O	ADJ	O
(	O	PUNCT	O
67	O	NUM	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
ATT	O	PROPN	B
-	O	PUNCT	O
ALF	B-Disease	PROPN	B
constituted	O	VERB	O
5	O	NUM	O
.	O	PUNCT	O


Central	B-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
complications	I-Disease	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
lymphoblastic	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
pediatric	O	ADJ	B
institution	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
analyzed	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
neurological	B-Disease	ADJ	B
complications	I-Disease	NOUN	I
during	O	ADP	O
ALL	B-Disease	NOUN	B
treatment	O	NOUN	B
in	O	ADP	O
a	O	DET	O
single	O	ADJ	O
pediatric	O	ADJ	B
institution	O	NOUN	B
,	O	PUNCT	O
focusing	O	VERB	O
on	O	ADP	O
clinical	O	ADJ	B
,	O	PUNCT	O
radiological	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
electrophysiological	O	ADJ	B
findings	O	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
a	O	DET	O
9	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
period	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
retrospectively	O	ADV	B
collected	O	VERB	O
27	O	NUM	O
neurological	O	ADJ	B
events	O	NOUN	I
(	O	PUNCT	O
11	O	NUM	O
%)	O	NOUN	O
in	O	ADP	O
as	O	ADV	O
many	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
from	O	ADP	O
253	O	NUM	O
children	O	NOUN	B
enrolled	O	VERB	O
in	O	ADP	O
the	O	DET	O
ALL	B-Disease	NOUN	B
front	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
protocol	O	NOUN	B
.	O	PUNCT	O


CNS	O	NOUN	B
complications	O	NOUN	B
included	O	VERB	O
posterior	O	ADJ	B
reversible	O	ADJ	O
leukoencephalopathy	B-Disease	NOUN	O
syndrome	O	NOUN	O
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
10	O	NUM	O
),	O	PUNCT	O
stroke	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
5	O	NUM	O
),	O	PUNCT	O
temporal	B-Disease	ADJ	B
lobe	I-Disease	NOUN	I
epilepsy	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
),	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
methotrexate	B-Chemical	NOUN	B
toxicity	B-Disease	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
2	O	NUM	O
),	O	PUNCT	O
syndrome	O	NOUN	B
of	O	ADP	O
inappropriate	B-Disease	ADJ	O
antidiuretic	I-Disease	ADJ	B
hormone	I-Disease	NOUN	I
secretion	I-Disease	NOUN	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
1	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
other	O	ADJ	O
unclassified	O	ADJ	O
events	O	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
).	O	PUNCT	O
In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
CNS	O	NOUN	B
complications	O	NOUN	B
are	O	AUX	O
frequent	O	ADJ	B
events	O	NOUN	B
during	O	ADP	O
ALL	B-Disease	NOUN	B


Safety	O	NOUN	B
of	O	ADP	O
capecitabine	B-Chemical	NOUN	B
:	O	PUNCT	O
a	O	DET	O
review	O	NOUN	B
.	O	PUNCT	O


WHAT	O	PRON	O
THE	O	DET	O
READER	O	PROPN	O
WILL	O	PROPN	O
GAIN	O	PROPN	O
:	O	PUNCT	O
The	O	DET	O
reader	O	NOUN	O
will	O	AUX	O
gain	O	VERB	O
better	O	ADJ	O
insight	O	NOUN	O
into	O	ADP	O
the	O	DET	O
safety	O	NOUN	B
of	O	ADP	O
capecitabine	B-Chemical	NOUN	B
in	O	ADP	O
special	O	ADJ	O
populations	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
renal	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
kidney	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
explore	O	VERB	O
different	O	ADJ	O
dosing	O	NOUN	B
and	O	CCONJ	O
schedules	O	NOUN	B
of	O	ADP	O
capecitabine	B-Chemical	NOUN	B
administration	O	NOUN	B
.	O	PUNCT	O


Capecitabine	B-Chemical	NOUN	B
has	O	AUX	O
a	O	DET	O
well	O	ADV	O
-	O	PUNCT	O
established	O	VERB	B
safety	O	NOUN	B
profile	O	NOUN	I
and	O	CCONJ	O
can	O	AUX	O
be	O	AUX	O
given	O	VERB	O
safely	O	ADV	O
to	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
hepatic	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
renal	I-Disease	ADJ	B
dysfunctions	I-Disease	NOUN	I


Previous	O	ADJ	O
studies	O	NOUN	B
have	O	AUX	O
indicated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
globus	O	NOUN	B
pallidus	O	NOUN	I
receives	O	VERB	O
neurotensinergic	O	ADJ	B
innervation	O	NOUN	I
from	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
systemic	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
a	O	DET	O
neurotensin	B-Chemical	NOUN	B
analog	O	NOUN	I
could	O	AUX	O
produce	O	VERB	O
antiparkinsonian	O	ADJ	B
effects	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
aimed	O	VERB	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
pallidal	O	ADJ	B
neurotensin	B-Chemical	NOUN	I
on	O	ADP	O
haloperidol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
parkinsonian	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
neurotensin	B-Chemical	NOUN	B
type-1	I-Chemical	NOUN	I
receptor	I-Chemical	NOUN	I
antagonist	I-Chemical	NOUN	I
SR48692	B-Chemical	NOUN	B
blocked	O	VERB	B
both	O	CCONJ	O
the	O	DET	O
behavioral	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
electrophysiological	O	ADJ	B
effects	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
neurotensin	B-Chemical	NOUN	B
.	O	PUNCT	O


Antihypertensive	O	ADJ	B
drugs	O	NOUN	I
and	O	CCONJ	O
depression	B-Disease	NOUN	B
:	O	PUNCT	O
a	O	DET	O
reappraisal	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
high	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
depression	B-Disease	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
preponderance	O	NOUN	O
in	O	ADP	O
the	O	DET	O
hypertensive	B-Disease	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
was	O	AUX	O
accounted	O	VERB	O
for	O	ADP	O
by	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
depressions	B-Disease	NOUN	B
occurring	O	VERB	O
in	O	ADP	O
methyl	B-Chemical	NOUN	B
dopa	I-Chemical	NOUN	I
treated	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
psychiatric	B-Disease	ADJ	B


The	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
continuous	O	ADJ	B
positive	O	ADJ	O
airway	O	NOUN	O
pressure	O	NOUN	O
(	O	PUNCT	O
CPAP	O	NOUN	B
)	O	PUNCT	O
on	O	ADP	O
cardiovascular	O	ADJ	B
dynamics	O	NOUN	B
and	O	CCONJ	O
pulmonary	O	ADJ	B
shunt	O	NOUN	I
(	O	PUNCT	O
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
)	O	PUNCT	O
were	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
12	O	NUM	O
dogs	O	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
during	O	ADP	O
sodium	B-Chemical	NOUN	B
nitroprusside	I-Chemical	NOUN	I
infusion	O	NOUN	B
that	O	PRON	O
decreased	O	VERB	B
mean	O	ADJ	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
40	O	NUM	O
-	O	SYM	O
50	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
.	O	PUNCT	O


Ten	O	NUM	O
cm	O	NOUN	O
H2O	B-Chemical	NOUN	O
CPAP	O	NOUN	O
before	O	ADP	O
nitroprusside	B-Chemical	NOUN	B
infusion	O	NOUN	B
produced	O	VERB	O
a	O	DET	O
further	O	ADJ	O
decrease	B-Disease	NOUN	B
in	I-Disease	ADP	O
arterial	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
and	O	CCONJ	O
significantly	O	ADV	O
increased	O	VERB	B
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
decreased	B-Disease	VERB	B
cardiac	I-Disease	ADJ	B
output	I-Disease	NOUN	I
and	O	CCONJ	O
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
.	O	PUNCT	O


Five	O	NUM	O
cm	O	NOUN	O
H2O	B-Chemical	NOUN	B
CPAP	O	NOUN	I
during	O	ADP	O
nitroprusside	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
further	O	ADV	O
alter	O	VERB	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
above	O	ADJ	B
-	O	PUNCT	O
mentioned	O	VERB	B
variables	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
nitroprusside	B-Chemical	NOUN	B
infusion	O	NOUN	B
rates	O	NOUN	B
that	O	PRON	O
decrease	O	VERB	B
mean	O	ADJ	O
arterial	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
by	O	ADP	O
40	O	NUM	O
-	O	SYM	O
50	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
do	O	AUX	O
not	O	PART	O
change	O	VERB	O
cardiac	O	ADJ	B
output	O	NOUN	I
or	O	CCONJ	O
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
.	O	PUNCT	O


During	O	ADP	O
nitroprusside	B-Chemical	NOUN	B
infusion	O	NOUN	B
low	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
CPAP	O	NOUN	B
do	O	AUX	O
not	O	PART	O
markedly	O	ADV	O
alter	O	VERB	O
cardiovascular	O	ADJ	B
dynamics	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
high	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
CPAP	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
cm	O	NOUN	O
H2O	B-Chemical	NOUN	B
),	O	PUNCT	O
while	O	SCONJ	O
decreasing	O	VERB	B
QS	O	PROPN	B
/	O	SYM	O
QT	O	PROPN	B
,	O	PUNCT	O
produce	O	VERB	O
marked	O	ADJ	O
decreases	B-Disease	NOUN	B
in	I-Disease	ADP	O
arterial	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
cardiac	I-Disease	ADJ	B
output	I-Disease	NOUN	I


v	O	ADP	O
.)	O	NOUN	O
decreased	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
after	O	ADP	O
extracerebral	O	ADJ	B
decarboxylase	O	NOUN	I
inhibition	O	NOUN	B
with	O	ADP	O
MK-486	B-Chemical	NOUN	B
(	O	PUNCT	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
reflex	O	ADJ	B
bradycardia	B-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
injected	O	VERB	B
norepinephrine	B-Chemical	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
enhanced	O	VERB	B
by	O	ADP	O
L-dopa	B-Chemical	NOUN	B
,	O	PUNCT	O
DL-Threo-dihydroxyphenylserine	B-Chemical	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
,	O	PUNCT	O
heart	O	NOUN	B
rate	O	NOUN	I
or	O	CCONJ	O
reflex	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
norepinephrine	B-Chemical	NOUN	B
.	O	PUNCT	O


Pimozide	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
actions	O	NOUN	B
of	O	ADP	O
L-dopa	B-Chemical	NOUN	B
on	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
but	O	CCONJ	O
completely	O	ADV	O
blocked	O	VERB	B
the	O	DET	O
enhancement	O	NOUN	B
of	O	ADP	O
reflexes	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
L-dopa	B-Chemical	NOUN	B
restored	O	VERB	B
the	O	DET	O
bradycardia	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
decreasing	O	VERB	B
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
.	O	PUNCT	O


5-HTP	B-Chemical	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
L-dopa	B-Chemical	NOUN	B
enhances	O	VERB	O
reflex	O	ADJ	B
bradycardia	B-Disease	NOUN	I
through	O	ADP	O
central	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
receptor	O	NOUN	B
stimulation	O	NOUN	B
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
experimental	O	ADJ	B
data	O	NOUN	O
published	O	VERB	O
to	O	PART	O
date	O	NOUN	O
suggest	O	VERB	O
several	O	ADJ	O
possible	O	ADJ	O
mechanisms	O	NOUN	B
by	O	ADP	O
which	O	DET	O
cocaine	B-Chemical	NOUN	B
may	O	AUX	O
result	O	VERB	O
in	O	ADP	O
acute	B-Disease	ADJ	B
myocardial	I-Disease	ADJ	I
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
other	O	ADJ	O
individuals	O	NOUN	B
with	O	ADP	O
no	O	DET	O
underlying	O	ADJ	O
atherosclerotic	B-Disease	ADJ	B
obstruction	I-Disease	NOUN	I
,	O	PUNCT	O
coronary	B-Disease	ADJ	B
occlusion	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	ADP	O
spasm	B-Disease	NOUN	B
,	O	PUNCT	O
thrombus	B-Disease	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
both	O	DET	O
.	O	PUNCT	O


With	O	ADP	O
regard	O	NOUN	O
to	O	ADP	O
spasm	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
clinical	O	ADJ	B
findings	O	NOUN	I
are	O	AUX	O
largely	O	ADV	O
circumstantial	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
locus	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vasoconstriction	O	NOUN	B
remains	O	VERB	O
speculative	O	ADJ	O
.	O	PUNCT	O


Diffuse	O	ADJ	B
intramural	O	ADJ	I
vasoconstriction	O	NOUN	I
is	O	AUX	O
not	O	PART	O
consistent	O	ADJ	B
with	O	ADP	I
reports	O	NOUN	B
of	O	ADP	O
segmental	O	ADJ	B
,	O	PUNCT	O
discrete	O	ADJ	B
infarction	B-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
finding	O	NOUN	B
of	O	ADP	O
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
vasoconstriction	O	NOUN	B
in	O	ADP	O
segments	O	NOUN	B
of	O	ADP	O
(	O	PUNCT	O
noninnervated	O	ADJ	B
)	O	PUNCT	O
human	O	ADJ	O
umbilical	O	ADJ	O
artery	O	NOUN	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
presence	O	NOUN	B
or	O	CCONJ	O
absence	O	NOUN	B
of	O	ADP	O
intact	O	ADJ	B
innervation	O	NOUN	B
is	O	AUX	O
not	O	PART	O
sufficient	O	ADJ	O
to	O	PART	O
explain	O	VERB	O
the	O	DET	O
discrepant	O	ADJ	O
data	O	NOUN	B
involving	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
alpha	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
effects	O	NOUN	B
.	O	PUNCT	O


Rabbit	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
antidepressant	B-Chemical	ADJ	B
use	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cerebral	O	ADJ	B
perfusion	O	NOUN	I
SPECT	O	NOUN	I
scan	O	NOUN	I
findings	O	NOUN	B
.	O	PUNCT	O


Repeated	O	VERB	B
cerebral	O	ADJ	B
perfusion	O	NOUN	I
SPECT	O	NOUN	O
scans	O	NOUN	O
revealed	O	VERB	O
decreased	B-Disease	VERB	B
basal	I-Disease	ADJ	B
ganglia	I-Disease	NOUN	I
perfusion	I-Disease	NOUN	B
while	O	SCONJ	O
the	O	DET	O
movement	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
was	O	AUX	O
present	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
return	O	NOUN	B
to	O	ADP	I
normal	O	ADJ	I
perfusion	O	NOUN	I
when	O	SCONJ	O
the	O	DET	O
rabbit	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I


The	O	DET	O
bronchodilator	O	NOUN	B
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
ipratropium	B-Chemical	NOUN	B
bromide	I-Chemical	NOUN	I
aerosol	O	NOUN	B
(	O	PUNCT	O
36	O	NUM	O
micrograms	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
short	O	ADJ	B
-	O	PUNCT	O
acting	O	VERB	B
theophylline	B-Chemical	NOUN	B
tablets	O	NOUN	B
(	O	PUNCT	O
dose	O	NOUN	B
titrated	O	VERB	B
to	O	PART	O
produce	O	VERB	O
serum	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
10	O	NUM	O
-	O	SYM	O
20	O	NUM	O
micrograms	O	NOUN	B
/	O	PUNCT	O
mL	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
compared	O	VERB	B
in	O	ADP	O
a	O	DET	O
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
crossover	O	NOUN	B
study	O	NOUN	I
in	O	ADP	O
21	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
stable	O	ADJ	B
,	O	PUNCT	O
chronic	B-Disease	ADJ	B
obstructive	I-Disease	ADJ	I
pulmonary	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Mean	O	VERB	O
peak	O	NOUN	B
forced	O	ADJ	I
expiratory	O	ADJ	I
volume	O	NOUN	I
in	O	ADP	O
1	O	NUM	O
second	O	NOUN	O
(	O	PUNCT	O
FEV1	O	NOUN	B
)	O	PUNCT	O
increases	O	VERB	B
over	O	ADP	O
baseline	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
attaining	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
a	O	DET	O
15	O	NUM	O
%	O	NOUN	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
FEV1	O	NOUN	B
(	O	PUNCT	O
responders	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
31	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
90	O	NUM	O
%,	O	NOUN	B
respectively	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
ipratropium	B-Chemical	NOUN	B
and	O	CCONJ	O
17	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
50	O	NUM	O
%,	O	ADJ	B
respectively	O	ADV	O
,	O	PUNCT	O
for	O	ADP	O
theophylline	B-Chemical	NOUN	B
.	O	PUNCT	O


8	O	NUM	O
hours	O	NOUN	O
with	O	ADP	O
ipratropium	B-Chemical	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
ipratropium	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
more	O	ADV	O
potent	O	ADJ	O
bronchodilator	O	NOUN	B
than	O	ADP	O
oral	O	ADJ	B
theophylline	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronic	B-Disease	ADJ	B
airflow	I-Disease	NOUN	I
obstruction	I-Disease	NOUN	I


This	O	DET	O
study	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
prolonged	O	ADJ	B
analgesic	O	NOUN	B
treatment	O	NOUN	I
in	O	ADP	O
Fischer	O	NOUN	O
344	O	NUM	O
rats	O	NOUN	B
causes	O	VERB	O
progressive	O	ADJ	B
and	O	CCONJ	O
irreversible	O	ADJ	B
damage	O	NOUN	B
to	O	PART	O
the	O	DET	O
interstitial	O	ADJ	B
matrix	O	NOUN	I
and	O	CCONJ	O
type	O	NOUN	O
1	O	NUM	O
interstitial	O	ADJ	B
cells	O	NOUN	I
leading	O	VERB	O
to	O	PART	O
RPN	B-Disease	NOUN	B


Less	O	ADV	O
frequent	O	ADJ	B
lithium	B-Chemical	NOUN	B
administration	O	NOUN	O
and	O	CCONJ	O
lower	O	ADJ	B
urine	O	NOUN	B
volume	O	NOUN	I
.	O	PUNCT	O


METHOD	O	NOUN	B
:	O	PUNCT	O
This	O	DET	O
was	O	AUX	O
a	O	DET	O
cross	O	NOUN	B
-	O	PUNCT	O
sectional	O	ADJ	B
study	O	NOUN	I
of	O	ADP	O
85	O	NUM	O
patients	O	NOUN	B
from	O	ADP	O
a	O	DET	O
lithium	B-Chemical	NOUN	B
clinic	O	NOUN	I
who	O	PRON	O
received	O	VERB	O
different	O	ADJ	O
dose	O	NOUN	B
schedules	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
Multiple	O	ADJ	B
daily	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
higher	O	ADJ	O
urine	O	NOUN	B
volumes	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
Urine	O	NOUN	B
volume	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
giving	O	VERB	O
lithium	B-Chemical	NOUN	B
once	O	SCONJ	B
daily	O	ADV	I
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
by	O	ADP	O
lowering	O	VERB	B
the	O	DET	O
total	O	ADJ	O
daily	O	ADJ	O
dose	O	NOUN	O
.	O	PUNCT	O


Lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
polyuria	B-Disease	NOUN	B


Thermal	O	ADJ	B
enhancement	O	NOUN	O
of	O	ADP	O
Adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
antitumor	O	NOUN	B
activity	O	NOUN	O
and	O	CCONJ	O
normal	O	ADJ	O
tissue	O	NOUN	B
toxicities	B-Disease	NOUN	B
by	O	ADP	O
whole	O	ADJ	B
body	O	NOUN	I
hyperthermia	B-Disease	NOUN	I
were	O	AUX	O
compared	O	VERB	O
using	O	VERB	O
a	O	DET	O
F344	O	NOUN	B
rat	O	NOUN	I
model	O	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
normal	O	ADJ	I
tissue	O	NOUN	I
toxicities	B-Disease	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


e	O	X	O
.,	O	PUNCT	O
myocardial	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
kidney	I-Disease	NOUN	B
injury	I-Disease	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
functional	O	ADJ	B
/	O	PUNCT	O
physiological	O	ADJ	B
assays	O	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
morphological	O	ADJ	B
techniques	O	NOUN	B
.	O	PUNCT	O


3	O	NUM	O
,	O	PUNCT	O
whereas	O	SCONJ	O
those	O	DET	O
estimated	O	VERB	B
for	O	ADP	O
"	O	PUNCT	O
late	O	ADJ	B
"	O	PUNCT	O
damage	O	NOUN	B
(	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
morphological	O	ADJ	B
cardiac	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
renal	I-Disease	ADJ	B
lesions	I-Disease	NOUN	I
)	O	PUNCT	O
varied	O	VERB	O
between	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


Prazosin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
stress	B-Disease	NOUN	B
incontinence	I-Disease	NOUN	I
.	O	PUNCT	O


Prazosin	B-Chemical	NOUN	B
exerts	O	VERB	O
its	O	PRON	O
antihypertensive	O	ADJ	B
effects	O	NOUN	I
through	O	ADP	O
vasodilatation	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
selective	O	ADJ	O
blockade	O	NOUN	B
of	O	ADP	O
postsynaptic	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
1	O	NUM	O
adrenergic	O	ADJ	B
receptors	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
present	O	VERB	O
with	O	ADP	O
stress	B-Disease	NOUN	B
incontinence	I-Disease	NOUN	I
while	O	SCONJ	O
taking	O	VERB	O
prazosin	B-Chemical	NOUN	B
should	O	AUX	O
change	O	VERB	O
their	O	PRON	O
antihypertensive	O	ADJ	B
medication	O	NOUN	I
before	O	ADP	O
considering	O	VERB	O
surgery	O	NOUN	B
,	O	PUNCT	O
because	O	SCONJ	O
their	O	PRON	O
incontinence	B-Disease	NOUN	B


A	O	DET	O
78	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
with	O	ADP	O
healed	O	VERB	B
septal	O	ADJ	B
necrosis	B-Disease	NOUN	I
suffered	O	VERB	O
a	O	DET	O
recurrent	O	ADJ	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
anterior	O	ADJ	B
wall	O	NOUN	O
following	O	VERB	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
isosorbide	B-Chemical	NOUN	B
dinitrate	I-Chemical	NOUN	O
5	O	NUM	O
mg	O	NOUN	O
sublingually	O	ADV	B
.	O	PUNCT	O


After	O	ADP	O
detailing	O	VERB	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
events	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
discuss	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
paradoxical	O	ADJ	B
coronary	O	ADJ	B
spasm	B-Disease	NOUN	I
and	O	CCONJ	O
hypotension	B-Disease	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
myocardial	B-Disease	ADJ	B
ischemia	I-Disease	NOUN	I
occurring	O	VERB	O
downstream	O	ADJ	B
to	O	PART	O
significant	O	ADJ	O
coronary	B-Disease	ADJ	B
arterial	I-Disease	ADJ	I
stenosis	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
acute	B-Disease	ADJ	B
coronary	I-Disease	ADJ	I
insufficiency	I-Disease	NOUN	I


Five	O	NUM	O
patients	O	NOUN	B
receiving	O	VERB	O
fluoxetine	B-Chemical	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
obsessive	B-Disease	ADJ	B
compulsive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
or	O	CCONJ	O
major	B-Disease	ADJ	O
depression	I-Disease	NOUN	B
developed	O	VERB	O
akathisia	B-Disease	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
had	O	AUX	O
experienced	O	VERB	O
neuroleptic	O	ADJ	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
past	O	NOUN	O
reported	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
symptoms	O	NOUN	B
of	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
were	O	AUX	O
identical	O	ADJ	B
,	O	PUNCT	O
although	O	SCONJ	O
somewhat	O	ADV	O
milder	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
fluoxetine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
serotonergically	O	ADV	B
mediated	O	VERB	O
inhibition	O	NOUN	B
of	O	ADP	O
dopaminergic	O	ADJ	B
neurotransmission	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
pathophysiology	O	NOUN	B
of	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
akathisia	B-Disease	NOUN	B
and	O	CCONJ	O
tricyclic	O	ADJ	B
antidepressant	B-Chemical	NOUN	I


Diclofenac	B-Chemical	ADJ	B
sodium	I-Chemical	NOUN	I
(	O	PUNCT	O
Voltarol	B-Chemical	PROPN	B
,	O	PUNCT	O
Geigy	O	PROPN	B
Pharmaceuticals	O	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
steroidal	O	ADJ	B
anti	O	ADJ	B
-	O	PUNCT	O
inflammatory	O	ADJ	B
derivative	O	NOUN	B
of	O	ADP	O
phenylacetic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
generally	O	ADV	O
well	O	ADV	B
-	O	PUNCT	O
tolerated	O	VERB	B
,	O	PUNCT	O
asymptomatic	O	ADJ	B
abnormalities	B-Disease	NOUN	B
of	I-Disease	ADP	O
liver	I-Disease	NOUN	B
function	I-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
recorded	O	VERB	O
and	O	CCONJ	O
,	O	PUNCT	O
less	O	ADV	O
commonly	O	ADV	O
,	O	PUNCT	O
severe	O	ADJ	B
hepatitis	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
diclofenac	B-Chemical	NOUN	B
.	O	PUNCT	O


Stroke	B-Disease	NOUN	B
associated	O	VERB	B
with	O	ADP	I
cocaine	B-Chemical	NOUN	B
use	O	NOUN	I
.	O	PUNCT	O


Stroke	B-Disease	NOUN	B
followed	O	VERB	O
cocaine	B-Chemical	NOUN	B
use	O	NOUN	O
by	O	ADP	O
inhalation	O	NOUN	B
,	O	PUNCT	O
intranasal	O	ADJ	B
,	O	PUNCT	O
intravenous	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
intramuscular	O	ADJ	B
routes	O	NOUN	B
.	O	PUNCT	O


Glyburide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hepatitis	B-Disease	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
glyburide	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
second	O	ADV	B
-	O	PUNCT	O
generation	O	NOUN	B
sulfonylurea	B-Chemical	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
two	O	NUM	O
brief	O	ADJ	O
reports	O	NOUN	B
of	O	ADP	O
hepatotoxicity	B-Disease	NOUN	B
exist	O	VERB	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
serologic	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
viral	B-Disease	ADJ	B
infection	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
liver	O	NOUN	B
biopsy	O	NOUN	I
sample	O	NOUN	O
showed	O	VERB	O
a	O	DET	O
histologic	O	ADJ	B
pattern	O	NOUN	O
consistent	O	ADJ	B
with	O	ADP	I
drug-induced	B-Disease	ADJ	B
hepatitis	I-Disease	NOUN	I
.	O	PUNCT	O


Glyburide	B-Chemical	NOUN	B
can	O	AUX	O
produce	O	VERB	O
an	O	DET	O
acute	B-Disease	ADJ	B
hepatitis-like	I-Disease	ADJ	O
illness	I-Disease	NOUN	O


Mean	O	VERB	O
arterial	O	ADJ	B
pressure	O	NOUN	I
was	O	AUX	O
decreased	O	VERB	B
to	O	ADP	O
50	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
for	O	ADP	O
30	O	NUM	O
minutes	O	NOUN	B
either	O	CCONJ	O
by	O	ADP	O
hemorrhage	B-Disease	NOUN	B
(	O	PUNCT	O
HEM	B-Disease	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
by	O	ADP	O
continuous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
sodium	B-Chemical	NOUN	B
nitroprusside	I-Chemical	NOUN	I
(	O	PUNCT	O
SNP	B-Chemical	NOUN	B
,	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
).	O	PUNCT	O
During	O	ADP	O
HEM	B-Disease	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
the	O	DET	O
cardiac	O	ADJ	B
output	O	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
and	O	CCONJ	O
systemic	O	ADJ	B
vascular	O	ADJ	B
resistance	O	NOUN	I
higher	O	ADV	O
compared	O	VERB	B
with	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
SNP	B-Chemical	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
SPV	O	NOUN	B
during	O	ADP	O
hypotension	B-Disease	NOUN	B
was	O	AUX	O
15	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mm	O	X	B
Hg	O	NOUN	I
in	O	ADP	O
the	O	DET	O
SNP	B-Chemical	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


02	O	NUM	O
).	O	PUNCT	O
It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
increases	O	VERB	B
in	O	ADP	O
the	O	DET	O
SPV	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
delta	O	NOUN	B
down	O	ADP	I
are	O	AUX	O
characteristic	O	ADJ	O
of	O	ADP	O
a	O	DET	O
hypotensive	B-Disease	ADJ	B
state	O	NOUN	I
due	O	ADP	O
to	O	ADP	O
a	O	DET	O
predominant	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
preload	O	NOUN	B
.	O	PUNCT	O


Drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
arterial	O	ADJ	B
spasm	B-Disease	NOUN	I
relieved	O	VERB	O
by	O	ADP	O
lidocaine	B-Chemical	NOUN	B
.	O	PUNCT	O


Intense	O	ADJ	B
vasospasm	B-Disease	NOUN	B
with	O	ADP	O
threatened	O	ADJ	B
gangrene	B-Disease	NOUN	B
arose	O	VERB	O
in	O	ADP	O
the	O	DET	O
arm	O	NOUN	B
used	O	VERB	O
for	O	ADP	O
the	O	DET	O
infusion	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
cranial	O	ADJ	B
condition	O	NOUN	I
precluded	O	VERB	O
use	O	NOUN	O
of	O	ADP	O
more	O	ADV	O
usual	O	ADJ	O
methods	O	NOUN	B
,	O	PUNCT	O
lidocaine	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
intra	O	ADJ	B
-	O	PUNCT	O
arterially	O	ADJ	B
,	O	PUNCT	O
with	O	ADP	O
careful	O	ADJ	O
cardiovascular	O	ADJ	B
monitoring	O	NOUN	B
,	O	PUNCT	O
to	O	PART	O
counteract	O	VERB	O
the	O	DET	O
vasospasm	B-Disease	NOUN	B


Cerebral	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
and	O	CCONJ	O
cerebral	O	ADJ	B
metabolic	O	ADJ	O
rate	O	NOUN	O
for	O	ADP	O
oxygen	B-Chemical	NOUN	B
were	O	AUX	O
measured	O	VERB	O
during	O	ADP	O
isoflurane	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
in	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
subjected	O	VERB	O
to	O	ADP	O
craniotomy	O	NOUN	B
for	O	ADP	O
clipping	O	VERB	B
of	O	ADP	O
a	O	DET	O
cerebral	B-Disease	ADJ	B
aneurysm	I-Disease	NOUN	I
.	O	PUNCT	O


75	O	NUM	O
%(	O	NOUN	O
plus	O	CCONJ	O
67	O	NUM	O
%	O	NOUN	O
nitrous	B-Chemical	ADJ	B
oxide	I-Chemical	NOUN	I
in	O	ADP	O
oxygen	B-Chemical	NOUN	B
),	O	PUNCT	O
during	O	ADP	O
which	O	DET	O
CBF	O	NOUN	B
and	O	CCONJ	O
CMRO2	O	NOUN	B
were	O	AUX	O
34	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
kPa	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	O
+/-	O	CCONJ	O
SEM	O	NOUN	B
).	O	PUNCT	O
Controlled	O	ADJ	B
hypotension	B-Disease	NOUN	I
to	O	PART	O
an	O	DET	O
average	O	ADJ	B
MAP	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
-	O	SYM	O
55	O	NUM	O
mm	O	X	B
Hg	B-Chemical	NOUN	I
was	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
increasing	O	VERB	B
the	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
isoflurane	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
maintained	O	VERB	B
at	O	ADP	O
an	O	DET	O
inspired	O	ADJ	B
concentration	O	NOUN	I
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


These	O	DET	O
changes	O	NOUN	B
might	O	AUX	O
offer	O	VERB	O
protection	O	NOUN	B
to	O	PART	O
brain	O	NOUN	B
tissue	O	NOUN	I
during	O	ADP	O
periods	O	NOUN	B
of	O	ADP	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B


Allergic	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I
to	O	PART	O
5-fluorouracil	B-Chemical	NOUN	B
infusion	O	NOUN	B
.	O	PUNCT	O


Oral	O	ADJ	B
diphenhydramine	B-Chemical	NOUN	I
and	O	CCONJ	O
prednisone	B-Chemical	NOUN	B
were	O	AUX	O
ineffective	O	ADJ	B
in	O	ADP	O
preventing	O	VERB	B
the	O	DET	O
recurrence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
allergic	B-Disease	ADJ	B
reaction	I-Disease	NOUN	I


We	O	PRON	O
observed	O	VERB	O
sinoatrial	B-Disease	ADJ	B
block	I-Disease	NOUN	I
due	O	ADJ	O
to	O	PART	O
chronic	O	ADJ	B
amiodarone	B-Chemical	NOUN	O
administration	O	NOUN	B
in	O	ADP	O
a	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
boy	O	NOUN	B
with	O	ADP	O
primary	B-Disease	ADJ	B
cardiomyopathy	I-Disease	NOUN	I
,	O	PUNCT	O
Wolff-Parkinson-White	B-Disease	ADJ	B
syndrome	I-Disease	NOUN	I
and	O	CCONJ	O
supraventricular	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
infants	O	NOUN	B
,	O	PUNCT	O
born	O	VERB	B
of	O	ADP	O
two	O	NUM	O
mothers	O	NOUN	B
with	O	ADP	O
inflammatory	B-Disease	ADJ	B
bowel	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
who	O	PRON	O
received	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
sulphasalazine	B-Chemical	NOUN	B
throughout	O	ADP	O
pregnancy	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
major	O	ADJ	O
congenital	B-Disease	ADJ	B
anomalies	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
twin	O	NOUN	B
pregnancy	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
mother	O	NOUN	B
had	O	AUX	O
Crohn's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
twin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
male	O	NOUN	B
,	O	PUNCT	O
had	O	AUX	O
some	O	DET	O
features	O	NOUN	B
of	O	ADP	O
Potter's	B-Disease	NOUN	B
facies	I-Disease	NOUN	B
,	O	PUNCT	O
hypoplastic	B-Disease	ADJ	B
lungs	I-Disease	NOUN	I
,	O	PUNCT	O
absent	B-Disease	ADJ	B
kidneys	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
ureters	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
talipes	B-Disease	NOUN	B
equinovarus	I-Disease	NOUN	I
.	O	PUNCT	O


Despite	O	SCONJ	O
reports	O	NOUN	B
to	O	ADP	O
the	O	DET	O
contrary	O	NOUN	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
sulphasalazine	B-Chemical	NOUN	B


A	O	DET	O
case	O	NOUN	B
of	O	ADP	O
veno-occlusive	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
liver	I-Disease	NOUN	B
with	O	ADP	O
fatal	O	ADJ	B
outcome	O	NOUN	B
after	O	ADP	O
dacarbazine	B-Chemical	NOUN	B
(	O	PUNCT	O
DTIC	B-Chemical	NOUN	B
)	O	PUNCT	O
therapy	O	NOUN	B
for	O	ADP	O
melanoma	B-Disease	NOUN	B
is	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


At	O	ADP	O
autopsy	O	NOUN	B
the	O	DET	O
liver	O	NOUN	B
was	O	AUX	O
enlarged	O	ADJ	B
and	O	CCONJ	O
firm	O	NOUN	O
with	O	ADP	O
signs	O	NOUN	O
of	O	ADP	O
venous	B-Disease	ADJ	B
congestion	I-Disease	NOUN	I
.	O	PUNCT	O


Abnormal	B-Disease	ADJ	B
involuntary	I-Disease	ADJ	B
movements	I-Disease	NOUN	B
appeared	O	VERB	O
in	O	ADP	O
the	O	DET	O
mouth	O	NOUN	B
,	O	PUNCT	O
tongue	O	NOUN	B
,	O	PUNCT	O
neck	O	NOUN	B
and	O	CCONJ	O
abdomen	O	NOUN	B
of	O	ADP	O
a	O	DET	O
64	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
male	O	NOUN	B
patient	O	NOUN	B
after	O	ADP	O
he	O	PRON	O
took	O	VERB	O
metoclopramide	B-Chemical	NOUN	B
for	O	ADP	O
gastrointestinal	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
regimen	O	NOUN	B
of	O	ADP	O
30	O	NUM	O
mg	O	NOUN	O
per	O	ADP	O
day	O	NOUN	B
for	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
about	O	ADV	O
260	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Attention	O	NOUN	B
to	O	ADP	O
the	O	DET	O
possible	O	ADJ	O
induction	O	NOUN	B
of	O	ADP	O
specific	O	ADJ	O
tardive	B-Disease	ADJ	B
dyskinesia	I-Disease	NOUN	B


A	O	DET	O
case	O	NOUN	B
is	O	AUX	O
presented	O	VERB	O
of	O	ADP	O
a	O	DET	O
reversible	O	ADJ	B
intra-Hisian	B-Disease	ADJ	B
block	I-Disease	NOUN	I
occurring	O	VERB	O
under	O	ADP	O
amiodarone	B-Chemical	NOUN	B
treatment	O	NOUN	B
for	O	ADP	O
atrial	B-Disease	ADJ	B
tachycardia	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
without	O	ADP	O
clear	O	ADJ	O
intraventricular	B-Disease	ADJ	B
conduction	I-Disease	NOUN	O
abnormalities	I-Disease	NOUN	O
.	O	PUNCT	O


Amiodarone	B-Chemical	NOUN	B


Busulfan	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
similarity	O	NOUN	B
between	O	ADP	O
the	O	DET	O
histologic	O	ADJ	B
appearances	O	NOUN	B
of	O	ADP	O
busulfan	B-Chemical	NOUN	B
cystitis	B-Disease	NOUN	B
and	O	CCONJ	O
both	O	CCONJ	O
radiation	O	NOUN	B
and	O	CCONJ	O
cyclophosphamide	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
cystitis	B-Disease	NOUN	B
is	O	AUX	O
discussed	O	VERB	O
and	O	CCONJ	O
the	O	DET	O
world	O	NOUN	B
literature	O	NOUN	I
reviewed	O	VERB	B
.	O	PUNCT	O


Rebound	O	ADJ	B
hypertensive	B-Disease	NOUN	I
after	O	ADP	O
sodium	B-Chemical	NOUN	B
nitroprusside	I-Chemical	NOUN	I
prevented	O	VERB	B
by	O	ADP	O
saralasin	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
second	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
rats	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
identically	O	ADV	O
and	O	CCONJ	O
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
received	O	VERB	O
an	O	DET	O
infusion	O	NOUN	B
of	O	ADP	O
saralasin	B-Chemical	NOUN	B
(	O	PUNCT	O
a	O	DET	O
competitive	O	ADJ	B
inhibitor	O	NOUN	B
of	O	ADP	O
angiotensin	B-Chemical	NOUN	B
II	I-Chemical	NUM	I
)	O	PUNCT	O
throughout	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
period	O	NOUN	O
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
SNP	B-Chemical	NOUN	B
infusion	O	NOUN	B
the	O	DET	O
control	O	NOUN	B
animals	O	NOUN	I
demonstrated	O	VERB	O
a	O	DET	O
progressive	O	ADJ	B
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
blood	I-Disease	NOUN	B
pressure	I-Disease	NOUN	I
to	O	PART	O
61	O	NUM	O
torr	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
saralasin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
animals	O	NOUN	B
showed	O	VERB	O
no	O	DET	O
change	O	NOUN	O
.	O	PUNCT	O


Following	O	VERB	O
discontinuation	O	NOUN	B
of	O	ADP	O
SNP	B-Chemical	NOUN	B
,	O	PUNCT	O
blood	O	NOUN	B
pressure	O	NOUN	I
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
animals	O	NOUN	I
rebounded	O	VERB	O
to	O	PART	O
94	O	NUM	O
torr	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
78	O	NUM	O
torr	O	NOUN	B
in	O	ADP	O
the	O	DET	O
saralasin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


Toxic	B-Disease	NOUN	B
hepatitis	I-Disease	NOUN	I
induced	O	VERB	B
by	O	ADP	O
antithyroid	O	ADJ	B
drugs	O	NOUN	I
:	O	PUNCT	O
four	O	NUM	O
cases	O	NOUN	B
including	O	VERB	O
one	O	NUM	O
with	O	ADP	O
cross	O	NOUN	B
-	O	PUNCT	O
reactivity	O	NOUN	B
between	O	ADP	O
carbimazole	B-Chemical	NOUN	B
and	O	CCONJ	O
benzylthiouracil	B-Chemical	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
:	O	PUNCT	O
Retrospective	O	ADJ	B
review	O	NOUN	I
of	O	ADP	O
medical	O	ADJ	B
records	O	NOUN	I
of	O	ADP	O
236	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
hyperthyroidism	B-Disease	NOUN	B
admitted	O	VERB	B
in	O	ADP	O
our	O	PRON	O
department	O	NOUN	B
(	O	PUNCT	O
in	O	ADP	O
-	O	PUNCT	O
or	O	CCONJ	O
out	O	ADJ	B
-	O	PUNCT	O
patients	O	NOUN	B
)	O	PUNCT	O
from	O	ADP	O
1986	O	NUM	O
to	O	ADP	O
1992	O	NUM	O
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
two	O	NUM	O
patients	O	NOUN	B
further	O	ADV	O
experienced	O	VERB	O
a	O	DET	O
cytolytic	O	ADJ	B
hepatitis	B-Disease	NOUN	I
which	O	DET	O
appeared	O	VERB	O
after	O	ADP	O
Benzylthiouracil	B-Chemical	NOUN	B
(	O	PUNCT	O
Basd	B-Chemical	PROPN	B
ne	I-Chemical	X	O
)	O	PUNCT	O
had	O	AUX	O
replaced	O	VERB	O
carbimazole	B-Chemical	NOUN	B
.	O	PUNCT	O


Biological	O	ADJ	B
features	O	NOUN	B
of	O	ADP	O
hepatitis	B-Disease	NOUN	B
disappeared	O	VERB	O
in	O	ADP	O
all	O	DET	O
cases	O	NOUN	B
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
incriminated	O	VERB	B
drug	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
biliary	O	ADJ	B
,	O	PUNCT	O
viral	O	ADJ	B
and	O	CCONJ	O
immunological	O	ADJ	B
searches	O	NOUN	O
were	O	AUX	O
negative	O	ADJ	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
:	O	PUNCT	O
Toxic	B-Disease	NOUN	B
hepatitis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
potential	O	ADJ	B
adverse	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
antithyroid	O	ADJ	B
drugs	O	NOUN	I
which	O	DET	O
warrants	O	VERB	O
,	O	PUNCT	O
as	O	ADP	O
for	O	ADP	O
haematological	O	ADJ	B
disturbances	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
pre	O	ADJ	B
-	O	PUNCT	O
therapeutic	O	ADJ	B
determination	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
careful	O	ADJ	O
follow	O	NOUN	B
-	O	PUNCT	O
up	O	NOUN	O
of	O	ADP	O
relevant	O	ADJ	B
biological	O	ADJ	B
markers	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
prospective	O	ADJ	B
,	O	PUNCT	O
randomized	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
conducted	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
B12	I-Chemical	NOUN	I
and	O	CCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
supplementation	O	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
zidovudine	B-Chemical	NOUN	B
(	O	PUNCT	O
ZDV	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
bone	B-Disease	NOUN	B
marrow	I-Disease	NOUN	I
suppression	I-Disease	NOUN	B
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
vitamin	B-Chemical	NOUN	B
B12	I-Chemical	NOUN	I
and	O	CCONJ	O
folate	B-Chemical	NOUN	B
levels	O	NOUN	I
were	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
group	O	NOUN	B
II	O	NUM	I
patients	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
hemoglobin	O	NOUN	B
,	O	PUNCT	O
hematocrit	O	NOUN	B
,	O	PUNCT	O
mean	O	ADJ	B
corpuscular	O	ADJ	I
volume	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
white	O	ADJ	B
-	O	PUNCT	O
cell	O	NOUN	B
,	O	PUNCT	O
neutrophil	O	NOUN	B
and	O	CCONJ	O
platelet	O	NOUN	B
counts	O	NOUN	I
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
at	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Severe	O	ADJ	B
hematologic	O	ADJ	B
toxicity	B-Disease	NOUN	B
(	O	PUNCT	O
neutrophil	O	NOUN	B
count	O	NOUN	O
<	O	X	O
1000	O	NUM	O
/	O	SYM	O
mm3	O	NUM	B
and	O	CCONJ	O
/	O	SYM	B
or	O	CCONJ	O
hemoglobin	O	NOUN	B
<	O	NOUN	O
8	O	NUM	O
g	O	NOUN	B
/	O	SYM	O
dl	O	NOUN	B
)	O	PUNCT	O
occurred	O	VERB	O
in	O	ADP	O
4	O	NUM	O
patients	O	NOUN	B
assigned	O	VERB	O
to	O	PART	O
group	O	NOUN	B
I	O	NUM	I
and	O	CCONJ	O
7	O	NUM	O
assigned	O	VERB	B
to	O	PART	O
group	O	NOUN	B
II	O	NUM	I
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
vitamin	B-Chemical	NOUN	B
B12	I-Chemical	NOUN	I
or	O	CCONJ	O
folate	B-Chemical	NOUN	B
levels	O	NOUN	I
and	O	CCONJ	O
development	O	NOUN	B
of	O	ADP	O
myelosuppression	B-Disease	NOUN	B
.	O	PUNCT	O


Acute	O	ADJ	B
confusion	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
a	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
infusion	O	NOUN	B
of	O	ADP	O
5-fluorouracil	B-Chemical	NOUN	B
and	O	CCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
.	O	PUNCT	O


He	O	PRON	O
developed	O	VERB	O
acute	O	ADJ	B
neurologic	O	ADJ	O
symptoms	O	NOUN	O
of	O	ADP	O
mental	O	ADJ	B
confusion	B-Disease	NOUN	I
,	O	PUNCT	O
disorientation	B-Disease	NOUN	B
and	O	CCONJ	O
irritability	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
lapsed	O	VERB	B
into	O	ADP	O
a	O	DET	O
deep	O	ADJ	B
coma	B-Disease	NOUN	I
,	O	PUNCT	O
lasting	O	VERB	O
for	O	ADP	O
approximately	O	ADV	B
40	O	NUM	O
hours	O	NOUN	B
during	O	ADP	O
the	O	DET	O
first	O	ADJ	B
dose	O	NOUN	I
(	O	PUNCT	O
day	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
5-fluorouracil	B-Chemical	NOUN	B
and	O	CCONJ	O
folinic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
infusion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
5-fluorouracil	B-Chemical	NOUN	B
neurotoxicity	B-Disease	NOUN	B
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
Krebs	O	NOUN	B
cycle	O	NOUN	I
blockade	O	NOUN	I
by	O	ADP	O
fluoroacetate	B-Chemical	NOUN	B
and	O	CCONJ	O
fluorocitrate	B-Chemical	NOUN	B
,	O	PUNCT	O
thiamine	B-Chemical	NOUN	B
deficiency	O	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
dihydrouracil	B-Chemical	NOUN	B
dehydrogenase	O	NOUN	I
deficiency	O	NOUN	I
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
switching	O	VERB	B
carbamazepine	B-Chemical	NOUN	B
to	O	ADP	O
oxcarbazepine	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
neuroleptics	O	NOUN	B
.	O	PUNCT	O


Carbamazepine	B-Chemical	PROPN	B
was	O	AUX	O
switched	O	VERB	O
to	O	ADP	O
its	O	PRON	O
10	O	NUM	O
-	O	PUNCT	O
keto	O	NOUN	B
analogue	O	NOUN	B
oxcarbazepine	B-Chemical	NOUN	B
among	O	ADP	O
six	O	NUM	O
difficult	O	ADJ	B
-	O	PUNCT	O
to	O	PART	O
-	O	PUNCT	O
treat	O	VERB	B
schizophrenic	B-Disease	ADJ	B
or	O	CCONJ	O
organic	B-Disease	ADJ	B
psychotic	I-Disease	ADJ	B
patients	O	NOUN	B
using	O	VERB	O
concomitantly	O	ADV	O
haloperidol	B-Chemical	NOUN	B
,	O	PUNCT	O
chlorpromazine	B-Chemical	NOUN	B
or	O	CCONJ	O
clozapine	B-Chemical	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
:	O	PUNCT	O
To	O	PART	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
erythema	B-Disease	NOUN	B
multiforme	I-Disease	NOUN	I
and	O	CCONJ	O
hypersensitivity	B-Disease	NOUN	B
myocarditis	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
ampicillin	B-Chemical	NOUN	B
.	O	PUNCT	O


Medications	O	NOUN	B
were	O	AUX	O
discontinued	O	VERB	B
when	O	SCONJ	O
erythema	B-Disease	NOUN	B
multiforme	I-Disease	NOUN	I
and	O	CCONJ	O
congestive	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
failure	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
myocarditis	B-Disease	NOUN	B
occurred	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
methylprednisolone	B-Chemical	NOUN	B
and	O	CCONJ	O
gradually	O	ADV	O
improved	O	VERB	B
.	O	PUNCT	O


Positive	O	ADJ	B
MIF	O	NOUN	O
test	O	NOUN	O
for	O	ADP	O
ampicillin	B-Chemical	NOUN	B
showed	O	VERB	O
sensitization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
lymphocytes	O	NOUN	B
to	O	PART	O
ampicillin	B-Chemical	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
:	O	PUNCT	O
Hypersensitivity	B-Disease	NOUN	B
myocarditis	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
and	O	CCONJ	O
dangerous	O	ADJ	O
manifestation	O	NOUN	B
of	O	ADP	O
allergy	B-Disease	NOUN	B
to	O	PART	O
penicillins	B-Chemical	NOUN	B


A	O	DET	O
large	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
suspected	O	VERB	B
allergic	B-Disease	ADJ	B
reactions	I-Disease	NOUN	I
to	O	PART	O
beta-lactam	B-Chemical	NOUN	B
antibiotics	O	NOUN	I
was	O	AUX	O
evaluated	O	VERB	B
.	O	PUNCT	O


RAST	O	NOUN	B
for	O	ADP	O
BPO-PLL	B-Chemical	NOUN	B
and	O	CCONJ	O
AX	B-Chemical	PROPN	B
-	O	PUNCT	O
PLL	O	PROPN	B
was	O	AUX	O
done	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
177	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
diagnosed	O	VERB	B
as	O	ADP	O
allergic	B-Disease	ADJ	B
to	O	PART	O
beta-lactam	B-Chemical	NOUN	B
antibiotics	O	NOUN	I
.	O	PUNCT	O


Anaphylaxis	B-Disease	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
37	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
69	O	NUM	O
%),	O	VERB	O
the	O	DET	O
other	O	ADJ	O
17	O	NUM	O
(	O	PUNCT	O
31	O	NUM	O
%)	O	NOUN	O
having	O	VERB	O
urticaria	B-Disease	NOUN	B
and	O	CCONJ	O
/	O	SYM	B
or	O	CCONJ	O
angioedema	B-Disease	NOUN	B
.	O	PUNCT	O


All	O	DET	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
skin	O	NOUN	B
test	O	NOUN	I
negative	O	ADJ	B
to	O	ADP	O
BPO	B-Chemical	NOUN	B
;	O	PUNCT	O
49	O	NUM	O
of	O	ADP	O
51	O	NUM	O
(	O	PUNCT	O
96	O	NUM	O
%)	O	NOUN	O
were	O	AUX	O
also	O	ADV	O
negative	O	ADJ	B
to	O	PART	O
MDM	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
44	O	NUM	O
of	O	ADP	O
46	O	NUM	O
(	O	PUNCT	O
96	O	NUM	O
%)	O	NOUN	O
to	O	PART	O
PG	B-Chemical	NOUN	B
.	O	PUNCT	O


Skin	O	NOUN	B
tests	O	NOUN	I
with	O	ADP	O
AX	B-Chemical	NOUN	B
were	O	AUX	O
positive	O	ADJ	B
in	O	ADP	O
34	O	NUM	O
(	O	PUNCT	O
63	O	NUM	O
%)	O	NOUN	O
patients	O	NOUN	B
.	O	PUNCT	O


PG	B-Chemical	NOUN	B
was	O	AUX	O
well	O	ADV	O
tolerated	O	VERB	B
by	O	ADP	O
all	O	DET	O
54	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
largest	O	ADJ	O
group	O	NOUN	B
of	O	ADP	O
AX	B-Chemical	PROPN	B
-	O	PUNCT	O
allergic	B-Disease	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
tolerated	O	VERB	B
PG	B-Chemical	NOUN	B
reported	O	VERB	O
so	O	ADV	O
far	O	ADV	O
.	O	PUNCT	O


Reports	O	NOUN	B
of	O	ADP	O
persistent	O	ADJ	B
paralysis	B-Disease	NOUN	B
after	O	ADP	O
the	O	DET	O
discontinuance	O	NOUN	B
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B
have	O	AUX	O
most	O	ADV	O
often	O	ADV	O
involved	O	VERB	O
aminosteroid	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
NMBAs	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
vecuronium	B-Chemical	NOUN	B
bromide	I-Chemical	NOUN	I
,	O	PUNCT	O
especially	O	ADV	O
when	O	SCONJ	O
used	O	VERB	O
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
corticosteroids	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
atracurium	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
paralysis	B-Disease	NOUN	B


Six	O	NUM	O
epidemiologic	O	ADJ	B
studies	O	NOUN	I
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
and	O	CCONJ	O
Europe	O	PROPN	B
indicate	O	VERB	O
that	O	SCONJ	O
habitual	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
phenacetin	B-Chemical	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
and	O	CCONJ	O
end-stage	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
ESRD	B-Disease	NOUN	B
),	O	PUNCT	O
with	O	ADP	O
a	O	DET	O
relative	O	ADJ	B
risk	O	NOUN	I
in	O	ADP	O
the	O	DET	O
range	O	NOUN	B
of	O	ADP	O
4	O	NUM	O
to	O	PART	O
19	O	NUM	O
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
these	O	DET	O
and	O	CCONJ	O
other	O	ADJ	O
studies	O	NOUN	B
,	O	PUNCT	O
phenacetin	B-Chemical	NOUN	B
has	O	AUX	O
now	O	ADV	O
been	O	AUX	O
withdrawn	O	VERB	O
from	O	ADP	O
the	O	DET	O
market	O	NOUN	B
in	O	ADP	O
most	O	ADJ	O
countries	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
phenacetin	B-Chemical	NOUN	B
and	O	CCONJ	O
acetaminophen	B-Chemical	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
burden	O	NOUN	B
of	O	ADP	O
ESRD	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
being	O	AUX	O
somewhat	O	ADV	O
less	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
former	O	NOUN	O
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
both	O	CCONJ	O
as	O	ADP	O
a	O	DET	O
single	O	ADJ	O
agent	O	NOUN	O
and	O	CCONJ	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
analgesics	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
phenacetin	B-Chemical	NOUN	B
was	O	AUX	O
available	O	ADJ	O
only	O	ADV	O
in	O	ADP	O
combinations	O	NOUN	B
.	O	PUNCT	O


Reduction	O	NOUN	B
of	O	ADP	O
heparan	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
anionic	O	ADJ	B
sites	O	NOUN	I
in	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
basement	O	NOUN	I
membrane	O	NOUN	I
of	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetic	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
anionic	O	ADJ	B
sites	O	NOUN	I
(	O	PUNCT	O
74	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
diabetic	B-Disease	ADJ	B
and	O	CCONJ	O
81	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
control	O	ADJ	B
rats	O	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
within	O	ADP	O
the	O	DET	O
lamina	O	NOUN	B
rara	O	X	O
externa	O	NOUN	O
of	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
basement	O	NOUN	I
membrane	O	NOUN	I
.	O	PUNCT	O


002	O	NUM	O
).	O	PUNCT	B
At	O	ADP	O
the	O	DET	O
same	O	ADJ	O
time	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
heparan	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	B
anionic	O	ADJ	B
sites	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
total	O	ADJ	O
anionic	O	ADJ	B
site	O	NOUN	I
surface	O	NOUN	B
(	O	PUNCT	O
number	O	NOUN	O
of	O	ADP	O
anionic	O	ADJ	B
sites	O	NOUN	I
x	O	NOUN	O
mean	O	ADJ	O
anionic	O	ADJ	B
site	O	NOUN	I
surface	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
lamina	O	NOUN	B
rara	O	X	I
externa	O	NOUN	I
of	O	ADP	O
the	O	DET	O
glomerular	O	ADJ	B
basement	O	NOUN	I
membrane	O	NOUN	I
was	O	AUX	O
reduced	O	VERB	B
by	O	ADP	O
19	O	NUM	O
%(	O	NOUN	O
p	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
streptozotocin	B-Chemical	NOUN	B
-	O	PUNCT	O
diabetic	B-Disease	ADJ	B
rats	O	NOUN	B
with	O	ADP	O
an	O	DET	O
increased	O	VERB	B
urinary	O	ADJ	B
albumin	O	NOUN	I
excretion	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
reduced	O	VERB	B
heparan	B-Chemical	NOUN	B
sulphate	I-Chemical	NOUN	O


Effect	O	NOUN	B
of	O	ADP	O
some	O	DET	O
anticancer	O	NOUN	B
drugs	O	NOUN	I
and	O	CCONJ	O
combined	O	ADJ	B
chemotherapy	O	NOUN	I
on	O	ADP	O
renal	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
MTX	B-Chemical	NOUN	B
administration	O	NOUN	B
a	O	DET	O
significant	O	ADJ	O
increase	O	NOUN	B
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


0001	O	NUM	O
)	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
compared	O	VERB	O
to	O	PART	O
controls	O	NOUN	B
.	O	PUNCT	O


0343	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
creatinine	B-Chemical	NOUN	B
clearance	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
creatinine	B-Chemical	NOUN	B
concentration	O	NOUN	B
did	O	AUX	O
not	O	PART	O
increase	O	VERB	B
significantly	O	ADV	O
compared	O	VERB	O
to	O	PART	O
controls	O	NOUN	B
.	O	PUNCT	O


CY	B-Chemical	PROPN	B
caused	O	VERB	O
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
in	O	ADP	O
40	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
rats	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
it	O	PRON	O
did	O	AUX	O
not	O	PART	O
cause	O	VERB	O
this	O	DET	O
complication	O	NOUN	B
when	O	SCONJ	O
combined	O	VERB	B
with	O	ADP	O
5-FU	B-Chemical	NOUN	B
and	O	CCONJ	O
MTX	B-Chemical	NOUN	B
.	O	PUNCT	O


Lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
cognitive	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
functional	I-Disease	ADJ	B
deficits	I-Disease	NOUN	I
reduced	O	VERB	B
by	O	ADP	O
a	O	DET	O
switch	O	NOUN	B
to	O	PART	O
divalproex	B-Chemical	NOUN	B
sodium	I-Chemical	NOUN	I
:	O	PUNCT	O
a	O	DET	O
case	O	NOUN	B
series	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
much	O	ADJ	O
has	O	AUX	O
been	O	AUX	O
written	O	VERB	B
about	O	ADP	O
the	O	DET	O
management	O	NOUN	B
of	O	ADP	O
the	O	DET	O
more	O	ADV	O
common	O	ADJ	O
adverse	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
lithium	B-Chemical	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
polyuria	B-Disease	NOUN	B
and	O	CCONJ	O
tremor	B-Disease	NOUN	B
,	O	PUNCT	O
more	O	ADV	O
subtle	O	ADJ	O
lithium	B-Chemical	NOUN	B
side	O	NOUN	B
effects	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
cognitive	B-Disease	ADJ	B
deficits	I-Disease	NOUN	I
,	O	PUNCT	O
loss	B-Disease	NOUN	B
of	I-Disease	ADP	O
creativity	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
functional	B-Disease	ADJ	B
impairments	I-Disease	NOUN	I
remain	O	VERB	O
understudied	O	ADJ	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
report	O	VERB	O
seven	O	NUM	O
cases	O	NOUN	B
where	O	SCONJ	O
substitution	O	NOUN	B
of	O	ADP	O
lithium	B-Chemical	NOUN	B
,	O	PUNCT	O
either	O	CCONJ	O
fully	O	ADV	O
or	O	CCONJ	O
partially	O	ADV	B
,	O	PUNCT	O
with	O	ADP	O
divalproex	B-Chemical	NOUN	B
sodium	I-Chemical	NOUN	I
was	O	AUX	O
extremely	O	ADV	O
helpful	O	ADJ	O
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
cognitive,	B-Disease	PROPN	B
motivational,	I-Disease	NOUN	B
or	I-Disease	CCONJ	O
creative	I-Disease	ADJ	B
deficits	I-Disease	NOUN	I
attributed	O	VERB	O
to	O	PART	O
lithium	B-Chemical	NOUN	B
in	O	ADP	O
our	O	PRON	O
bipolar	B-Disease	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
of	O	ADP	O
previously	O	ADV	O
treated	O	VERB	B
metastatic	O	ADJ	B
breast	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
by	O	ADP	O
mitoxantrone	B-Chemical	NOUN	B
and	O	CCONJ	O
48	O	NUM	O
-	O	PUNCT	O
hour	O	NOUN	B
continuous	O	ADJ	B
infusion	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
5-FU	B-Chemical	NOUN	B
and	O	CCONJ	O
leucovorin	B-Chemical	NOUN	B
(	O	PUNCT	O
MFL	B-Chemical	PROPN	B
):	O	PUNCT	O
low	O	ADJ	B
palliative	O	ADJ	B
benefit	O	NOUN	I
and	O	CCONJ	O
high	O	ADJ	B
treatment	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Combination	O	NOUN	B
chemotherapy	O	NOUN	I
with	O	ADP	O
mitoxantrone	B-Chemical	NOUN	B
,	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
dose	O	NOUN	B
5-fluorouracil	B-Chemical	NOUN	B
(	O	PUNCT	O
5-FU	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
leucovorin	B-Chemical	NOUN	B
(	O	PUNCT	O
MFL	B-Chemical	PROPN	B
regimen	I-Chemical	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
as	O	ADP	O
an	O	DET	O
effective	O	ADJ	B
and	O	CCONJ	O
well	O	ADV	O
tolerated	O	ADJ	B
regimen	O	NOUN	B
.	O	PUNCT	O


Median	O	ADJ	B
number	O	NOUN	O
of	O	ADP	O
courses	O	NOUN	B
of	O	ADP	O
MFL	B-Chemical	PROPN	B
regimen	I-Chemical	NOUN	B
given	O	VERB	O
was	O	AUX	O
six	O	NUM	O
and	O	CCONJ	O
the	O	DET	O
median	O	ADJ	B
cumulative	O	ADJ	B
dose	O	NOUN	B
of	O	ADP	O
mitoxantrone	B-Chemical	NOUN	B
was	O	AUX	O
68	O	NUM	O
.	O	PUNCT	O


Major	O	ADJ	O
toxicities	B-Disease	NOUN	B
were	O	AUX	O
cardiotoxicity	B-Disease	NOUN	B
and	O	CCONJ	O
leukopenia	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
MFL	B-Chemical	PROPN	B
regimen	I-Chemical	NOUN	B
achieves	O	VERB	O
little	O	ADJ	O
palliative	O	ADJ	B
benefit	O	NOUN	I
and	O	CCONJ	O
induces	O	VERB	O
severe	O	ADJ	B
toxicity	B-Disease	NOUN	B
at	O	ADP	O
a	O	DET	O
fairly	O	ADV	O
high	O	ADJ	O
rate	O	NOUN	B
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
this	O	DET	O
regimen	O	NOUN	B
to	O	PART	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
been	O	AUX	O
treated	O	VERB	B
by	O	ADP	O
chemotherapy	O	NOUN	B
and	O	CCONJ	O
those	O	DET	O
with	O	ADP	O
impaired	B-Disease	ADJ	B
heart	I-Disease	NOUN	O
function	I-Disease	NOUN	O


The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
arginine	B-Chemical	NOUN	B
vasopressin	I-Chemical	NOUN	I
(	O	PUNCT	I
AVP	B-Chemical	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
in	O	ADP	O
the	O	DET	O
paraventricular	O	NOUN	B
(	O	PUNCT	O
PVN	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
supraoptic	O	ADJ	B
nuclei	O	NOUN	I
(	O	PUNCT	O
SON	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
rats	O	NOUN	B
with	O	ADP	O
lithium	B-Chemical	NOUN	B
(	O	PUNCT	O
Li	B-Chemical	PROPN	B
)-	O	ADJ	O
induced	O	VERB	B
polyuria	B-Disease	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
histochemistry	O	NOUN	I
and	O	CCONJ	O
radioimmunoassay	O	NOUN	B
.	O	PUNCT	O


Plasma	O	NOUN	B
sodium	B-Chemical	NOUN	B
concentrations	O	NOUN	I
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
slightly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
Li	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
in	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
dehydration	B-Disease	NOUN	B
and	O	CCONJ	O
/	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
activation	O	NOUN	B
of	O	ADP	O
visceral	O	ADJ	B
afferent	O	NOUN	B
inputs	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
the	O	DET	O
elevation	O	NOUN	B
of	O	ADP	O
plasma	O	NOUN	B
AVP	B-Chemical	NOUN	B
and	O	CCONJ	O
the	O	DET	O
upregulation	O	NOUN	B
of	O	ADP	O
AVP	B-Chemical	NOUN	B
gene	O	NOUN	B
expression	O	NOUN	I
in	O	ADP	O
the	O	DET	O
PVN	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
SON	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Li	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
diabetes	B-Disease	NOUN	B
insipidus	I-Disease	NOUN	I


The	O	DET	O
serum	O	NOUN	B
level	O	NOUN	B
of	O	ADP	O
potassium	B-Chemical	NOUN	B
was	O	AUX	O
observed	O	VERB	O
to	O	PART	O
be	O	AUX	O
8	O	NUM	O
.	O	PUNCT	O


225	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
for	O	ADP	O
correction	O	NOUN	B
of	O	ADP	O
Dupuytren's	B-Disease	PROPN	B
contracture	I-Disease	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
labetalol	B-Chemical	NOUN	B
,	O	PUNCT	O
metoprolol	B-Chemical	NOUN	B
and	O	CCONJ	O
midazolam	B-Chemical	NOUN	B
the	O	DET	O
patient	O	NOUN	B
'	O	PART	O
s	O	NOUN	O
condition	O	NOUN	B
improved	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
15	O	NUM	O
min	O	NOUN	O
later	O	ADV	O
he	O	PRON	O
woke	O	VERB	O
up	O	ADP	O
.	O	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
histopathologic	O	ADJ	B
examination	O	NOUN	I
of	O	ADP	O
renal	O	ADJ	B
allografts	O	NOUN	I
treated	O	VERB	B
with	O	ADP	I
tacrolimus	B-Chemical	NOUN	B
(	O	PUNCT	O
FK506	B-Chemical	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
at	O	ADP	O
least	O	ADV	O
one	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


Memory	O	NOUN	B
facilitation	O	NOUN	I
and	O	CCONJ	O
stimulation	O	NOUN	B
of	O	ADP	O
endogenous	O	ADJ	B
nerve	O	NOUN	B
growth	O	NOUN	I
factor	O	NOUN	I
synthesis	O	NOUN	I
by	O	ADP	O
the	O	DET	O
acetylcholine	B-Chemical	NOUN	B
releaser	O	NOUN	I
PG-9	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
passive	O	ADJ	B
-	O	PUNCT	O
avoidance	O	NOUN	B
test	O	NOUN	I
,	O	PUNCT	O
PG-9	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
30	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


v	O	DET	O
.)	O	NOUN	O
was	O	AUX	O
also	O	ADV	O
able	O	ADJ	O
to	O	PART	O
prevent	O	VERB	O
antimuscarine	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
amnesia	B-Disease	NOUN	B
,	O	PUNCT	O
demonstrating	O	VERB	O
a	O	DET	O
central	O	ADJ	O
localization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
highest	O	ADJ	O
effective	O	ADJ	B
doses	O	NOUN	B
,	O	PUNCT	O
PG-9	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
produce	O	VERB	O
any	O	DET	O
collateral	O	ADJ	B
symptoms	O	NOUN	I
as	O	ADP	O
revealed	O	VERB	O
by	O	ADP	O
the	O	DET	O
Irwin	O	PROPN	B
test	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
did	O	AUX	O
not	O	PART	O
modify	O	VERB	O
spontaneous	O	ADJ	B
motility	O	NOUN	B
and	O	CCONJ	O
inspection	O	NOUN	B
activity	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
revealed	O	VERB	O
by	O	ADP	O
the	O	DET	O
hole	O	NOUN	B
-	O	PUNCT	O
board	O	NOUN	B
test	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
maximal	O	ADJ	B
NGF	O	NOUN	B
contents	O	NOUN	B
obtained	O	VERB	O
by	O	ADP	O
PG-9	B-Chemical	NOUN	B
were	O	AUX	O
17	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
work	O	NOUN	O
indicates	O	VERB	O
the	O	DET	O
ability	O	NOUN	O
of	O	ADP	O
PG-9	B-Chemical	NOUN	B
to	O	PART	O
induce	O	VERB	B
beneficial	O	ADJ	O
effects	O	NOUN	B
on	O	ADP	O
cognitive	O	ADJ	B
processes	O	NOUN	I
and	O	CCONJ	O
stimulate	O	VERB	B
activity	O	NOUN	B
of	O	ADP	O
NGF	O	NOUN	B
synthesis	O	NOUN	B
in	O	ADP	O
astroglial	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


Accumulation	O	NOUN	B
of	O	ADP	O
atracurium	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
intravenous	O	ADJ	B
line	O	NOUN	I
led	O	VERB	O
to	O	PART	O
recurarization	O	NOUN	B
after	O	ADP	O
flushing	O	VERB	B
the	O	DET	O
line	O	NOUN	O
in	O	ADP	O
the	O	DET	O
recovery	O	NOUN	B
room	O	NOUN	I
.	O	PUNCT	O


Circumstances	O	NOUN	B
leading	O	VERB	O
to	O	ADP	O
this	O	DET	O
event	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
mechanisms	O	NOUN	B
enabling	O	VERB	O
a	O	DET	O
neuromuscular	B-Disease	ADJ	B
blockade	I-Disease	NOUN	I


Over	O	ADP	O
the	O	DET	O
period	O	NOUN	B
1993	O	NUM	O
-	O	SYM	O
1996	O	NUM	O
,	O	PUNCT	O
551	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
VTE	B-Disease	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
Germany	O	PROPN	B
and	O	CCONJ	O
the	O	DET	O
UK	O	PROPN	B
along	O	ADP	O
with	O	ADP	O
2066	O	NUM	O
controls	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
development	O	NOUN	B
of	O	ADP	O
apomorphine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


once	O	ADV	B
daily	O	ADV	I
)	O	PUNCT	O
aggressive	B-Disease	ADJ	B
behavior	I-Disease	NOUN	I
of	O	ADP	O
adult	O	ADJ	B
male	O	NOUN	B
and	O	CCONJ	O
female	O	ADJ	B
Wistar	O	PROPN	B
rats	O	NOUN	I
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
breeder	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
two	O	NUM	O
consecutive	O	ADJ	B
sets	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
urinary	B-Disease	ADJ	B
incontinence	I-Disease	NOUN	I
is	O	AUX	O
listed	O	VERB	O
as	O	ADP	O
one	O	NUM	O
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
these	O	DET	O
drugs	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
package	O	NOUN	B
inserts	O	NOUN	I
there	O	PRON	O
is	O	AUX	O
only	O	ADV	O
one	O	NUM	O
report	O	NOUN	B
in	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
spasticity	B-Disease	NOUN	B
,	O	PUNCT	O
certain	O	ADJ	O
adverse	O	ADJ	B
cardiorespiratory	O	ADJ	B
effects	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
:	O	PUNCT	O
An	O	DET	O
association	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
between	O	ADP	O
transplant	B-Disease	NOUN	B
glomerulopathy	I-Disease	NOUN	I
(	O	PUNCT	O
TG	B-Disease	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
reduplication	O	NOUN	B
of	O	ADP	O
peritubular	O	ADJ	B
capillary	O	ADJ	I
basement	O	NOUN	O
membranes	O	NOUN	O
(	O	PUNCT	O
PTCR	O	NOUN	B
).	O	PUNCT	O
Although	O	SCONJ	O
such	O	DET	O
an	O	DET	O
association	O	NOUN	B
is	O	AUX	O
of	O	ADP	O
practical	O	ADJ	B
and	O	CCONJ	O
theoretical	O	ADJ	B
importance	O	NOUN	O
,	O	PUNCT	O
only	O	ADV	O
one	O	NUM	O
prospective	O	ADJ	B
study	O	NOUN	I
has	O	AUX	O
tried	O	VERB	O
to	O	PART	O
confirm	O	VERB	O
it	O	PRON	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
:	O	PUNCT	O
We	O	PRON	O
found	O	VERB	O
PTCR	O	NOUN	B
in	O	ADP	O
14	O	NUM	O
of	O	ADP	O
15	O	NUM	O
cases	O	NOUN	B
of	O	ADP	O
TG	B-Disease	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
7	O	NUM	O
transplant	O	NOUN	B
biopsy	O	NOUN	B
specimens	O	NOUN	I
without	O	ADP	O
TG	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
13	O	NUM	O
of	O	ADP	O
143	O	NUM	O
native	O	ADJ	B
kidney	O	NOUN	O
biopsy	O	NOUN	O
specimens	O	NOUN	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
:	O	PUNCT	O
We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
transplants	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
strong	O	ADJ	O
association	O	NOUN	B
between	O	ADP	O
well	O	ADV	O
-	O	PUNCT	O
developed	O	VERB	B
PTCR	O	NOUN	B
and	O	CCONJ	O
TG	B-Disease	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
significance	O	NOUN	B
of	O	ADP	O
mild	O	ADJ	B
PTCR	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
predictive	O	ADJ	B
value	O	NOUN	I
in	O	ADP	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
TG	B-Disease	NOUN	B
is	O	AUX	O
unclear	O	ADJ	B
.	O	PUNCT	O


We	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
repeated	O	VERB	O
endothelial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
immunologic	B-Disease	ADJ	B
injury	I-Disease	NOUN	I


Conformationally	O	ADV	B
restricted	O	ADJ	I
analogs	O	NOUN	B
of	O	ADP	O
BD1008	B-Chemical	NOUN	B
and	O	CCONJ	O
an	O	DET	O
antisense	O	ADJ	B
oligodeoxynucleotide	B-Chemical	NOUN	I
targeting	O	NOUN	O
sigma1	O	NOUN	B
receptors	O	NOUN	I
produce	O	VERB	O
anti	O	ADJ	B
-	O	PUNCT	O
cocaine	B-Chemical	NOUN	B
effects	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
three	O	NUM	O
novel	O	ADJ	B
sigma	O	NOUN	B
receptor	O	NOUN	I
ligands	O	NOUN	B
with	O	ADP	O
antagonist	O	NOUN	B
activity	O	NOUN	B
were	O	AUX	O
evaluated	O	VERB	B
in	O	ADP	O
Swiss	O	ADJ	B
Webster	O	PROPN	I
mice	O	NOUN	I
:	O	PUNCT	O
BD1018	B-Chemical	NOUN	B
(	O	PUNCT	O
3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	B-Chemical	NOUN	O
),	O	PUNCT	O
BD1063	B-Chemical	NOUN	B
(	O	PUNCT	O
1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine	B-Chemical	NOUN	B
),	O	PUNCT	O
and	O	CCONJ	O
LR132	B-Chemical	NOUN	B
(	O	PUNCT	O
1R	O	NOUN	B
,	O	PUNCT	O
2S	O	NOUN	B
-(+)-	O	NOUN	I
cis	O	NOUN	I
-	O	PUNCT	O
N	O	NOUN	B
-[	O	NOUN	O
2	O	NUM	O
-(	O	NOUN	O
3	O	NUM	O
,	O	PUNCT	O
4	O	NUM	O
-	O	PUNCT	O
dichlorophenyl	O	NOUN	B
)	O	PUNCT	O
ethyl	O	NOUN	B
]-	O	NOUN	I
2	O	NUM	O
-(	O	NOUN	O
1	O	NUM	O
-	O	PUNCT	O
pyrrolidinyl	O	NOUN	B
)	O	PUNCT	O
cyclohexylamine	O	NOUN	B
).	O	PUNCT	B
Competition	O	NOUN	O
binding	O	NOUN	O
assays	O	NOUN	O
demonstrated	O	VERB	O
that	O	SCONJ	O
all	O	DET	O
three	O	NUM	O
compounds	O	NOUN	B
have	O	AUX	O
high	O	ADJ	O
affinities	O	NOUN	B
for	O	ADP	O
sigma1	O	NOUN	B
receptors	O	NOUN	I
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
post	O	NOUN	B
-	O	PUNCT	O
treatment	O	NOUN	B
with	O	ADP	O
LR132	B-Chemical	NOUN	B
prevented	O	VERB	B
cocaine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
lethality	O	NOUN	B
in	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
animals	O	NOUN	B
.	O	PUNCT	O


Together	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
data	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
functional	O	ADJ	B
antagonism	O	NOUN	B
of	O	ADP	O
sigma	O	NOUN	B
receptors	O	NOUN	I
is	O	AUX	O
capable	O	ADJ	O
of	O	ADP	O
attenuating	O	VERB	B
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
cocaine	B-Chemical	NOUN	B


terfenadine	B-Chemical	NOUN	B
and	O	CCONJ	O
terodiline	B-Chemical	NOUN	B
).	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
potential	O	NOUN	B
of	O	ADP	O
compounds	O	NOUN	B
to	O	PART	O
cause	O	VERB	O
TDP	B-Disease	NOUN	B
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
monitoring	O	VERB	B
their	O	PRON	O
effects	O	NOUN	B
on	O	ADP	O
MAPD	O	NOUN	B
in	O	ADP	O
dog	O	NOUN	B
.	O	PUNCT	O


9	O	NUM	O
nM	O	NOUN	O
),	O	PUNCT	O
terodiline	B-Chemical	NOUN	B
(	O	PUNCT	O
76	O	NUM	O
nM	O	NOUN	O
),	O	PUNCT	O
cisapride	B-Chemical	NOUN	B
(	O	PUNCT	O
11	O	NUM	O
nM	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
E4031	B-Chemical	NOUN	B
(	O	PUNCT	O
1	O	NUM	O
.	O	PUNCT	O


Clinically	O	ADV	B
,	O	PUNCT	O
the	O	DET	O
onset	O	NOUN	O
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
the	O	DET	O
signs	O	NOUN	O
of	O	ADP	O
opistothonus,	B-Disease	ADJ	O
sensory	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
motor	I-Disease	NOUN	B
dysfunction	I-Disease	NOUN	I
and	O	CCONJ	O
ascending	O	VERB	B
paralysis	B-Disease	NOUN	B
.	O	PUNCT	O


A	O	DET	O
better	O	ADV	O
controlled	O	VERB	B
regimen	O	NOUN	I
for	O	ADP	O
administering	O	VERB	B
vincristine	B-Chemical	NOUN	B


The	O	DET	O
intensity	O	NOUN	B
of	O	ADP	O
headache	B-Disease	NOUN	B
and	O	CCONJ	O
nausea	B-Disease	NOUN	B
was	O	AUX	O
measured	O	VERB	B
with	O	ADP	O
a	O	DET	O
100	O	NUM	O
-	O	PUNCT	O
mm	O	NOUN	B
visual	O	ADJ	I
analog	O	NOUN	I
scale	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
cholinergic	O	ADJ	B
activity	O	NOUN	B
and	O	CCONJ	O
responsiveness	O	NOUN	B
and	O	CCONJ	O
alcohol	B-Chemical	NOUN	B
withdrawal	O	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
a	O	DET	O
genetic	O	ADJ	B
animal	O	NOUN	I
model	O	NOUN	O
of	O	ADP	O
ethanol	B-Chemical	NOUN	B
withdrawal	O	NOUN	O
severity	O	NOUN	B
.	O	PUNCT	O


Potassium	B-Chemical	NOUN	B
was	O	AUX	O
applied	O	VERB	O
by	O	ADP	O
reverse	O	ADJ	B
dialysis	O	NOUN	I
twice	O	ADV	O
,	O	PUNCT	O
separated	O	VERB	O
by	O	ADP	O
75	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
release	O	NOUN	B
of	O	ADP	O
ACh	B-Chemical	NOUN	B
produced	O	VERB	O
by	O	ADP	O
the	O	DET	O
first	O	ADJ	O
application	O	NOUN	B
of	O	ADP	O
KCl	B-Chemical	NOUN	B
was	O	AUX	O
2	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
higher	O	ADJ	B
in	O	ADP	O
WSP	O	NOUN	B
versus	O	CCONJ	O
WSR	O	NOUN	B
mice	O	NOUN	I
.	O	PUNCT	O


Six	O	NUM	B
-	O	PUNCT	O
to	O	ADP	O
9	O	NUM	B
-	O	PUNCT	O
month	O	NOUN	B
old	O	ADJ	O
rats	O	NOUN	B
receiving	O	VERB	O
prenatal	O	ADJ	B
dexamethasone	B-Chemical	NOUN	B
on	O	ADP	O
days	O	NOUN	B
17	O	NUM	O
and	O	CCONJ	O
18	O	NUM	O
of	O	ADP	O
gestation	O	NOUN	B
had	O	AUX	O
a	O	DET	O
17	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
glomeruli	O	NOUN	B
(	O	PUNCT	O
23	O	NUM	O
380	O	NUM	O
+/-	O	CCONJ	O
587	O	NUM	O
)	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
control	O	ADJ	B
rats	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


08	O	NUM	O
)	O	PUNCT	O
for	O	ADP	O
CPA	B-Chemical	NOUN	B
/	O	PUNCT	O
EE	B-Chemical	PROPN	B
use	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
an	O	DET	O
OR	O	NOUN	B
(	O	PUNCT	O
adj	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
2	O	NUM	O
.	O	PUNCT	O


Risks	O	NOUN	B
of	O	ADP	O
the	O	DET	O
consumption	O	NOUN	B
of	O	ADP	O
beverages	O	NOUN	B
containing	O	VERB	O
quinine	B-Chemical	NOUN	B
.	O	PUNCT	O


The	O	DET	O
protective	O	ADJ	B
action	O	NOUN	I
of	O	ADP	O
subcutaneously	O	ADV	B
(	O	PUNCT	O
SC	O	NOUN	B
)	O	PUNCT	O
administered	O	VERB	B
antidotes	O	NOUN	B
or	O	CCONJ	O
their	O	PRON	O
combinations	O	NOUN	B
in	O	ADP	O
DFP	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


0	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BW	O	NOUN	B
),	O	PUNCT	O
anticonvulsant	O	ADJ	B
diazepam	B-Chemical	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
.	O	PUNCT	O


